US8124829B2	NNP	O
-	:	O
Transgenic	JJ	O
mice	NN	O
over-expressing	JJ	O
receptor	NN	O
for	IN	O
advanced	JJ	O
glycation	NN	O
endproduct	NN	O
(	(	O
RAGE	NNP	O
)	)	O
in	IN	O
brain	NN	O
and	CC	O
uses	VBZ	O
thereof	SYM	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
U.S.	NNP	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
09/638,653	CD	O
,	,	O
filed	VBN	O
Aug.	NNP	O
14	CD	O
,	,	O
2000	CD	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,919,670	CD	O
,	,	O
the	DT	O
contents	NNS	O
of	IN	O
which	WDT	O
is	VBZ	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Throughout	NNP	O
this	DT	O
application	NN	O
,	,	O
various	JJ	O
publications	NNS	O
are	VBP	O
referenced	VBN	O
by	IN	O
number	NN	O
.	.	O
Full	NNP	O
citations	NNS	O
for	IN	O
these	DT	O
publications	NNS	O
may	MD	O
be	VB	O
found	VBN	O
listed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
specification	NN	O
immediately	RB	O
preceding	VBG	O
the	DT	O
claims	NNS	O
.	.	O
The	DT	O
disclosures	NNS	O
of	IN	O
these	DT	O
publications	NNS	O
in	IN	O
their	PRP$	O
entireties	NNS	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
into	IN	O
this	DT	O
application	NN	O
in	IN	O
order	NN	O
to	TO	O
more	RBR	O
fully	RB	O
describe	VB	O
the	DT	O
state	NN	O
of	IN	O
the	DT	O
art	NN	O
as	IN	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
therein	RB	O
as	IN	O
of	IN	O
the	DT	O
date	NN	O
of	IN	O
the	DT	O
invention	NN	O
described	VBD	O
and	CC	O
claimed	VBD	O
herein	NN	O
.	.	O
The	DT	O
pain	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
results	NNS	O
directly	RB	O
from	IN	O
the	DT	O
memory	NN	O
loss	NN	O
and	CC	O
cognitive	JJ	O
deficits	NNS	O
suffered	VBN	O
by	IN	O
the	DT	O
patient	NN	O
.	.	O
These	DT	O
eventually	RB	O
result	NN	O
in	IN	O
the	DT	O
patient	NN	O
's	POS	O
loss	NN	O
of	IN	O
identity	NN	O
,	,	O
autonomy	NN	O
,	,	O
and	CC	O
freedom	NN	O
.	.	O
As	IN	O
a	DT	O
step	NN	O
toward	IN	O
curing	VBG	O
this	DT	O
disease	NN	O
,	,	O
alleviating	VBG	O
its	PRP$	O
symptoms	NNS	O
,	,	O
or	CC	O
retarding	VBG	O
its	PRP$	O
progression	NN	O
,	,	O
it	PRP	O
would	MD	O
be	VB	O
desirable	JJ	O
to	TO	O
develop	VB	O
a	DT	O
transgenic	JJ	O
animal	NN	O
model	NN	O
exhibiting	VBG	O
the	DT	O
main	JJ	O
debilitating	NN	O
phenotype	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
that	WDT	O
is	VBZ	O
,	,	O
memory	JJ	O
loss	NN	O
,	,	O
expressed	VBN	O
concomitantly	RB	O
with	IN	O
the	DT	O
neuropathological	JJ	O
correlates	NNS	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
beta-amyloid	JJ	O
accumulation	NN	O
,	,	O
increased	VBD	O
glial	JJ	O
reactivity	NN	O
,	,	O
and	CC	O
hippocampal	JJ	O
cell	NN	O
loss	NN	O
.	.	O
It	PRP	O
is	VBZ	O
estimated	VBN	O
that	IN	O
over	IN	O
5	CD	O
%	NN	O
of	IN	O
the	DT	O
U.S.	NNP	O
population	NN	O
over	IN	O
65	CD	O
and	CC	O
over	RB	O
15	CD	O
%	NN	O
of	IN	O
the	DT	O
U.S.	NNP	O
population	NN	O
over	IN	O
85	CD	O
are	VBP	O
beset	VBN	O
with	IN	O
some	DT	O
form	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
(	(	O
Cross	NNP	B
,	,	I
A.	NNP	I
J.	NNP	I
,	,	I
Eur	NNP	I
J	NNP	I
Pharmacol	NNP	I
(	(	I
1982	CD	I
)	)	I
82:77-80	CD	I
;	:	O
Terry	NNP	B
,	,	I
R.	NNP	I
D.	NNP	I
,	,	I
at	IN	I
al.	NN	I
,	,	I
Ann	NNP	I
Neurol	NNP	I
(	(	I
1983	CD	I
)	)	I
14:497506	CD	I
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
believed	VBN	O
that	IN	O
the	DT	O
principal	NN	O
cause	NN	O
for	IN	O
confinement	NN	O
of	IN	O
the	DT	O
elderly	JJ	O
in	IN	O
long	JJ	O
term	NN	O
care	NN	O
facilities	NNS	O
is	VBZ	O
due	JJ	O
to	TO	O
this	DT	O
disease	NN	O
,	,	O
and	CC	O
approximately	RB	O
656	CD	O
of	IN	O
those	DT	O
dying	VBG	O
in	IN	O
skilled	JJ	O
nursing	NN	O
facilities	NNS	O
suffer	VBP	O
from	IN	O
it	PRP	O
.	.	O
Certain	NNP	O
facts	NNS	O
about	IN	O
the	DT	O
biochemical	JJ	O
and	CC	O
metabolic	JJ	O
phenomena	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
presence	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
are	VBP	O
known	VBN	O
.	.	O
Two	CD	O
morphological	JJ	O
and	CC	O
histopathological	JJ	O
changes	NNS	O
noted	VBN	O
in	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
brains	NNS	O
are	VBP	O
neurofibrillary	JJ	O
tangles	NNS	O
(	(	O
NFT	NNP	O
)	)	O
and	CC	O
amyloid	JJ	O
deposits	NNS	O
.	.	O
Intraneuronal	NNP	O
neurofibrillary	JJ	O
tangles	NNS	O
are	VBP	O
present	JJ	O
in	IN	O
other	JJ	O
degenerative	JJ	O
diseases	NNS	O
as	RB	O
well	RB	O
,	,	O
but	CC	O
the	DT	O
presence	NN	O
of	IN	O
amyloid	NN	O
deposits	NNS	O
both	DT	O
in	IN	O
the	DT	O
interneuronal	JJ	O
spaces	NNS	O
(	(	O
neuritic	JJ	O
plaques	NNS	O
)	)	O
and	CC	O
in	IN	O
the	DT	O
surrounding	NN	O
microvasculature	NN	O
(	(	O
vascular	JJ	O
plaques	NNS	O
)	)	O
seems	VBZ	O
to	TO	O
be	VB	O
characteristic	JJ	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
.	.	O
Of	IN	O
these	DT	O
,	,	O
the	DT	O
neuritic	JJ	O
plaques	NNS	O
seem	VBP	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
prevalent	JJ	O
(	(	O
Price	NNP	B
,	,	I
D.	NNP	I
L.	NNP	I
,	,	I
et	FW	I
al.	RB	I
,	,	I
Drug	NNP	I
Development	NNP	I
Research	NNP	I
(	(	I
1985	CD	I
)	)	I
5:59-68	CD	I
)	)	O
.	.	O
Plaques	NNS	O
are	VBP	O
also	RB	O
seen	VBN	O
in	IN	O
the	DT	O
brains	NNS	O
of	IN	O
aged	VBN	O
Down	NNP	O
's	POS	O
Syndrome	JJ	O
patients	NNS	O
who	WP	O
develop	VBP	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
.	.	O
SUMMARY	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
for	IN	O
a	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
whose	WP$	O
cells	NNS	O
contain	VBP	O
a	DT	O
DNA	NN	O
sequence	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
a	DT	O
nerve	NN	O
tissue	NN	O
specific	JJ	O
promoter	NN	O
;	:	O
and	CC	O
(	(	O
b	NN	O
)	)	O
a	DT	O
DNA	NN	O
sequence	NN	O
which	WDT	O
encodes	VBZ	O
a	DT	O
receptor	NN	O
for	IN	O
advanced	JJ	O
glycation	NN	O
endproducts	NNS	O
(	(	O
RAGE	NNP	O
)	)	O
,	,	O
wherein	VBD	O
the	DT	O
promoter	NN	O
and	CC	O
the	DT	O
DNA	NNP	O
sequence	NN	O
which	WDT	O
encodes	VBZ	O
the	DT	O
receptor	NN	O
for	IN	O
advanced	JJ	O
glycation	NN	O
endproducts	NNS	O
(	(	O
RAGE	NNP	O
)	)	O
are	VBP	O
operatively	RB	O
linked	VBN	O
to	TO	O
each	DT	O
other	JJ	O
and	CC	O
integrated	VBN	O
in	IN	O
the	DT	O
genome	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
animal	NN	O
,	,	O
and	CC	O
wherein	NN	O
said	VBD	O
non-human	JJ	O
animal	JJ	O
exhibits	NNS	O
a	DT	O
reduced	JJ	O
amount	NN	O
of	IN	O
cerebral	JJ	O
tissue	NN	O
infarcted	VBD	O
following	VBG	O
a	DT	O
transient	JJ	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
occlusion	NN	O
compared	VBN	O
to	TO	O
an	DT	O
identical	JJ	O
non-human	JJ	O
animal	NN	O
lacking	NN	O
said	VBD	O
DNA	NNP	O
sequence	NN	O
.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
FIGURES	NNP	O
FIGS	NNP	O
.	.	O
1A-1B	JJ	O
.	.	O
Schematic	JJ	O
depiction	NN	O
of	IN	O
strategy	NN	O
for	IN	O
making	VBG	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
FIG	NNP	O
.	.	O
2	CD	O
.	.	O
Southern	JJ	O
analysis	NN	O
of	IN	O
three	CD	O
founders	NNS	O
for	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
:	:	O
lanes	NNS	O
1,3,6	CD	O
show	NN	O
mice	NNS	O
positive	JJ	O
for	IN	O
the	DT	O
transgene	NN	O
and	CC	O
lanes	NNS	O
2,4-5	CD	O
are	VBP	O
nontransgenic	JJ	O
littermates	NNS	O
.	.	O
FIG	NNP	O
.	.	O
3	CD	O
.	.	O
Identification	NN	O
of	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
(	(	O
+	NNP	O
)	)	O
and	CC	O
nontransgenic	JJ	O
littermate	NN	O
controls	NNS	O
(	(	O
−	NN	O
)	)	O
by	IN	O
PCR	NNP	O
.	.	O
FIGS	NNP	O
.	.	O
4A-4B	JJ	O
.	.	O
RAGE	NNP	O
expression	NN	O
in	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
(	(	O
+	NNP	O
)	)	O
compared	VBN	O
with	IN	O
nontransgenic	JJ	O
littermate	NN	O
controls	NNS	O
(	(	O
−	NN	O
)	)	O
.	.	O
A	DT	O
(	(	O
Northern	NNP	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
Western	NNP	O
)	)	O
analysis	NN	O
of	IN	O
homogenates	NNS	O
of	IN	O
cerebral	JJ	O
cortex	NN	O
.	.	O
Equal	JJ	O
amounts	NNS	O
of	IN	O
RNA	NNP	O
(	(	O
note	VBP	O
approximately	RB	O
equal	JJ	O
intensity	NN	O
of	IN	O
28S	CD	O
ribosomal	JJ	O
RNA	NNP	O
band	NN	O
on	IN	O
the	DT	O
ethidium	NN	O
bromide	NN	O
stained	VBD	O
gel	NN	O
)	)	O
and	CC	O
protein	$	O
were	VBD	O
loaded	VBN	O
in	IN	O
each	DT	O
lane	NN	O
.	.	O
FIG	NNP	O
.	.	O
5	CD	O
.	.	O
RAGE	NNP	O
expression	NN	O
in	IN	O
brain	NN	O
subregions	NNS	O
of	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
compared	VBN	O
with	IN	O
nontransgenic	JJ	O
littermate	NN	O
controls	NNS	O
(	(	O
nonTg	NN	O
)	)	O
.	.	O
Immunoblotting	NN	O
was	VBD	O
performed	VBN	O
protein	JJ	O
extracts	NNS	O
of	IN	O
brain	NN	O
homogenates	NNS	O
derived	VBD	O
from	IN	O
the	DT	O
indicated	JJ	O
brain	NN	O
subregion	NN	O
.	.	O
FIG	NNP	O
.	.	O
6A-6B	JJ	O
.	.	O
Immunohistochemical	JJ	O
identification	NN	O
of	IN	O
RAGE	NNP	O
in	IN	O
cerebral	JJ	O
cortex	NN	O
from	IN	O
a	DT	O
Tg	NNP	O
PD-RAGE	NN	O
mouse	NN	O
(	(	O
FIG	NNP	O
.	.	O
6A	CD	O
)	)	O
and	CC	O
a	DT	O
nontransgenic	JJ	O
littermate	NN	O
control	NN	O
(	(	O
FIG	NNP	O
.	.	O
6B	CD	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
7	CD	O
.	.	O
Transient	NNP	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
occlusion	NN	O
model	NN	O
of	IN	O
stroke	NN	O
in	IN	O
mice	NN	O
:	:	O
comparison	NN	O
of	IN	O
infarct	JJ	O
volume	NN	O
in	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
and	CC	O
nontransgenic	JJ	O
littermate	NN	O
controls	NNS	O
(	(	O
nonTg	NN	O
)	)	O
.	.	O
*P	JJ	O
<	$	O
0.05	CD	O
.	.	O
FIG	NNP	O
.	.	O
8	CD	O
.	.	O
Identification	NN	O
of	IN	O
double	JJ	O
transgenic	JJ	O
mice	NN	O
overexpressing	VBG	O
RAGE	NNP	O
and	CC	O
mutant	JJ	O
human	JJ	O
APP	NNP	O
by	IN	O
PCR	NNP	O
.	.	O
FIGS	NNP	O
.	.	O
9A	CD	O
,	,	O
9B1	CD	O
,	,	O
9B2	CD	O
,	,	O
9B3	CD	O
,	,	O
9C	CD	O
.	.	O
Increased	VBN	O
expression	NN	O
of	IN	O
M-CSF	NNP	O
in	IN	O
cerebral	JJ	O
cortex	NN	O
from	IN	O
double	JJ	O
Tg	NNP	O
mice	NN	O
overexpressing	VBG	O
RAGE	NNP	O
and	CC	O
mutant	JJ	O
human	JJ	O
APP	NNP	O
(	(	O
hAPP	NN	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
9A	CD	O
,	,	O
Northern	NNP	O
analysis	NN	O
for	IN	O
M-CSF	NNP	O
transcripts	NNS	O
.	.	O
FIGS	NNP	O
.	.	O
9B1-9B3	CD	O
,	,	O
immunostaining	VBG	O
for	IN	O
M-CSF	NNP	O
.	.	O
FIG	NNP	O
.	.	O
9C	CD	O
,	,	O
Quantitation	NNP	O
of	IN	O
immunocytochemical	JJ	O
results	NNS	O
.	.	O
FIGS	NNP	O
.	.	O
10A	CD	O
,	,	O
10B1	CD	O
,	,	O
10B2	CD	O
,	,	O
10B3	CD	O
,	,	O
10C	CD	O
.	.	O
Increased	VBN	O
expression	NN	O
of	IN	O
Interleukin	NNP	O
(	(	O
IL	NNP	O
)	)	O
-6	NN	O
in	IN	O
cerebral	JJ	O
cortex	NN	O
from	IN	O
double	JJ	O
Tg	NNP	O
mice	NN	O
overexpressing	VBG	O
RAGE	NNP	O
and	CC	O
mutant	JJ	O
human	JJ	O
APP	NNP	O
(	(	O
hAPP	NN	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
10A	CD	O
,	,	O
Northern	NNP	O
analysis	NN	O
for	IN	O
IL-6	NNP	O
transcripts	NNS	O
.	.	O
FIGS	NNP	O
.	.	O
10B1-10B3	JJ	O
,	,	O
immunostaining	VBG	O
for	IN	O
IL-6	NNP	O
.	.	O
FIG	NNP	O
.	.	O
10C	CD	O
,	,	O
Quantitation	NNP	O
of	IN	O
immunocytochemical	JJ	O
results	NNS	O
.	.	O
FIG	NNP	O
.	.	O
11	CD	O
.	.	O
EMSA	NNP	O
for	IN	O
NF-kB	NNP	O
on	IN	O
nuclear	JJ	O
extracts	NNS	O
from	IN	O
cerebral	JJ	O
cortex	NN	O
of	IN	O
mice	NNS	O
overexpressing	VBG	O
RAGE	NNP	O
(	(	O
2,3	CD	O
)	)	O
,	,	O
mutant	JJ	O
human	JJ	O
APP	NNP	O
(	(	O
hAPP	NN	O
;	:	O
4,5	CD	O
)	)	O
,	,	O
both	DT	O
transgenes	NNS	O
(	(	O
6-9	JJ	O
)	)	O
,	,	O
and	CC	O
a	DT	O
nontransgenic	JJ	O
littermate	NN	O
control	NN	O
(	(	O
1	CD	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
12	CD	O
.	.	O
Semiquantitative	JJ	O
analysis	NN	O
of	IN	O
synaptophysin	NN	O
immunoreactivity	NN	O
in	IN	O
hippocampus	NN	O
of	IN	O
Tg	NNP	O
PD-RAGE/hAPP	NNP	O
,	,	O
Tg	NNP	O
PD-RAGE	NNP	O
,	,	O
Tg	NNP	O
hAPP	NN	O
,	,	O
and	CC	O
nontransgenic	JJ	O
littermate	NN	O
control	NN	O
mice	NN	O
at	IN	O
4	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O
FIG	NNP	O
.	.	O
13	CD	O
.	.	O
Semiquantitative	JJ	O
analysis	NN	O
of	IN	O
MAP-2	NNP	O
immunoreactivity	NN	O
in	IN	O
hippocampus	NN	O
of	IN	O
Tg	NNP	O
PD-RAGE/hAPP	NNP	O
,	,	O
Tg	NNP	O
PD-RAGE	NNP	O
,	,	O
Tg	NNP	O
hAPP	NN	O
,	,	O
and	CC	O
nontransgenic	JJ	O
littermate	NN	O
control	NN	O
mice	NN	O
at	IN	O
4	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O
FIGS	NNP	O
.	.	O
14A1	CD	O
,	,	O
14A2	CD	O
,	,	O
14A3	CD	O
,	,	O
14A4	CD	O
,	,	O
and	CC	O
14B	CD	O
.	.	O
Increased	VBN	O
expression	NN	O
of	IN	O
activated	JJ	O
caspase-3	NN	O
in	IN	O
cerebral	JJ	O
cortex	NN	O
from	IN	O
Tg	NNP	O
PD-RAGE/hAPP	NNP	O
mice	NN	O
.	.	O
FIGS	NNP	O
.	.	O
14A1-4	JJ	O
,	,	O
immunostaining	VBG	O
for	IN	O
activated	VBN	O
caspase-3	NN	O
.	.	O
FIG	NNP	O
.	.	O
14B	CD	O
,	,	O
quantitation	NN	O
of	IN	O
immunocytochemical	JJ	O
results	NNS	O
from	IN	O
multiple	JJ	O
fields	NNS	O
of	IN	O
all	DT	O
mice	NNS	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
experimental	JJ	O
groups	NNS	O
.	.	O
Scale	NNP	O
bar	NN	O
,	,	O
10	CD	O
μm	NN	O
.	.	O
FIGS	NNP	O
.	.	O
15A1	CD	O
,	,	O
15A2	CD	O
,	,	O
15A3	CD	O
,	,	O
15A4	CD	O
,	,	O
and	CC	O
15B	CD	O
.	.	O
Immunostaining	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
15A1-4	JJ	O
)	)	O
with	IN	O
antibody	NN	O
to	TO	O
phosphorylated	VBN	O
tau	NN	O
(	(	O
AT8	NNP	O
)	)	O
in	IN	O
cerebral	JJ	O
cortex	NN	O
of	IN	O
the	DT	O
indicated	JJ	O
transgenic	JJ	O
mice	NN	O
.	.	O
FIG	NNP	O
.	.	O
15B	CD	O
demonstrates	NNS	O
image	NN	O
analysis	NN	O
of	IN	O
multiple	JJ	O
microscopic	NN	O
fields	NNS	O
from	IN	O
all	DT	O
of	IN	O
the	DT	O
mice	NN	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
experimental	JJ	O
groups	NNS	O
.	.	O
Scale	NNP	O
bar	NN	O
,	,	O
10	CD	O
μm	NN	O
.	.	O
FIG	NNP	O
.	.	O
16	CD	O
.	.	O
Immunoblotting	NN	O
of	IN	O
E16	NNP	O
cortical	JJ	O
neuron	NN	O
cultures	NNS	O
with	IN	O
anti-human	JJ	O
RAGE	NNP	O
IgG	NNP	O
.	.	O
(	(	O
+	NN	O
)	)	O
indicates	VBZ	O
neurons	NNS	O
obtained	VBN	O
from	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
and	CC	O
(	(	O
−	NNP	O
)	)	O
indicates	VBZ	O
neurons	NNS	O
are	VBP	O
from	IN	O
nontransgenic	JJ	O
littermate	NN	O
controls	NNS	O
.	.	O
FIGS	NNP	O
.	.	O
17A-17B	JJ	O
.	.	O
NF-kB	JJ	O
activation	NN	O
in	IN	O
primary	JJ	O
cortical	JJ	O
neuron	NN	O
cultures	NNS	O
from	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
and	CC	O
nontransgenic	JJ	O
littermates	NNS	O
exposed	VBD	O
for	IN	O
5	CD	O
hrs	NN	O
to	TO	O
preformed	VB	O
Aβ	NNP	O
(	(	O
1-40	JJ	O
)	)	O
fibrils	NNS	O
(	(	O
500	CD	O
nM	RB	O
)	)	O
alone	RB	O
(	(	O
FIG	NNP	O
.	.	O
17A	CD	O
(	(	O
left	JJ	O
panel	NN	O
)	)	O
)	)	O
or	CC	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
anti-RAGE	JJ	O
IgG	NNP	O
or	CC	O
nonimmune	NN	O
(	(	O
NI	NNP	O
)	)	O
IgG	NNP	O
(	(	O
FIG	NNP	O
.	.	O
17B	CD	O
(	(	O
right	JJ	O
panel	NN	O
)	)	O
)	)	O
.	.	O
Gel	NNP	O
shift	NN	O
analysis	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
32P-labelled	JJ	O
NF-kB	JJ	O
probe	NN	O
.	.	O
FIG	NNP	O
.	.	O
18	CD	O
.	.	O
Cortical	JJ	O
neuron	NN	O
cultures	NNS	O
(	(	O
as	IN	O
in	IN	O
FIGS	NNP	O
.	.	O
16-17	JJ	O
)	)	O
were	VBD	O
exposed	VBN	O
to	TO	O
preformed	VB	O
Aβ	NNP	O
(	(	O
1-40	JJ	O
)	)	O
fibrils	NNS	O
(	(	O
2	CD	O
μM	NN	O
)	)	O
for	IN	O
30	CD	O
or	CC	O
40	CD	O
hours	NNS	O
,	,	O
and	CC	O
caspase-3	JJ	O
activity	NN	O
was	VBD	O
monitored	VBN	O
.	.	O
Neurons	NNS	O
were	VBD	O
derived	VBN	O
from	IN	O
Tg	NNP	O
PD	NNP	O
.	.	O
FIGS	NNP	O
.	.	O
19A-19B	JJ	O
.	.	O
Volume	NN	O
of	IN	O
infarcted	JJ	O
cerebral	JJ	O
tissue	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
RAGE	NNP	O
overexpressing	VBG	O
transgenic	JJ	O
mice	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
mice	NN	O
.	.	O
The	DT	O
volume	NN	O
was	VBD	O
reduced	VBN	O
about	IN	O
50	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
transgenic	JJ	O
mice	NN	O
compared	VBN	O
with	IN	O
normal	JJ	O
mice	NNS	O
.	.	O
FIG	NNP	O
.	.	O
19A	CD	O
shows	NNS	O
results	NNS	O
of	IN	O
studies	NNS	O
in	IN	O
all	DT	O
mice	NN	O
;	:	O
FIG	NNP	O
.	.	O
19B	CD	O
shows	NNS	O
triphenyl	VBP	O
tetrazolium	JJ	O
chloride	NN	O
staining	NN	O
of	IN	O
selected	VBN	O
cerebral	JJ	O
sections	NNS	O
.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
for	IN	O
a	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
whose	WP$	O
cells	NNS	O
contain	VBP	O
a	DT	O
DNA	NN	O
sequence	NN	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
a	DT	O
nerve	NN	O
tissue	NN	O
specific	JJ	O
promoter	NN	O
;	:	O
and	CC	O
(	(	O
b	NN	O
)	)	O
a	DT	O
DNA	NN	O
sequence	NN	O
which	WDT	O
encodes	VBZ	O
a	DT	O
receptor	NN	O
for	IN	O
advanced	JJ	O
glycation	NN	O
endproducts	NNS	O
(	(	O
RAGE	NNP	O
)	)	O
,	,	O
wherein	VBD	O
the	DT	O
promoter	NN	O
and	CC	O
the	DT	O
DNA	NNP	O
sequence	NN	O
which	WDT	O
encodes	VBZ	O
the	DT	O
receptor	NN	O
for	IN	O
advanced	JJ	O
glycation	NN	O
endproducts	NNS	O
(	(	O
RAGE	NNP	O
)	)	O
are	VBP	O
operatively	RB	O
linked	VBN	O
to	TO	O
each	DT	O
other	JJ	O
and	CC	O
integrated	VBN	O
in	IN	O
the	DT	O
genome	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
animal	NN	O
,	,	O
and	CC	O
wherein	NN	O
said	VBD	O
non-human	JJ	O
animal	JJ	O
exhibits	NNS	O
a	DT	O
reduced	JJ	O
amount	NN	O
of	IN	O
cerebral	JJ	O
tissue	NN	O
infarcted	VBD	O
following	VBG	O
a	DT	O
transient	JJ	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
occlusion	NN	O
compared	VBN	O
to	TO	O
an	DT	O
identical	JJ	O
non-human	JJ	O
animal	NN	O
lacking	NN	O
said	VBD	O
DNA	NNP	O
sequence	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
promoter	NN	O
is	VBZ	O
platelet	JJ	O
derived	JJ	O
growth	NN	O
factor	NN	O
(	(	O
PDGF	NNP	O
)	)	O
-B-chain	VBP	O
promoter	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
DNA	NNP	O
sequence	NN	O
which	WDT	O
encodes	VBZ	O
amyloid-beta	JJ	O
peptide	NN	O
alcohol	NN	O
dehydrogenase	NN	O
is	VBZ	O
a	DT	O
human	JJ	O
DNA	NN	O
sequence	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
reduction	NN	O
of	IN	O
infarcted	JJ	O
cerebral	JJ	O
tissue	NN	O
is	VBZ	O
about	IN	O
a	DT	O
50	CD	O
%	NN	O
reduction	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
is	VBZ	O
a	DT	O
mouse	NN	O
,	,	O
a	DT	O
rat	NN	O
,	,	O
a	DT	O
sheep	NN	O
,	,	O
a	DT	O
dog	NN	O
,	,	O
a	DT	O
primate	NN	O
,	,	O
or	CC	O
a	DT	O
reptile	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
non-human	JJ	O
animal	NN	O
is	VBZ	O
a	DT	O
mammal	NN	O
.	.	O
This	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
for	IN	O
a	DT	O
method	NN	O
for	IN	O
evaluating	VBG	O
in	IN	O
a	DT	O
non-human	JJ	O
transgenic	NN	O
animal	IN	O
the	DT	O
potential	JJ	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
an	DT	O
agent	NN	O
for	IN	O
treating	VBG	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
in	IN	O
a	DT	O
human	NN	O
,	,	O
which	WDT	O
comprises	VBZ	O
:	:	O
(	(	O
a	DT	O
)	)	O
administering	VBG	O
an	DT	O
agent	NN	O
to	TO	O
a	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
whose	WP$	O
cells	NNS	O
comprise	VBP	O
a	DT	O
nerve	NN	O
tissue	NN	O
specific	JJ	O
promoter	NN	O
operatively	RB	O
linked	VBN	O
to	TO	O
a	DT	O
DNA	NN	O
sequence	NN	O
which	WDT	O
encodes	VBZ	O
receptor	NN	O
for	IN	O
advanced	JJ	O
glycation	NN	O
endproducts	NNS	O
(	(	O
RAGE	NNP	O
)	)	O
;	:	O
and	CC	O
(	(	O
b	NN	O
)	)	O
determining	VBG	O
the	DT	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
the	DT	O
agent	NN	O
on	IN	O
the	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
by	IN	O
monitoring	VBG	O
basal	JJ	O
synaptic	JJ	O
transmission	NN	O
or	CC	O
synaptic	JJ	O
plasticity	NN	O
,	,	O
wherein	VBP	O
an	DT	O
increase	NN	O
in	IN	O
basal	JJ	O
synaptic	JJ	O
transmission	NN	O
or	CC	O
synaptic	JJ	O
plasticity	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
agent	NN	O
would	MD	O
have	VB	O
a	DT	O
potential	JJ	O
therapeutic	JJ	O
effect	NN	O
on	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
in	IN	O
a	DT	O
human	JJ	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
for	IN	O
a	DT	O
method	NN	O
for	IN	O
identifying	VBG	O
whether	IN	O
an	DT	O
agent	NN	O
or	CC	O
a	DT	O
compound	NN	O
is	VBZ	O
an	DT	O
inhibitor	NN	O
of	IN	O
receptor	NN	O
for	IN	O
advanced	JJ	O
glycation	NN	O
endproduct	NN	O
(	(	O
RAGE	NNP	O
)	)	O
in	IN	O
vivo	NN	O
,	,	O
which	WDT	O
comprises	VBZ	O
(	(	O
a	DT	O
)	)	O
obtaining	VBG	O
a	DT	O
non-human	JJ	O
transgenic	JJ	O
animal	NN	O
whose	WP$	O
cells	NNS	O
overexpress	JJ	O
RAGE	NNP	O
in	IN	O
neurons	NNS	O
;	:	O
(	(	O
b	NN	O
)	)	O
administering	VBG	O
an	DT	O
agent	NN	O
or	CC	O
compound	NN	O
to	TO	O
the	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
;	:	O
(	(	O
c	NN	O
)	)	O
determining	VBG	O
whether	IN	O
the	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
from	IN	O
step	NN	O
(	(	O
b	NN	O
)	)	O
exhibits	VBZ	O
a	DT	O
change	NN	O
in	IN	O
neuronal	JJ	O
function	NN	O
from	IN	O
an	DT	O
identical	JJ	O
transgenic	JJ	O
non-human	NN	O
animal	NN	O
which	WDT	O
was	VBD	O
not	RB	O
administered	VBN	O
the	DT	O
agent	NN	O
or	CC	O
compound	NN	O
;	:	O
wherein	CC	O
a	DT	O
determination	NN	O
of	IN	O
change	NN	O
in	IN	O
neuronal	JJ	O
function	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
agent	NN	O
or	CC	O
compound	NN	O
is	VBZ	O
an	DT	O
inhibitor	NN	O
of	IN	O
RAGE	NNP	O
in	IN	O
vivo	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
promoter	NN	O
of	IN	O
both	DT	O
element	NN	O
(	(	O
a	DT	O
)	)	O
and	CC	O
(	(	O
b	NN	O
)	)	O
is	VBZ	O
platelet	JJ	O
derived	JJ	O
growth	NN	O
factor	NN	O
(	(	O
PDGF	NNP	O
)	)	O
-B-chain	VBP	O
promoter	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
non-human	JJ	O
animal	NN	O
is	VBZ	O
a	DT	O
mouse	NN	O
,	,	O
a	DT	O
rat	NN	O
,	,	O
a	DT	O
sheep	NN	O
,	,	O
a	DT	O
dog	NN	O
,	,	O
a	DT	O
primate	NN	O
,	,	O
or	CC	O
a	DT	O
reptile	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
a	DT	O
mammal	NN	O
.	.	O
The	DT	O
phenotype	NN	O
observed	VBD	O
in	IN	O
the	DT	O
transgenic	JJ	O
RAGE	NNP	O
overexpressing	VBG	O
mice	RB	O
described	VBN	O
herein	NN	O
was	VBD	O
not	RB	O
obvious	JJ	O
prior	RB	O
to	TO	O
the	DT	O
creation	NN	O
of	IN	O
such	JJ	O
mice	NNS	O
.	.	O
The	DT	O
transgenic	JJ	O
mice	NN	O
described	VBD	O
herein	RB	O
only	RB	O
overexpress	JJ	O
RAGE	NNP	O
in	IN	O
neurons	NNS	O
,	,	O
whereas	NNS	O
in	IN	O
the	DT	O
normal	JJ	O
animal	NN	O
,	,	O
RAGE	NNP	O
is	VBZ	O
also	RB	O
expressed	VBN	O
in	IN	O
the	DT	O
microglia	NN	O
at	IN	O
high	JJ	O
levels	NNS	O
(	(	O
the	DT	O
microglia	NN	O
are	VBP	O
considered	VBN	O
important	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
)	)	O
.	.	O
Therefore	RB	O
,	,	O
prior	RB	O
to	TO	O
creating	VBG	O
and	CC	O
studying	VBG	O
the	DT	O
actual	JJ	O
transgenic	NN	O
,	,	O
one	CD	O
could	MD	O
have	VB	O
imagined	VBN	O
that	IN	O
overexpression	NN	O
of	IN	O
RAGE	NNP	O
in	IN	O
neurons	NNS	O
alone	RB	O
would	MD	O
not	RB	O
have	VB	O
had	VBD	O
a	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
resulting	VBG	O
transgenic	JJ	O
animal	NN	O
.	.	O
However	RB	O
,	,	O
as	IN	O
described	VBN	O
hereinbelow	NN	O
,	,	O
there	EX	O
is	VBZ	O
evidence	NN	O
that	IN	O
RAGE	NNP	O
overexpressing	VBG	O
mice	JJ	O
exhibit	NN	O
a	DT	O
reduced	VBN	O
neurologic	JJ	O
deficit	NN	O
score	NN	O
and	CC	O
that	DT	O
RAGE	NNP	O
overexpressing	VBG	O
mice	NNS	O
have	VBP	O
a	DT	O
reduced	JJ	O
volume	NN	O
of	IN	O
infarcted	JJ	O
cerebral	JJ	O
tissue	NN	O
when	WRB	O
subjected	VBN	O
to	TO	O
the	DT	O
transient	NN	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
occlusion	NN	O
procedure	NN	O
(	(	O
described	VBN	O
below	IN	O
)	)	O
.	.	O
Nucleotide	NNP	O
and	CC	O
Amino	NNP	O
Acid	NNP	O
Sequences	NNP	O
of	IN	O
RAGE	NNP	O
The	DT	O
nucleotide	NN	O
and	CC	O
protein	NN	O
(	(	O
amino	JJ	O
acid	NN	O
)	)	O
sequences	NNS	O
for	IN	O
RAGE	NNP	O
(	(	O
both	DT	O
human	NN	O
and	CC	O
murine	NN	O
and	CC	O
bovine	NN	O
)	)	O
are	VBP	O
known	VBN	O
.	.	O
The	DT	O
following	JJ	O
references	NNS	O
which	WDT	O
recite	VBP	O
these	DT	O
sequences	NNS	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
:	:	O
RAGE	NN	O
sequences	NNS	O
(	(	O
DNA	NNP	O
sequence	NN	O
and	CC	O
translation	NN	O
)	)	O
from	IN	O
bovine	NN	O
,	,	O
murine	NN	O
and	CC	O
homo	NN	O
sapien	NN	O
are	VBP	O
listed	VBN	O
hereinbelow	NN	O
.	.	O
These	DT	O
sequences	NNS	O
are	VBP	O
available	JJ	O
from	IN	O
GenBank	NNP	O
as	IN	O
are	VBP	O
other	JJ	O
sequences	NNS	O
of	IN	O
RAGE	NNP	O
from	IN	O
other	JJ	O
species	NNS	O
:	:	O
Definitions	NNS	O
“	VBP	O
DNA	NNP	O
sequence	NN	O
”	NN	O
is	VBZ	O
a	DT	O
linear	JJ	O
sequence	NN	O
comprised	VBN	O
of	IN	O
any	DT	O
combination	NN	O
of	IN	O
the	DT	O
four	CD	O
DNA	NN	O
monomers	NNS	O
,	,	O
i.e.	FW	O
,	,	O
nucleotides	NNS	O
of	IN	O
adenine	NN	O
,	,	O
guanine	NN	O
,	,	O
cytosine	NN	O
and	CC	O
thymine	NN	O
,	,	O
which	WDT	O
codes	VBZ	O
for	IN	O
genetic	JJ	O
information	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
code	NN	O
for	IN	O
an	DT	O
amino	NN	O
acid	NN	O
,	,	O
a	DT	O
promoter	NN	O
,	,	O
a	DT	O
control	NN	O
or	CC	O
a	DT	O
gene	NN	O
product	NN	O
.	.	O
A	DT	O
specific	JJ	O
DNA	NNP	O
sequence	NN	O
is	VBZ	O
one	CD	O
which	WDT	O
has	VBZ	O
a	DT	O
known	VBN	O
specific	JJ	O
function	NN	O
,	,	O
e.g.	NN	O
,	,	O
codes	NNS	O
for	IN	O
a	DT	O
particular	JJ	O
polypeptide	NN	O
,	,	O
a	DT	O
particular	JJ	O
genetic	JJ	O
trait	NN	O
or	CC	O
affects	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
particular	JJ	O
phenotype	NN	O
.	.	O
“	JJ	O
Genotype	NNP	O
”	NN	O
is	VBZ	O
the	DT	O
genetic	JJ	O
constitution	NN	O
of	IN	O
an	DT	O
organism	NN	O
.	.	O
“	JJ	O
Phenotype	NNP	O
”	NN	O
is	VBZ	O
a	DT	O
collection	NN	O
of	IN	O
morphological	JJ	O
,	,	O
physiological	JJ	O
and	CC	O
biochemical	JJ	O
traits	NNS	O
possessed	VBN	O
by	IN	O
a	DT	O
cell	NN	O
or	CC	O
organism	NN	O
that	WDT	O
results	NNS	O
from	IN	O
the	DT	O
interaction	NN	O
of	IN	O
the	DT	O
genotype	NN	O
and	CC	O
the	DT	O
environment	NN	O
.	.	O
“	JJ	O
Phenotypic	NNP	O
expression	NN	O
”	NN	O
is	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
code	NN	O
of	IN	O
a	DT	O
DNA	NN	O
sequence	NN	O
or	CC	O
sequences	NNS	O
which	WDT	O
results	NNS	O
in	IN	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
product	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
polypeptide	NN	O
or	CC	O
protein	NN	O
,	,	O
or	CC	O
alters	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
zygote	NN	O
's	POS	O
or	CC	O
the	DT	O
organisms	JJ	O
natural	JJ	O
phenotype	NN	O
.	.	O
“	JJ	O
Zygote	NNP	O
”	NNP	O
is	VBZ	O
a	DT	O
diploid	NN	O
cell	NN	O
having	VBG	O
the	DT	O
potential	JJ	O
for	IN	O
development	NN	O
into	IN	O
a	DT	O
complete	JJ	O
organism	NN	O
.	.	O
The	DT	O
zygote	NN	O
can	MD	O
result	VB	O
from	IN	O
parthenogenesis	NN	O
,	,	O
nuclear	JJ	O
transplantation	NN	O
,	,	O
the	DT	O
merger	NN	O
of	IN	O
two	CD	O
gametes	NNS	O
by	IN	O
artificial	NN	O
or	CC	O
natural	JJ	O
fertilization	NN	O
or	CC	O
any	DT	O
other	JJ	O
method	NN	O
which	WDT	O
creates	VBZ	O
a	DT	O
diploid	NN	O
cell	NN	O
having	VBG	O
the	DT	O
potential	JJ	O
for	IN	O
development	NN	O
into	IN	O
a	DT	O
complete	JJ	O
organism	NN	O
.	.	O
The	DT	O
origin	NN	O
of	IN	O
the	DT	O
zygote	NN	O
can	MD	O
be	VB	O
from	IN	O
either	CC	O
the	DT	O
plant	NN	O
or	CC	O
animal	JJ	O
kingdom	NN	O
.	.	O
In	IN	O
the	DT	O
practice	NN	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
or	CC	O
preparation	NN	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
an	DT	O
“	NNP	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
”	NNP	O
is	VBZ	O
an	DT	O
amount	NN	O
which	WDT	O
is	VBZ	O
capable	JJ	O
of	IN	O
alleviating	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
the	DT	O
cognitive	JJ	O
disorder	NN	O
of	IN	O
memory	NN	O
or	CC	O
learning	NN	O
in	IN	O
the	DT	O
subject	NN	O
.	.	O
Accordingly	RB	O
,	,	O
the	DT	O
effective	JJ	O
amount	NN	O
will	MD	O
vary	VB	O
with	IN	O
the	DT	O
subject	NN	O
being	VBG	O
treated	VBN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
condition	NN	O
to	TO	O
be	VB	O
treated	VBN	O
.	.	O
For	IN	O
the	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
the	DT	O
methods	NNS	O
of	IN	O
administration	NN	O
are	VBP	O
to	TO	O
include	VB	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
administration	NN	O
cutaneously	RB	O
,	,	O
subcutaneously	RB	O
,	,	O
intravenously	RB	O
,	,	O
parenterally	RB	O
,	,	O
orally	RB	O
,	,	O
topically	RB	O
,	,	O
or	CC	O
by	IN	O
aerosol	NN	O
.	.	O
By	IN	O
“	NNP	O
nervous	JJ	O
system-specific	JJ	O
”	NN	O
is	VBZ	O
meant	VBN	O
that	IN	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
occurs	VBZ	O
substantially	RB	O
in	IN	O
a	DT	O
nervous	JJ	O
system	NN	O
tissue	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
brain	NN	O
or	CC	O
spinal	JJ	O
cord	NN	O
)	)	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
in	IN	O
the	DT	O
nervous	JJ	O
system	NN	O
tissue	NN	O
represents	VBZ	O
at	IN	O
least	JJS	O
a	DT	O
5-fold	JJ	O
,	,	O
more	RBR	O
preferably	RB	O
,	,	O
a	DT	O
10-fold	JJ	O
,	,	O
and	CC	O
,	,	O
most	RBS	O
preferably	RB	O
,	,	O
a	DT	O
100-fold	JJ	O
increase	NN	O
over	IN	O
expression	NN	O
in	IN	O
non-nervous	JJ	O
system	NN	O
tissue	NN	O
.	.	O
The	DT	O
“	JJ	O
non-human	JJ	O
animals	NNS	O
”	CD	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
vertebrates	NNS	O
such	JJ	O
as	IN	O
rodents	NNS	O
,	,	O
non-human	JJ	O
primates	NNS	O
,	,	O
sheep	NN	O
,	,	O
dog	NN	O
,	,	O
cow	NN	O
,	,	O
amphibians	NNS	O
,	,	O
reptiles	NNS	O
,	,	O
etc	FW	O
.	.	O
Preferred	VBN	O
non-human	JJ	O
animals	NNS	O
are	VBP	O
selected	VBN	O
from	IN	O
the	DT	O
rodent	JJ	O
family	NN	O
including	VBG	O
rat	NN	O
and	CC	O
mouse	NN	O
,	,	O
most	RBS	O
preferably	RB	O
mouse	NN	O
.	.	O
The	DT	O
“	NNP	O
transgenic	JJ	O
non-human	JJ	O
animals	NNS	O
”	CD	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
produced	VBN	O
by	IN	O
introducing	VBG	O
“	JJ	O
transgenes	NNS	O
”	RB	O
into	IN	O
the	DT	O
germline	NN	O
of	IN	O
the	DT	O
non-human	JJ	O
animal	NN	O
.	.	O
Advantages	NNS	O
of	IN	O
the	DT	O
Present	JJ	O
Invention	NNP	O
The	DT	O
transgenic	JJ	O
non-human	JJ	O
mammals	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
will	MD	O
provide	VB	O
insights	NNS	O
with	IN	O
respect	NN	O
to	TO	O
how	WRB	O
and	CC	O
where	WRB	O
protein	JJ	O
interactions	NNS	O
occur	VBP	O
in	IN	O
Alzheimer	NNP	O
's	POS	O
Disease	NNP	O
and	CC	O
thus	RB	O
provide	VB	O
more	JJR	O
useful	JJ	O
models	NNS	O
for	IN	O
testing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
certain	JJ	O
drugs	NNS	O
in	IN	O
preventing	VBG	O
or	CC	O
reducing	VBG	O
the	DT	O
onset	NN	O
or	CC	O
progression	NN	O
of	IN	O
this	DT	O
disease	NN	O
.	.	O
The	DT	O
transgenic	JJ	O
non-human	JJ	O
mammals	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
recombinant	JJ	O
genetic	JJ	O
material	NN	O
comprised	VBN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
RAGE	NNP	O
fused	VBD	O
to	TO	O
specific	JJ	O
promoters	NNS	O
capable	JJ	O
of	IN	O
expressing	VBG	O
the	DT	O
protein	NN	O
in	IN	O
specific	JJ	O
tissues	NNS	O
such	JJ	O
as	IN	O
nerve	NN	O
tissues	NNS	O
generally	RB	O
and/or	VBP	O
specific	JJ	O
types	NNS	O
of	IN	O
nerve	NN	O
tissue	NN	O
,	,	O
e.g.	NN	O
,	,	O
the	DT	O
brain	NN	O
.	.	O
As	IN	O
described	VBN	O
herein	NN	O
,	,	O
the	DT	O
current	JJ	O
invention	NN	O
provides	VBZ	O
a	DT	O
number	NN	O
of	IN	O
advantages	NNS	O
.	.	O
First	RB	O
,	,	O
because	IN	O
transgenic	JJ	O
animals	NNS	O
are	VBP	O
generally	RB	O
useful	JJ	O
for	IN	O
the	DT	O
investigation	NN	O
of	IN	O
specific	JJ	O
biological	JJ	O
processes	NNS	O
and	CC	O
for	IN	O
reproducing	VBG	O
particular	JJ	O
aspects	NNS	O
of	IN	O
human	JJ	O
disease	NN	O
,	,	O
the	DT	O
transgenic	JJ	O
animals	NNS	O
of	IN	O
the	DT	O
invention	NN	O
provide	VBP	O
an	DT	O
important	JJ	O
,	,	O
reproducible	JJ	O
and	CC	O
accurate	JJ	O
means	NNS	O
for	IN	O
screening	VBG	O
drugs	NNS	O
to	TO	O
isolate	VB	O
therapeutic	JJ	O
agents	NNS	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
the	DT	O
transgenic	JJ	O
animals	NNS	O
that	WDT	O
are	VBP	O
described	VBN	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
herein	NN	O
have	VBP	O
the	DT	O
advantage	NN	O
of	IN	O
mimicking	VBG	O
the	DT	O
defects	NNS	O
observed	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
.	.	O
Accordingly	RB	O
,	,	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
particular	JJ	O
therapy	NN	O
may	MD	O
be	VB	O
examined	VBN	O
in	IN	O
the	DT	O
same	JJ	O
animal	NN	O
at	IN	O
different	JJ	O
disease	NN	O
stages	NNS	O
.	.	O
Importantly	RB	O
,	,	O
because	IN	O
this	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
transgenic	JJ	O
animal	JJ	O
model	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
with	IN	O
measurable	JJ	O
phenotypes	NNS	O
,	,	O
compounds	NNS	O
may	MD	O
be	VB	O
screened	VBN	O
to	TO	O
identify	VB	O
those	DT	O
which	WDT	O
alleviate	VBP	O
this	DT	O
symptom	NN	O
,	,	O
even	RB	O
absent	JJ	O
knowledge	NN	O
of	IN	O
the	DT	O
symptom	NN	O
's	POS	O
underlying	JJ	O
biological	JJ	O
cause	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
although	IN	O
not	RB	O
strictly	RB	O
required	VBN	O
for	IN	O
drug	NN	O
screening	NN	O
,	,	O
the	DT	O
associated	VBN	O
neuro-pathological	JJ	O
symptoms	NNS	O
exhibited	VBN	O
by	IN	O
the	DT	O
transgenic	JJ	O
animal	NN	O
models	NNS	O
described	VBN	O
herein	JJ	O
provide	VBP	O
the	DT	O
unique	JJ	O
advantage	NN	O
of	IN	O
allowing	VBG	O
the	DT	O
investigation	NN	O
of	IN	O
the	DT	O
etiology	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
appearance	NN	O
of	IN	O
reduced	VBN	O
synaptic	JJ	O
plasticity	NN	O
or	CC	O
the	DT	O
reduced	VBN	O
basal	NN	O
synaptic	JJ	O
transmission	NN	O
may	MD	O
be	VB	O
correlated	VBN	O
with	IN	O
the	DT	O
appearance	NN	O
of	IN	O
specific	JJ	O
behavioral	JJ	O
impairments	NNS	O
within	IN	O
individuals	NNS	O
or	CC	O
groups	NNS	O
of	IN	O
animals	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
treatments	NNS	O
which	WDT	O
are	VBP	O
shown	VBN	O
to	TO	O
improve	VB	O
memory	NN	O
function	NN	O
may	MD	O
be	VB	O
tested	VBN	O
for	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
selectively	RB	O
improve	VB	O
certain	JJ	O
pathological	JJ	O
symptoms	NNS	O
.	.	O
Another	DT	O
advantage	NN	O
of	IN	O
this	DT	O
invention	NN	O
is	VBZ	O
the	DT	O
ease	NN	O
with	IN	O
which	WDT	O
these	DT	O
transgenic	JJ	O
animals	NNS	O
are	VBP	O
bred	VBN	O
to	TO	O
produce	VB	O
identical	JJ	O
transgenic	JJ	O
progeny	NN	O
.	.	O
The	DT	O
animals	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
generated	VBN	O
in	IN	O
sufficient	JJ	O
quantity	NN	O
to	TO	O
make	VB	O
them	PRP	O
widely	RB	O
and	CC	O
rapidly	RB	O
available	JJ	O
to	TO	O
researchers	NNS	O
in	IN	O
this	DT	O
field	NN	O
.	.	O
FURTHER	NNP	O
DETAILED	NNP	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
provides	VBZ	O
for	IN	O
a	DT	O
transgenic	JJ	O
nonhuman	NN	O
animal	NN	O
whose	WP$	O
germ	NN	O
or	CC	O
somatic	JJ	O
cells	NNS	O
contain	VBP	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
which	WDT	O
comprises	VBZ	O
:	:	O
(	(	O
a	DT	O
)	)	O
a	DT	O
neuronal	JJ	O
tissue	NN	O
specific	JJ	O
promoter	NN	O
operatively	RB	O
linked	VBN	O
to	TO	O
a	DT	O
DNA	NN	O
sequence	NN	O
encoding	VBG	O
a	DT	O
receptor	NN	O
for	IN	O
advanced	JJ	O
glycation	NN	O
endproduct	NN	O
(	(	O
RAGE	NNP	O
)	)	O
,	,	O
introduced	VBN	O
into	IN	O
the	DT	O
mammal	NN	O
,	,	O
or	CC	O
an	DT	O
ancestor	NN	O
thereof	NN	O
,	,	O
at	IN	O
an	DT	O
embryonic	JJ	O
stage	NN	O
.	.	O
This	DT	O
transgenic	JJ	O
animal	NN	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
screening	VBG	O
methods	NNS	O
for	IN	O
compounds	NNS	O
which	WDT	O
would	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
neurological	JJ	O
disorders	NNS	O
in	IN	O
humans	NNS	O
.	.	O
A	DT	O
method	NN	O
for	IN	O
screening	VBG	O
compounds	NNS	O
for	IN	O
their	PRP$	O
potential	JJ	O
use	NN	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
which	WDT	O
comprises	VBZ	O
administering	VBG	O
to	TO	O
the	DT	O
transgenic	JJ	O
non-human	JJ	O
mammal	NN	O
described	VBD	O
herein	PDT	O
the	DT	O
compound	NN	O
,	,	O
in	IN	O
various	JJ	O
amounts	NNS	O
,	,	O
and	CC	O
observing	VBG	O
whether	IN	O
the	DT	O
neurological	JJ	O
function	NN	O
of	IN	O
the	DT	O
transgenic	JJ	O
mammal	JJ	O
improves	NNS	O
or	CC	O
not	RB	O
(	(	O
as	IN	O
determined	VBN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
basal	NN	O
synaptic	JJ	O
transmission	NN	O
,	,	O
synaptic	JJ	O
plasticity	NN	O
,	,	O
neuronal	JJ	O
stress	NN	O
,	,	O
et	CC	O
al	RB	O
.	.	O
)	)	O
.	.	O
The	DT	O
neurological	JJ	O
disorder	NN	O
may	MD	O
be	VB	O
amnesia	JJ	O
,	,	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
,	,	O
amyotrophic	JJ	O
lateral	JJ	O
sclerosis	NN	O
,	,	O
a	DT	O
brain	NN	O
injury	NN	O
,	,	O
cerebral	JJ	O
senility	NN	O
,	,	O
chronic	JJ	O
peripheral	JJ	O
neuropathy	NN	O
,	,	O
a	DT	O
cognitive	JJ	O
disability	NN	O
,	,	O
a	DT	O
degenerative	JJ	O
disorder	NN	O
associated	VBN	O
with	IN	O
learning	NN	O
,	,	O
Down	NNP	O
's	POS	O
Syndrome	NNP	O
,	,	O
dyslexia	NN	O
,	,	O
electric	JJ	O
shock	NN	O
induced	VBD	O
amnesia	NN	O
or	CC	O
amnesia	NN	O
.	.	O
Guillain-Barre	JJ	O
syndrome	NN	O
,	,	O
head	NN	O
trauma	NN	O
,	,	O
Huntington	NNP	O
's	POS	O
disease	NN	O
,	,	O
a	DT	O
learning	JJ	O
disability	NN	O
,	,	O
a	DT	O
memory	NN	O
deficiency	NN	O
,	,	O
memory	NN	O
loss	NN	O
,	,	O
a	DT	O
mental	JJ	O
illness	NN	O
,	,	O
mental	JJ	O
retardation	NN	O
,	,	O
memory	NN	O
or	CC	O
cognitive	JJ	O
dysfunction	NN	O
,	,	O
multi-infarct	JJ	O
dementia	NN	O
and	CC	O
senile	JJ	O
dementia	NN	O
,	,	O
myasthenia	NN	O
gravis	NN	O
,	,	O
a	DT	O
neuromuscular	JJ	O
disorder	NN	O
,	,	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
,	,	O
Pick	NNP	O
's	POS	O
disease	NN	O
,	,	O
a	DT	O
reduction	NN	O
in	IN	O
spatial	JJ	O
memory	NN	O
retention	NN	O
,	,	O
senility	NN	O
,	,	O
or	CC	O
Turret	NNP	O
's	POS	O
syndrome	NN	O
.	.	O
The	DT	O
compound	NN	O
which	WDT	O
is	VBZ	O
tested	VBN	O
in	IN	O
the	DT	O
screening	NN	O
method	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
an	DT	O
organic	JJ	O
compound	NN	O
,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
,	,	O
a	DT	O
small	JJ	O
molecule	NN	O
,	,	O
an	DT	O
inorganic	JJ	O
compound	NN	O
,	,	O
a	DT	O
lipid	JJ	O
,	,	O
or	CC	O
a	DT	O
synthetic	JJ	O
compound	NN	O
.	.	O
The	DT	O
mammal	NN	O
may	MD	O
be	VB	O
a	DT	O
mouse	NN	O
,	,	O
a	DT	O
sheep	NN	O
,	,	O
a	DT	O
bovine	NN	O
,	,	O
a	DT	O
canine	NN	O
,	,	O
a	DT	O
porcine	NN	O
,	,	O
or	CC	O
a	DT	O
primate	NN	O
.	.	O
The	DT	O
administration	NN	O
may	MD	O
comprise	VB	O
intralesional	JJ	O
,	,	O
intraperitoneal	JJ	O
,	,	O
intramuscular	JJ	O
or	CC	O
intravenous	JJ	O
injection	NN	O
;	:	O
infusion	NN	O
;	:	O
liposome-mediated	JJ	O
delivery	NN	O
;	:	O
gene	NN	O
bombardment	NN	O
;	:	O
topical	JJ	O
,	,	O
nasal	JJ	O
,	,	O
oral	JJ	O
,	,	O
anal	JJ	O
,	,	O
ocular	JJ	O
or	CC	O
otic	JJ	O
delivery	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
provides	VBZ	O
for	IN	O
a	DT	O
method	NN	O
for	IN	O
alleviating	VBG	O
symptoms	NNS	O
in	IN	O
a	DT	O
subject	JJ	O
suffering	NN	O
from	IN	O
a	DT	O
neurological	JJ	O
disorder	NN	O
which	WDT	O
comprises	VBZ	O
administering	VBG	O
to	TO	O
the	DT	O
subject	NN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
compound	NN	O
evaluated	VBN	O
by	IN	O
the	DT	O
methods	NNS	O
hereinabove	VBP	O
in	IN	O
an	DT	O
amount	NN	O
effective	JJ	O
to	TO	O
treat	VB	O
the	DT	O
symptoms	NNS	O
in	IN	O
the	DT	O
subject	NN	O
suffering	VBG	O
from	IN	O
a	DT	O
neurological	JJ	O
disorder	NN	O
.	.	O
The	DT	O
administration	NN	O
may	MD	O
be	VB	O
intralesional	JJ	O
,	,	O
intraperitoneal	JJ	O
,	,	O
intramuscular	JJ	O
or	CC	O
intravenous	JJ	O
injection	NN	O
;	:	O
infusion	NN	O
;	:	O
liposome-mediated	JJ	O
delivery	NN	O
;	:	O
gene	NN	O
bombardment	NN	O
;	:	O
topical	JJ	O
,	,	O
nasal	JJ	O
,	,	O
oral	JJ	O
,	,	O
anal	JJ	O
,	,	O
ocular	JJ	O
or	CC	O
otic	JJ	O
delivery	NN	O
.	.	O
Pharmaceutical	JJ	O
Compositions	NNS	O
and	CC	O
Carriers	NNP	O
As	NNP	O
used	VBD	O
herein	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
suitable	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
”	JJ	O
encompasses	VBZ	O
any	DT	O
of	IN	O
the	DT	O
standard	NN	O
pharmaceutically	RB	O
accepted	VBD	O
carriers	NNS	O
,	,	O
such	JJ	O
as	IN	O
phosphate	NN	O
buffered	VBD	O
saline	JJ	O
solution	NN	O
,	,	O
water	NN	O
,	,	O
emulsions	NNS	O
such	JJ	O
as	IN	O
an	DT	O
oil/water	NN	O
emulsion	NN	O
or	CC	O
a	DT	O
triglyceride	JJ	O
emulsion	NN	O
,	,	O
various	JJ	O
types	NNS	O
of	IN	O
wetting	VBG	O
agents	NNS	O
,	,	O
tablets	NNS	O
,	,	O
coated	VBN	O
tablets	NNS	O
and	CC	O
capsules	NNS	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
an	DT	O
acceptable	JJ	O
triglyceride	NN	O
emulsion	NN	O
useful	JJ	O
in	IN	O
intravenous	JJ	O
and	CC	O
intraperitoneal	JJ	O
administration	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
is	VBZ	O
the	DT	O
triglyceride	JJ	O
emulsion	NN	O
commercially	RB	O
known	VBN	O
as	IN	O
Intralipid®	NNP	O
.	.	O
Typically	RB	O
such	JJ	O
carriers	NNS	O
contain	VBP	O
excipients	NNS	O
such	JJ	O
as	IN	O
starch	NN	O
,	,	O
milk	NN	O
,	,	O
sugar	NN	O
,	,	O
certain	JJ	O
types	NNS	O
of	IN	O
clay	NN	O
,	,	O
gelatin	NN	O
,	,	O
stearic	JJ	O
acid	NN	O
,	,	O
talc	NN	O
,	,	O
vegetable	JJ	O
fats	NNS	O
or	CC	O
oils	NNS	O
,	,	O
gums	NNS	O
,	,	O
glycols	NNS	O
,	,	O
or	CC	O
other	JJ	O
known	JJ	O
excipients	NNS	O
.	.	O
Such	JJ	O
carriers	NNS	O
may	MD	O
also	RB	O
include	VB	O
flavor	NN	O
and	CC	O
color	NN	O
additives	NNS	O
or	CC	O
other	JJ	O
ingredients	NNS	O
.	.	O
This	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
for	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
including	VBG	O
therapeutically	RB	O
effective	JJ	O
amounts	NNS	O
of	IN	O
protein	NN	O
compositions	NNS	O
and	CC	O
compounds	VBZ	O
together	RB	O
with	IN	O
suitable	JJ	O
diluents	NNS	O
,	,	O
preservatives	NNS	O
,	,	O
solubilizers	NNS	O
,	,	O
emulsifiers	NNS	O
,	,	O
adjuvants	NNS	O
and/or	VBP	O
carriers	NNS	O
useful	JJ	O
in	IN	O
treatment	NN	O
of	IN	O
neuronal	JJ	O
degradation	NN	O
due	JJ	O
to	TO	O
aging	VBG	O
,	,	O
a	DT	O
learning	JJ	O
disability	NN	O
,	,	O
or	CC	O
a	DT	O
neurological	JJ	O
disorder	NN	O
.	.	O
Such	JJ	O
compositions	NNS	O
are	VBP	O
liquids	NNS	O
or	CC	O
lyophilized	VBN	O
or	CC	O
otherwise	RB	O
dried	JJ	O
formulations	NNS	O
and	CC	O
include	VBP	O
diluents	NNS	O
of	IN	O
various	JJ	O
buffer	NN	O
content	NN	O
(	(	O
e.g.	JJ	O
,	,	O
Tris-HCl	NNP	O
,	,	O
acetate	NN	O
,	,	O
phosphate	NN	O
)	)	O
,	,	O
pH	NN	O
and	CC	O
ionic	JJ	O
strength	NN	O
,	,	O
additives	NNS	O
such	JJ	O
as	IN	O
albumin	NN	O
or	CC	O
gelatin	NN	O
to	TO	O
prevent	VB	O
absorption	NN	O
to	TO	O
surfaces	NNS	O
,	,	O
detergents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
Tween	NNP	O
20	CD	O
,	,	O
Tween	NNP	O
80	CD	O
,	,	O
Pluronic	NNP	O
F68	NNP	O
,	,	O
bile	JJ	O
acid	NN	O
salts	NNS	O
)	)	O
,	,	O
solubilizing	VBG	O
agents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
glycerol	NN	O
,	,	O
polyethylene	VB	O
glycerol	NN	O
)	)	O
,	,	O
anti-oxidants	NNS	O
(	(	O
e.g.	NN	O
,	,	O
ascorbic	JJ	O
acid	NN	O
,	,	O
sodium	NN	O
metabisulfite	NN	O
)	)	O
,	,	O
preservatives	NNS	O
(	(	O
e.g.	NN	O
,	,	O
Thimerosal	NNP	O
,	,	O
benzyl	NN	O
alcohol	NN	O
,	,	O
parabens	NNS	O
)	)	O
,	,	O
bulking	VBG	O
substances	NNS	O
or	CC	O
tonicity	NN	O
modifiers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
lactose	RB	O
,	,	O
mannitol	NN	O
)	)	O
,	,	O
covalent	JJ	O
attachment	NN	O
of	IN	O
polymers	NNS	O
such	JJ	O
as	IN	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
the	DT	O
compound	NN	O
,	,	O
complexation	NN	O
with	IN	O
metal	JJ	O
ions	NNS	O
,	,	O
or	CC	O
incorporation	NN	O
of	IN	O
the	DT	O
compound	NN	O
into	IN	O
or	CC	O
onto	IN	O
particulate	JJ	O
preparations	NNS	O
of	IN	O
polymeric	JJ	O
compounds	NNS	O
such	JJ	O
as	IN	O
polylactic	JJ	O
acid	NN	O
,	,	O
polglycolic	JJ	O
acid	NN	O
,	,	O
hydrogels	NNS	O
,	,	O
etc	FW	O
,	,	O
or	CC	O
onto	IN	O
liposomes	NNS	O
,	,	O
micro	JJ	O
emulsions	NNS	O
,	,	O
micelles	NNS	O
,	,	O
unilamellar	JJ	O
or	CC	O
multi	JJ	O
lamellar	JJ	O
vesicles	NNS	O
,	,	O
erythrocyte	JJ	O
ghosts	NNS	O
,	,	O
or	CC	O
spheroplasts	NNS	O
.	.	O
Such	JJ	O
compositions	NNS	O
will	MD	O
influence	VB	O
the	DT	O
physical	JJ	O
state	NN	O
,	,	O
solubility	NN	O
,	,	O
stability	NN	O
,	,	O
rate	NN	O
of	IN	O
in	IN	O
vivo	NN	O
release	NN	O
,	,	O
and	CC	O
rate	NN	O
of	IN	O
in	IN	O
vivo	JJ	O
clearance	NN	O
of	IN	O
the	DT	O
compound	NN	O
or	CC	O
composition	NN	O
.	.	O
The	DT	O
choice	NN	O
of	IN	O
compositions	NNS	O
will	MD	O
depend	VB	O
on	IN	O
the	DT	O
physical	JJ	O
and	CC	O
chemical	JJ	O
properties	NNS	O
of	IN	O
the	DT	O
compound	NN	O
.	.	O
Controlled	VBN	O
or	CC	O
sustained	VBN	O
release	NN	O
compositions	NNS	O
include	VBP	O
formulation	NN	O
in	IN	O
lipophilic	JJ	O
depots	NNS	O
(	(	O
e.g.	NN	O
,	,	O
fatty	JJ	O
acids	NNS	O
,	,	O
waxes	NNS	O
,	,	O
oils	NNS	O
)	)	O
.	.	O
Also	RB	O
comprehended	VBN	O
by	IN	O
the	DT	O
invention	NN	O
are	VBP	O
particulate	JJ	O
compositions	NNS	O
coated	VBN	O
with	IN	O
polymers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
poloxamers	NNS	O
or	CC	O
poloxamines	NNS	O
)	)	O
and	CC	O
the	DT	O
compound	NN	O
coupled	VBD	O
to	TO	O
antibodies	NNS	O
directed	VBN	O
against	IN	O
tissue-specific	JJ	O
receptors	NNS	O
,	,	O
ligands	VBZ	O
or	CC	O
antigens	VBZ	O
or	CC	O
coupled	VBN	O
to	TO	O
ligands	NNS	O
of	IN	O
tissue-specific	JJ	O
receptors	NNS	O
.	.	O
Other	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
incorporate	NN	O
particulate	NN	O
forms	NNS	O
protective	JJ	O
coatings	NNS	O
,	,	O
protease	NN	O
inhibitors	NNS	O
or	CC	O
permeation	NN	O
enhancers	NNS	O
for	IN	O
various	JJ	O
routes	NNS	O
of	IN	O
administration	NN	O
,	,	O
including	VBG	O
parenteral	JJ	O
,	,	O
pulmonary	JJ	O
,	,	O
nasal	JJ	O
and	CC	O
oral	JJ	O
.	.	O
Portions	NNS	O
of	IN	O
the	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
“	NNP	O
labeled	VBN	O
”	NNP	O
by	IN	O
association	NN	O
with	IN	O
a	DT	O
detectable	JJ	O
marker	NN	O
substance	NN	O
(	(	O
e.g.	JJ	O
,	,	O
radiolabeled	VBD	O
with	IN	O
125I	CD	O
or	CC	O
biotinylated	VBN	O
)	)	O
to	TO	O
provide	VB	O
reagents	NNS	O
useful	JJ	O
in	IN	O
detection	NN	O
and	CC	O
quantification	NN	O
of	IN	O
compound	NN	O
or	CC	O
its	PRP$	O
receptor	NN	O
bearing	NN	O
cells	NNS	O
or	CC	O
its	PRP$	O
derivatives	NNS	O
in	IN	O
solid	JJ	O
tissue	NN	O
and	CC	O
fluid	NN	O
samples	NNS	O
such	JJ	O
as	IN	O
blood	NN	O
,	,	O
cerebral	JJ	O
spinal	JJ	O
fluid	NN	O
or	CC	O
urine	NN	O
.	.	O
When	WRB	O
administered	VBN	O
,	,	O
compounds	NNS	O
are	VBP	O
often	RB	O
cleared	VBN	O
rapidly	RB	O
from	IN	O
the	DT	O
circulation	NN	O
and	CC	O
may	MD	O
therefore	VB	O
elicit	JJ	O
relatively	RB	O
short-lived	JJ	O
pharmacological	JJ	O
activity	NN	O
.	.	O
Consequently	RB	O
,	,	O
frequent	JJ	O
injections	NNS	O
of	IN	O
relatively	RB	O
large	JJ	O
doses	NNS	O
of	IN	O
bioactive	JJ	O
compounds	NNS	O
may	MD	O
by	IN	O
required	VBN	O
to	TO	O
sustain	VB	O
therapeutic	JJ	O
efficacy	NN	O
.	.	O
Compounds	NNS	O
modified	VBN	O
by	IN	O
the	DT	O
covalent	JJ	O
attachment	NN	O
of	IN	O
water-soluble	JJ	O
polymers	NNS	O
such	JJ	O
as	IN	O
polyethylene	NN	O
glycol	NN	O
,	,	O
copolymers	NNS	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
and	CC	O
polypropylene	NN	O
glycol	NN	O
,	,	O
carboxymethyl	NN	O
cellulose	NN	O
,	,	O
dextran	NN	O
,	,	O
polyvinyl	NN	O
alcohol	NN	O
,	,	O
polyvinylpyrrolidone	NN	O
or	CC	O
polyproline	NN	O
are	VBP	O
known	VBN	O
to	TO	O
exhibit	VB	O
substantially	RB	O
longer	JJR	O
half-lives	NNS	O
in	IN	O
blood	NN	O
following	VBG	O
intravenous	JJ	O
injection	NN	O
than	IN	O
do	VB	O
the	DT	O
corresponding	NN	O
unmodified	JJ	O
compounds	NNS	O
(	(	O
Abuchowski	NNP	B
et	RB	I
al.	RB	I
,	,	I
1981	CD	I
;	:	O
Newmark	NNP	B
et	FW	I
al.	NN	I
,	,	I
1982	CD	I
;	:	O
and	CC	O
Katre	NNP	B
et	VBP	I
al.	NN	I
,	,	I
1987	CD	I
)	)	O
.	.	O
Such	JJ	O
modifications	NNS	O
may	MD	O
also	RB	O
increase	VB	O
the	DT	O
compound	NN	O
's	POS	O
solubility	NN	O
in	IN	O
aqueous	JJ	O
solution	NN	O
,	,	O
eliminate	VB	O
aggregation	NN	O
,	,	O
enhance	VB	O
the	DT	O
physical	JJ	O
and	CC	O
chemical	JJ	O
stability	NN	O
of	IN	O
the	DT	O
compound	NN	O
,	,	O
and	CC	O
greatly	RB	O
reduce	VB	O
the	DT	O
immunogenicity	NN	O
and	CC	O
reactivity	NN	O
of	IN	O
the	DT	O
compound	NN	O
.	.	O
As	IN	O
a	DT	O
result	NN	O
,	,	O
the	DT	O
desired	VBN	O
in	IN	O
vivo	JJ	O
biological	JJ	O
activity	NN	O
may	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
the	DT	O
administration	NN	O
of	IN	O
such	JJ	O
polymer-compound	JJ	O
adducts	NNS	O
less	RBR	O
frequently	RB	O
or	CC	O
in	IN	O
lower	JJR	O
doses	NNS	O
than	IN	O
with	IN	O
the	DT	O
unmodified	JJ	O
compound	NN	O
.	.	O
Attachment	NN	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
to	TO	O
compounds	NNS	O
is	VBZ	O
particularly	RB	O
useful	JJ	O
because	IN	O
PEG	NNP	O
has	VBZ	O
very	RB	O
low	JJ	O
toxicity	NN	O
in	IN	O
mammals	NNS	O
(	(	O
Carpenter	NNP	B
et	RB	I
al.	RB	I
,	,	I
1971	CD	I
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
PEG	NNP	O
adduct	NN	O
of	IN	O
adenosine	JJ	O
deaminase	NN	O
was	VBD	O
approved	VBN	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
for	IN	O
use	NN	O
in	IN	O
humans	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
severe	JJ	O
combined	VBN	O
immunodeficiency	NN	O
syndrome	NN	O
.	.	O
A	DT	O
second	JJ	O
advantage	NN	O
afforded	VBN	O
by	IN	O
the	DT	O
conjugation	NN	O
of	IN	O
PEG	NNP	O
is	VBZ	O
that	IN	O
of	IN	O
effectively	RB	O
reducing	VBG	O
the	DT	O
immunogenicity	NN	O
and	CC	O
antigenicity	NN	O
of	IN	O
heterologous	JJ	O
compounds	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
PEG	NNP	O
adduct	NN	O
of	IN	O
a	DT	O
human	JJ	O
protein	NN	O
might	MD	O
be	VB	O
useful	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
disease	NN	O
in	IN	O
other	JJ	O
mammalian	JJ	O
species	NNS	O
without	IN	O
the	DT	O
risk	NN	O
of	IN	O
triggering	VBG	O
a	DT	O
severe	JJ	O
immune	JJ	O
response	NN	O
.	.	O
The	DT	O
compound	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
capable	NN	O
of	IN	O
alleviating	VBG	O
symptoms	NNS	O
of	IN	O
a	DT	O
cognitive	JJ	O
disorder	NN	O
of	IN	O
memory	NN	O
or	CC	O
learning	NN	O
may	MD	O
be	VB	O
delivered	VBN	O
in	IN	O
a	DT	O
microencapsulation	NN	O
device	NN	O
so	RB	O
as	IN	O
to	TO	O
reduce	VB	O
or	CC	O
prevent	VB	O
an	DT	O
host	NN	O
immune	JJ	O
response	NN	O
against	IN	O
the	DT	O
compound	NN	O
or	CC	O
against	IN	O
cells	NNS	O
which	WDT	O
may	MD	O
produce	VB	O
the	DT	O
compound	NN	O
.	.	O
The	DT	O
compound	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
delivered	VBN	O
microencapsulated	VBN	O
in	IN	O
a	DT	O
membrane	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
liposome	NN	O
.	.	O
Polymers	NNS	O
such	JJ	O
as	IN	O
PEG	NNP	O
may	MD	O
be	VB	O
conveniently	RB	O
attached	VBN	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
reactive	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
in	IN	O
a	DT	O
protein	NN	O
such	JJ	O
as	IN	O
the	DT	O
alpha-amino	JJ	O
group	NN	O
of	IN	O
the	DT	O
amino	JJ	O
terminal	JJ	O
amino	NN	O
acid	NN	O
,	,	O
the	DT	O
epsilon	NN	O
amino	NN	O
groups	NNS	O
of	IN	O
lysine	JJ	O
side	NN	O
chains	NNS	O
,	,	O
the	DT	O
sulfhydryl	NN	O
groups	NNS	O
of	IN	O
cysteine	JJ	O
side	NN	O
chains	NNS	O
,	,	O
the	DT	O
carboxyl	NN	O
groups	NNS	O
of	IN	O
aspartyl	NN	O
and	CC	O
glutamyl	JJ	O
side	NN	O
chains	NNS	O
,	,	O
the	DT	O
alpha-carboxyl	JJ	O
group	NN	O
of	IN	O
the	DT	O
carboxy-terminal	JJ	O
amino	NN	O
acid	NN	O
,	,	O
tyrosine	JJ	O
side	NN	O
chains	NNS	O
,	,	O
or	CC	O
to	TO	O
activated	VBN	O
derivatives	NNS	O
of	IN	O
glycosyl	NN	O
chains	NNS	O
attached	VBN	O
to	TO	O
certain	JJ	O
asparagine	NN	O
,	,	O
serine	NN	O
or	CC	O
threonine	NN	O
residues	NNS	O
.	.	O
Numerous	JJ	O
activated	VBD	O
forms	NNS	O
of	IN	O
PEG	NNP	O
suitable	JJ	O
for	IN	O
direct	JJ	O
reaction	NN	O
with	IN	O
proteins	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
.	.	O
Useful	JJ	O
PEG	NNP	O
reagents	NNS	O
for	IN	O
reaction	NN	O
with	IN	O
protein	NN	O
amino	NN	O
groups	NNS	O
include	VBP	O
active	JJ	O
esters	NNS	O
of	IN	O
carboxylic	JJ	O
acid	NN	O
or	CC	O
carbonate	NN	O
derivatives	NNS	O
,	,	O
particularly	RB	O
those	DT	O
in	IN	O
which	WDT	O
the	DT	O
leaving	VBG	O
groups	NNS	O
are	VBP	O
N-hydroxysuccinimide	JJ	O
,	,	O
p-nitrophenol	JJ	O
,	,	O
imidazole	JJ	O
or	CC	O
1-hydroxy-2-nitrobenzene-4-sulfonate	JJ	O
.	.	O
PEG	NNP	O
derivatives	NNS	O
containing	VBG	O
maleimido	NN	O
or	CC	O
haloacetyl	NN	O
groups	NNS	O
are	VBP	O
useful	JJ	O
reagents	NNS	O
for	IN	O
the	DT	O
modification	NN	O
of	IN	O
protein	JJ	O
free	JJ	O
sulfhydryl	NN	O
groups	NNS	O
.	.	O
Likewise	RB	O
,	,	O
PEG	NNP	O
reagents	VBZ	O
containing	VBG	O
amino	RP	O
hydrazine	NN	O
or	CC	O
hydrazide	NN	O
groups	NNS	O
are	VBP	O
useful	JJ	O
for	IN	O
reaction	NN	O
with	IN	O
aldehydes	NNS	O
generated	VBN	O
by	IN	O
periodate	JJ	O
oxidation	NN	O
of	IN	O
carbohydrate	NN	O
groups	NNS	O
in	IN	O
proteins	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
compound	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
pharmaceutical	JJ	O
carrier	NN	O
which	WDT	O
includes	VBZ	O
a	DT	O
pharmaceutical	JJ	O
composition	NN	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
carrier	NN	O
may	MD	O
be	VB	O
a	DT	O
liquid	NN	O
and	CC	O
the	DT	O
pharmaceutical	JJ	O
composition	NN	O
would	MD	O
be	VB	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
solution	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
is	VBZ	O
a	DT	O
solid	JJ	O
and	CC	O
the	DT	O
composition	NN	O
is	VBZ	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
powder	NN	O
or	CC	O
tablet	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
pharmaceutical	JJ	O
carrier	NN	O
is	VBZ	O
a	DT	O
gel	NN	O
and	CC	O
the	DT	O
composition	NN	O
is	VBZ	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
suppository	NN	O
or	CC	O
cream	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
the	DT	O
active	JJ	O
ingredient	NN	O
may	MD	O
be	VB	O
formulated	VBN	O
as	IN	O
a	DT	O
part	NN	O
of	IN	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
transdermal	JJ	O
patch	NN	O
.	.	O
Transgenic	NNP	O
Technology	NNP	O
and	CC	O
Methods	NNP	O
The	DT	O
following	JJ	O
U.S.	NNP	O
patents	NNS	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
:	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,025,539	CD	O
,	,	O
IL-5	NNP	O
transgenic	NN	O
mouse	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,023,010	CD	O
,	,	O
Transgenic	NNP	O
non-human	JJ	O
animals	NNS	O
depleted	VBN	O
in	IN	O
a	DT	O
mature	JJ	O
lymphocytic	JJ	O
cell-type	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,018,098	CD	O
,	,	O
In	IN	O
vivo	NN	O
and	CC	O
in	IN	O
vitro	JJ	O
model	NN	O
of	IN	O
cutaneous	JJ	O
photoaging	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,018,097	CD	O
,	,	O
Transgenic	NNP	O
mice	NN	O
expressing	VBG	O
human	JJ	O
insulin	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,008,434	CD	O
,	,	O
Growth	NNP	O
differentiation	NN	O
factor-11	NN	O
transgenic	JJ	O
mice	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,002,066	CD	O
;	:	O
H2-M	NNP	O
modified	VBD	O
transgenic	JJ	O
mice	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,994,618	CD	O
,	,	O
Growth	NNP	O
differentiation	NN	O
factor-8	NN	O
transgenic	JJ	O
mice	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,986,171	CD	O
,	,	O
Method	NNP	O
for	IN	O
examining	VBG	O
neurovirulence	NN	O
of	IN	O
polio	NN	O
virus	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,981,830	CD	O
,	,	O
Knockout	NNP	O
mice	NN	O
and	CC	O
their	PRP$	O
progeny	NN	O
with	IN	O
a	DT	O
disrupted	VBN	O
hepsin	NN	O
gene	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,981,829	CD	O
,	,	O
.DELTA.Nur77	NNP	O
transgenic	NNP	O
mouse	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,936,138	CD	O
;	:	O
Gene	NNP	O
encoding	VBG	O
mutant	JJ	O
L3T4	NNP	O
protein	NN	O
which	WDT	O
facilitates	VBZ	O
HIV	NNP	O
infection	NN	O
and	CC	O
transgenic	JJ	O
mouse	NN	O
expressing	VBG	O
such	JJ	O
protein	NNS	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,912,411	CD	O
,	,	O
Mice	NNP	O
transgenic	NN	O
for	IN	O
a	DT	O
tetracycline-inducible	JJ	O
transcriptional	JJ	O
activator	NN	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,894,078	CD	O
,	,	O
Transgenic	NNP	O
mouse	NN	O
expressing	VBG	O
C-100	NNP	O
app	NN	O
.	.	O
The	DT	O
methods	NNS	O
used	VBN	O
for	IN	O
generating	VBG	O
transgenic	JJ	O
mice	NN	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
one	CD	O
may	MD	O
use	VB	O
the	DT	O
manual	JJ	O
entitled	VBD	O
“	JJ	B
Manipulating	VBG	I
the	DT	I
Mouse	NNP	I
Embryo	NNP	I
”	NNP	I
by	IN	I
Brigid	NNP	I
Hogan	NNP	I
et	FW	I
al	NN	I
.	.	I
(	(	I
Ed	NNP	I
.	.	I
Cold	JJ	I
Spring	NN	I
Harbor	NNP	I
Laboratory	NNP	I
)	)	I
1986	CD	I
.	.	O
See	VB	O
for	IN	O
example	NN	O
,	,	O
Leder	NNP	O
and	CC	O
Stewart	NNP	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,736,866	CD	O
for	IN	O
methods	NNS	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
transgenic	JJ	O
mouse	NN	O
.	.	O
For	IN	O
sometime	NN	O
it	PRP	O
has	VBZ	O
been	VBN	O
known	VBN	O
that	IN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
carry	VB	O
out	RP	O
the	DT	O
genetic	JJ	O
transformation	NN	O
of	IN	O
a	DT	O
zygote	NN	O
(	(	O
and	CC	O
the	DT	O
embryo	NN	O
and	CC	O
mature	NN	O
organism	NN	O
which	WDT	O
result	VBP	O
therefrom	NN	O
)	)	O
by	IN	O
the	DT	O
placing	NN	O
or	CC	O
insertion	NN	O
of	IN	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
into	IN	O
the	DT	O
nucleus	NN	O
of	IN	O
the	DT	O
zygote	NN	O
or	CC	O
to	TO	O
any	DT	O
nucleic	JJ	O
genetic	JJ	O
material	NN	O
which	WDT	O
ultimately	RB	O
forms	VBZ	O
a	DT	O
part	NN	O
of	IN	O
the	DT	O
nucleus	NN	O
of	IN	O
the	DT	O
zygote	NN	O
.	.	O
The	DT	O
genotype	NN	O
of	IN	O
the	DT	O
zygote	NN	O
and	CC	O
the	DT	O
organism	NN	O
which	WDT	O
results	NNS	O
from	IN	O
a	DT	O
zygote	NN	O
will	MD	O
include	VB	O
the	DT	O
genotype	NN	O
of	IN	O
the	DT	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
.	.	O
Additionally	RB	O
,	,	O
the	DT	O
inclusion	NN	O
of	IN	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
in	IN	O
the	DT	O
zygote	NN	O
will	MD	O
result	VB	O
in	IN	O
a	DT	O
phenotype	JJ	O
expression	NN	O
of	IN	O
the	DT	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
.	.	O
The	DT	O
genotype	NN	O
of	IN	O
the	DT	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
is	VBZ	O
expressed	VBN	O
upon	IN	O
the	DT	O
cellular	JJ	O
division	NN	O
of	IN	O
the	DT	O
zygote	NN	O
.	.	O
However	RB	O
,	,	O
the	DT	O
phenotype	NN	O
expression	NN	O
,	,	O
e.g.	NN	O
,	,	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
protein	JJ	O
product	NN	O
or	CC	O
products	NNS	O
of	IN	O
the	DT	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
,	,	O
or	CC	O
alterations	NNS	O
of	IN	O
the	DT	O
zygote	NN	O
's	POS	O
or	CC	O
organism	NN	O
's	POS	O
natural	JJ	O
phenotype	NN	O
,	,	O
will	MD	O
occur	VB	O
at	IN	O
that	DT	O
point	NN	O
of	IN	O
the	DT	O
zygote	NN	O
's	POS	O
or	CC	O
organism	NN	O
's	POS	O
development	NN	O
during	IN	O
which	WDT	O
the	DT	O
particular	JJ	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
is	VBZ	O
active	JJ	O
.	.	O
Alterations	NNS	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
include	VBP	O
an	DT	O
enhancement	NN	O
or	CC	O
diminution	NN	O
in	IN	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
phenotype	NN	O
or	CC	O
an	DT	O
alteration	NN	O
in	IN	O
the	DT	O
promotion	NN	O
and/or	VBZ	O
control	NN	O
of	IN	O
a	DT	O
phenotype	NN	O
,	,	O
including	VBG	O
the	DT	O
addition	NN	O
of	IN	O
a	DT	O
new	JJ	O
promoter	NN	O
and/or	VBP	O
controller	NN	O
or	CC	O
supplementation	NN	O
of	IN	O
an	DT	O
existing	VBG	O
promoter	NN	O
and/or	JJ	O
controller	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
.	.	O
The	DT	O
genetic	JJ	O
transformation	NN	O
of	IN	O
various	JJ	O
types	NNS	O
of	IN	O
organisms	NN	O
is	VBZ	O
disclosed	VBN	O
and	CC	O
described	VBN	O
in	IN	O
detail	NN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,873,191	CD	O
,	,	O
issued	VBN	O
Oct.	NNP	O
10	CD	O
,	,	O
1989	CD	O
,	,	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
to	TO	O
disclose	VB	O
methods	NNS	O
of	IN	O
producing	VBG	O
transgenic	JJ	O
organisms	NNS	O
.	.	O
The	DT	O
genetic	JJ	O
transformation	NN	O
of	IN	O
organisms	NNS	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
in	IN	O
vivo	JJ	O
analysis	NN	O
of	IN	O
gene	NN	O
expression	NN	O
during	IN	O
differentiation	NN	O
and	CC	O
in	IN	O
the	DT	O
elimination	NN	O
or	CC	O
diminution	NN	O
of	IN	O
genetic	JJ	O
diseases	NNS	O
by	IN	O
either	DT	O
gene	NN	O
therapy	NN	O
or	CC	O
by	IN	O
using	VBG	O
a	DT	O
transgenic	JJ	O
non-human	JJ	O
mammal	NN	O
as	IN	O
a	DT	O
model	NN	O
system	NN	O
of	IN	O
a	DT	O
human	JJ	O
disease	NN	O
.	.	O
This	DT	O
model	NN	O
system	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
test	VB	O
putative	JJ	O
drugs	NNS	O
for	IN	O
their	PRP$	O
potential	JJ	O
therapeutic	JJ	O
value	NN	O
in	IN	O
humans	NNS	O
.	.	O
The	DT	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
can	MD	O
be	VB	O
placed	VBN	O
in	IN	O
the	DT	O
nucleus	NN	O
of	IN	O
a	DT	O
mature	NN	O
egg	NN	O
.	.	O
It	PRP	O
is	VBZ	O
preferred	VBN	O
that	IN	O
the	DT	O
egg	NN	O
be	VB	O
in	IN	O
a	DT	O
fertilized	JJ	O
or	CC	O
activated	VBN	O
(	(	O
by	IN	O
parthenogenesis	NN	O
)	)	O
state	NN	O
.	.	O
After	IN	O
the	DT	O
addition	NN	O
of	IN	O
the	DT	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
,	,	O
a	DT	O
complementary	JJ	O
haploid	NN	O
set	NN	O
of	IN	O
chromosomes	NNS	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
sperm	NN	O
cell	NN	O
or	CC	O
polar	JJ	O
body	NN	O
)	)	O
is	VBZ	O
added	VBN	O
to	TO	O
enable	VB	O
the	DT	O
formation	NN	O
of	IN	O
a	DT	O
zygote	NN	O
.	.	O
The	DT	O
zygote	NN	O
is	VBZ	O
allowed	VBN	O
to	TO	O
develop	VB	O
into	IN	O
an	DT	O
organism	NN	O
such	JJ	O
as	IN	O
by	IN	O
implanting	VBG	O
it	PRP	O
in	IN	O
a	DT	O
pseudopregnant	JJ	O
female	NN	O
.	.	O
The	DT	O
resulting	VBG	O
organism	NN	O
is	VBZ	O
analyzed	VBN	O
for	IN	O
the	DT	O
integration	NN	O
of	IN	O
the	DT	O
exogenous	JJ	O
genetic	JJ	O
material	NN	O
.	.	O
If	IN	O
positive	JJ	O
integration	NN	O
is	VBZ	O
determined	VBN	O
,	,	O
the	DT	O
organism	NN	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
in	IN	O
vivo	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
gene	NN	O
expression	NN	O
,	,	O
which	WDT	O
expression	NN	O
is	VBZ	O
believed	VBN	O
to	TO	O
be	VB	O
related	VBN	O
to	TO	O
a	DT	O
particular	JJ	O
genetic	JJ	O
disease	NN	O
.	.	O
Attempts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
study	VB	O
a	DT	O
number	NN	O
of	IN	O
different	JJ	O
types	NNS	O
of	IN	O
genetic	JJ	O
diseases	NNS	O
utilizing	VBG	O
such	JJ	O
transgenic	JJ	O
animals	NNS	O
.	.	O
Attempts	NNS	O
related	VBN	O
to	TO	O
studying	VBG	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
are	VBP	O
disclosed	VBN	O
within	IN	O
published	VBN	O
PCT	NNP	O
application	NN	O
WO89/06689	NNP	O
and	CC	O
PCT	NNP	O
application	NN	O
WO89/06693	NNP	O
,	,	O
both	DT	O
published	VBN	O
on	IN	O
Jul	NNP	O
.	.	O
27	CD	O
,	,	O
1989	CD	O
,	,	O
which	WDT	O
published	VBD	O
applications	NNS	O
are	VBP	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
to	TO	O
disclose	VB	O
genetic	JJ	O
sequences	NNS	O
coding	VBG	O
for	IN	O
Alzheimer	NNP	O
's	POS	O
.beta.-amyloid	JJ	O
protein	NN	O
and	CC	O
the	DT	O
incorporation	NN	O
of	IN	O
such	JJ	O
sequences	NNS	O
into	IN	O
the	DT	O
genome	NN	O
of	IN	O
transgenic	JJ	O
animals	NNS	O
.	.	O
Embryonal	NNP	O
target	NN	O
cells	NNS	O
at	IN	O
various	JJ	O
developmental	JJ	O
stages	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
introduce	VB	O
transgenes	NNS	O
.	.	O
Different	JJ	O
methods	NNS	O
are	VBP	O
used	VBN	O
depending	VBG	O
on	IN	O
the	DT	O
stage	NN	O
of	IN	O
development	NN	O
of	IN	O
the	DT	O
embryonal	JJ	O
target	NN	O
cell	NN	O
.	.	O
The	DT	O
zygote	NN	O
is	VBZ	O
the	DT	O
best	JJS	O
target	NN	O
for	IN	O
micro-injection	NN	O
.	.	O
In	IN	O
the	DT	O
mouse	NN	O
,	,	O
the	DT	O
male	NN	O
pronucleus	NN	O
reaches	VBZ	O
the	DT	O
size	NN	O
of	IN	O
approximately	RB	O
20	CD	O
micrometers	NNS	O
in	IN	O
diameter	NN	O
which	WDT	O
allows	VBZ	O
reproducible	JJ	O
injection	NN	O
of	IN	O
1-2	JJ	O
pl	NN	O
of	IN	O
DNA	NNP	O
solution	NN	O
.	.	O
The	DT	O
use	NN	O
of	IN	O
zygotes	NNS	O
as	IN	O
a	DT	O
target	NN	O
for	IN	O
gene	NN	O
transfer	NN	O
has	VBZ	O
a	DT	O
major	JJ	O
advantage	NN	O
in	IN	O
that	DT	O
in	IN	O
most	JJS	O
cases	NNS	O
the	DT	O
injected	JJ	O
DNA	NNP	O
will	MD	O
be	VB	O
incorporated	VBN	O
into	IN	O
the	DT	O
host	NN	O
gene	NN	O
before	IN	O
the	DT	O
first	JJ	O
cleavage	NN	O
(	(	O
Brinster	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1985	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
82	CD	I
,	,	I
4438-4442	JJ	I
)	)	O
.	.	O
As	IN	O
a	DT	O
consequence	NN	O
,	,	O
all	DT	O
cells	NNS	O
of	IN	O
the	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
will	MD	O
carry	VB	O
the	DT	O
incorporated	JJ	O
transgene	NN	O
.	.	O
This	DT	O
will	MD	O
in	IN	O
general	JJ	O
also	RB	O
be	VB	O
reflected	VBN	O
in	IN	O
the	DT	O
efficient	JJ	O
transmission	NN	O
of	IN	O
the	DT	O
transgene	NN	O
to	TO	O
offspring	NN	O
of	IN	O
the	DT	O
founder	NN	O
since	IN	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
germ	NN	O
cells	NNS	O
will	MD	O
harbor	VB	O
the	DT	O
transgene	NN	O
.	.	O
Microinjection	NN	O
of	IN	O
zygotes	NNS	O
is	VBZ	O
the	DT	O
preferred	JJ	O
method	NN	O
for	IN	O
incorporating	VBG	O
transgenes	NNS	O
in	IN	O
practicing	VBG	O
the	DT	O
invention	NN	O
.	.	O
Retroviral	JJ	O
infection	NN	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
introduce	VB	O
transgene	NN	O
into	IN	O
a	DT	O
non-human	JJ	O
animal	NN	O
.	.	O
The	DT	O
developing	VBG	O
non-human	JJ	O
embryo	NN	O
can	MD	O
be	VB	O
cultured	VBN	O
in	IN	O
vitro	NN	O
to	TO	O
the	DT	O
blastocyst	NN	O
stage	NN	O
.	.	O
During	IN	O
this	DT	O
time	NN	O
,	,	O
the	DT	O
blastomeres	NNS	O
can	MD	O
be	VB	O
targets	NNS	O
for	IN	O
retroviral	JJ	O
infection	NN	O
(	(	O
Jaenich	NNP	B
,	,	I
R.	NNP	I
(	(	I
1976	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
U.S.A.	NNP	I
73	CD	I
,	,	I
1260-1264	JJ	I
)	)	O
.	.	O
Efficient	JJ	O
infection	NN	O
of	IN	O
the	DT	O
blastomeres	NNS	O
is	VBZ	O
obtained	VBN	O
by	IN	O
enzymatic	JJ	O
treatment	NN	O
to	TO	O
remove	VB	O
the	DT	O
zona	NN	O
pellucida	NN	O
(	(	O
Hogan	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1986	CD	I
)	)	I
in	IN	I
Manipulating	VBG	I
the	DT	I
Mouse	NNP	I
Embryo	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
Laboratory	NNP	I
Press	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
,	,	I
N.Y.	NNP	I
)	)	I
.	.	O
The	DT	O
viral	JJ	O
vector	NN	O
system	NN	O
used	VBN	O
to	TO	O
introduce	VB	O
the	DT	O
transgene	NN	O
is	VBZ	O
typically	RB	O
a	DT	O
replication-defective	JJ	O
retrovirus	NN	O
carrying	VBG	O
the	DT	O
transgene	NN	O
(	(	O
Jahner	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1985	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
82	CD	I
,	,	I
6927-6931	JJ	I
;	:	O
Van	NNP	B
der	NN	I
Putten	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1985	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
U.S.A.	NNP	I
82	CD	I
,	,	I
6148-6152	JJ	I
)	)	O
.	.	O
Transfection	NN	O
is	VBZ	O
easily	RB	O
and	CC	O
efficiently	RB	O
obtained	VBN	O
by	IN	O
culturing	VBG	O
the	DT	O
blastomeres	NNS	O
on	IN	O
a	DT	O
monolayer	NN	O
of	IN	O
virus-producing	JJ	O
cells	NNS	O
(	(	O
Van	NNP	B
der	NN	I
Putten	NNP	I
,	,	I
supra	NN	I
;	:	O
Stewart	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1987	CD	I
)	)	I
EMBO	NNP	I
J	NNP	I
.	.	I
6	CD	I
,	,	I
383-388	JJ	I
)	)	O
.	.	O
Alternatively	RB	O
,	,	O
infection	NN	O
can	MD	O
be	VB	O
performed	VBN	O
at	IN	O
a	DT	O
later	JJ	O
stage	NN	O
.	.	O
Virus	NNP	O
or	CC	O
virus-producing	JJ	O
cells	NNS	O
can	MD	O
be	VB	O
injected	VBN	O
into	IN	O
the	DT	O
blastocoele	NN	O
(	(	O
Jahner	NNP	B
,	,	I
D.	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1982	CD	I
)	)	I
Nature	NN	I
298	CD	I
,	,	I
623-628	JJ	I
)	)	O
.	.	O
Most	JJS	O
of	IN	O
the	DT	O
founders	NNS	O
will	MD	O
be	VB	O
mosaic	VBN	O
for	IN	O
the	DT	O
transgene	NN	O
since	IN	O
incorporation	NN	O
occurs	VBZ	O
only	RB	O
in	IN	O
a	DT	O
subset	NN	O
of	IN	O
the	DT	O
cells	NNS	O
which	WDT	O
formed	VBD	O
the	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
founder	NN	O
may	MD	O
contain	VB	O
various	JJ	O
retroviral	JJ	O
insertions	NNS	O
of	IN	O
the	DT	O
transgene	NN	O
at	IN	O
different	JJ	O
positions	NNS	O
in	IN	O
the	DT	O
genome	NN	O
which	WDT	O
generally	RB	O
will	MD	O
segregate	VB	O
in	IN	O
the	DT	O
offspring	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
it	PRP	O
is	VBZ	O
also	RB	O
possible	JJ	O
to	TO	O
introduce	VB	O
transgenes	NNS	O
into	IN	O
the	DT	O
germ	JJ	O
line	NN	O
,	,	O
albeit	IN	O
with	IN	O
low	JJ	O
efficiency	NN	O
,	,	O
by	IN	O
intrauterine	JJ	O
retroviral	JJ	O
infection	NN	O
of	IN	O
the	DT	O
midgestation	NN	O
embryo	NN	O
(	(	O
Jahner	NNP	B
,	,	I
D.	NNP	I
et	CC	I
al	NN	I
.	.	I
(	(	I
1982	CD	I
)	)	I
supra	NN	I
)	)	O
.	.	O
A	DT	O
third	JJ	O
type	NN	O
of	IN	O
target	NN	O
cell	NN	O
for	IN	O
transgene	JJ	O
introduction	NN	O
is	VBZ	O
the	DT	O
embryonal	JJ	O
stem	NN	O
cell	NN	O
(	(	O
ES	NNP	O
)	)	O
.	.	O
ES	NNP	O
cells	NNS	O
are	VBP	O
obtained	VBN	O
from	IN	O
pre-implantation	NN	O
embryos	NN	O
cultured	VBN	O
in	IN	O
vitro	NN	O
and	CC	O
fused	VBN	O
with	IN	O
embryos	NN	O
(	(	O
Evans	NNPS	B
,	,	I
M.	NNP	I
J.	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1981	CD	I
)	)	I
Nature	NN	I
292	CD	I
,	,	I
154-156	CD	I
;	:	O
Bradley	NNP	B
,	,	I
M.	NNP	I
O.	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1984	CD	I
)	)	I
Nature	NN	I
309	CD	I
,	,	I
255-258	JJ	I
;	:	O
Gossler	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
1986	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
U.S.A.	NNP	I
83	CD	I
,	,	I
9065-9069	CD	I
;	:	O
and	CC	O
Robertson	NNP	B
,	,	I
at	IN	I
al	NN	I
.	.	I
(	(	I
1986	CD	I
)	)	I
Nature	NN	I
322	CD	I
,	,	I
445-448	JJ	I
)	)	O
.	.	O
Transgenes	NNS	O
can	MD	O
be	VB	O
efficiently	RB	O
introduced	VBN	O
into	IN	O
the	DT	O
ES	NNP	O
cells	NNS	O
by	IN	O
DNA	NNP	O
transfection	NN	O
or	CC	O
by	IN	O
retrovirus-mediated	JJ	O
transduction	NN	O
.	.	O
Such	JJ	O
transformed	VBD	O
ES	NNP	O
cells	NNS	O
can	MD	O
thereafter	RB	O
be	VB	O
combined	VBN	O
with	IN	O
blastocysts	NNS	O
from	IN	O
a	DT	O
non-human	JJ	O
animal	NN	O
.	.	O
The	DT	O
ES	NNP	O
cells	NNS	O
thereafter	RB	O
colonize	VBP	O
the	DT	O
embryo	NN	O
and	CC	O
contribute	NN	O
to	TO	O
the	DT	O
germ	JJ	O
line	NN	O
of	IN	O
the	DT	O
resulting	VBG	O
chimeric	JJ	O
animal	NN	O
.	.	O
For	IN	O
review	NN	O
see	VBP	O
Jaenisch	NNP	B
,	,	I
R.	NNP	I
(	(	I
1988	CD	I
)	)	I
Science	NN	I
240	CD	I
,	,	I
1468-1474	CD	I
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
a	DT	O
“	JJ	O
transgene	NN	O
”	NNP	O
is	VBZ	O
a	DT	O
DNA	NN	O
sequence	NN	O
introduced	VBD	O
into	IN	O
the	DT	O
germline	NN	O
of	IN	O
a	DT	O
non-human	JJ	O
animal	NN	O
by	IN	O
way	NN	O
of	IN	O
human	JJ	O
intervention	NN	O
such	JJ	O
as	IN	O
by	IN	O
way	NN	O
of	IN	O
the	DT	O
above	JJ	O
described	NN	O
methods	NNS	O
.	.	O
The	DT	O
disclosures	NNS	O
of	IN	O
publications	NNS	O
referenced	VBN	O
in	IN	O
this	DT	O
application	NN	O
in	IN	O
their	PRP$	O
entireties	NNS	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
into	IN	O
this	DT	O
application	NN	O
in	IN	O
order	NN	O
to	TO	O
more	RBR	O
fully	RB	O
describe	VB	O
the	DT	O
state	NN	O
of	IN	O
the	DT	O
art	NN	O
as	IN	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
therein	RB	O
as	IN	O
of	IN	O
the	DT	O
date	NN	O
of	IN	O
the	DT	O
invention	NN	O
described	VBD	O
and	CC	O
claimed	VBD	O
herein	NN	O
.	.	O
This	DT	O
invention	NN	O
is	VBZ	O
illustrated	VBN	O
in	IN	O
the	DT	O
Experimental	NNP	O
Details	NNP	O
section	NN	O
which	WDT	O
follows	VBZ	O
.	.	O
These	DT	O
sections	NNS	O
are	VBP	O
set	VBN	O
forth	NN	O
to	TO	O
aid	NN	O
in	IN	O
an	DT	O
understanding	NN	O
of	IN	O
the	DT	O
invention	NN	O
but	CC	O
are	VBP	O
not	RB	O
intended	VBN	O
to	TO	O
,	,	O
and	CC	O
should	MD	O
not	RB	O
be	VB	O
construed	VBN	O
to	TO	O
,	,	O
limit	NN	O
in	IN	O
any	DT	O
way	NN	O
the	DT	O
invention	NN	O
as	IN	O
set	VBN	O
forth	NN	O
in	IN	O
the	DT	O
claims	NNS	O
which	WDT	O
follow	VBP	O
thereafter	RB	O
.	.	O
EXPERIMENTAL	NNP	O
DETAILS	NNP	O
Example	NNP	O
1	CD	O
Generation	NNP	O
of	IN	O
Transgenic	NNP	O
Mice	NNP	O
with	IN	O
Targeted	NNP	O
Overexpression	NNP	O
of	IN	O
Receptor	NNP	O
for	IN	O
Advanced	NNP	O
Glycation	NNP	O
Endproducts	NNP	O
(	(	O
RAGE	NNP	O
)	)	O
in	IN	O
Neurons	NNP	O
This	DT	O
paper	NN	O
describes	VBZ	O
a	DT	O
means	NN	O
of	IN	O
making	VBG	O
transgenic	JJ	O
mice	NN	O
with	IN	O
targeted	JJ	O
overexpression	NN	O
of	IN	O
RAGE	NNP	O
in	IN	O
neurons	NNS	O
using	VBG	O
the	DT	O
PDGF	NNP	O
B-chain	NNP	O
promoter	NN	O
and	CC	O
the	DT	O
cDNA	NN	O
for	IN	O
human	JJ	O
full-length	JJ	O
RAGE	NN	O
.	.	O
The	DT	O
mice	NN	O
,	,	O
termed	VBD	O
Tg	NNP	O
PD-RAGE	NNP	O
,	,	O
which	WDT	O
have	VBP	O
been	VBN	O
produced	VBN	O
provide	IN	O
a	DT	O
model	NN	O
system	NN	O
for	IN	O
determining	VBG	O
the	DT	O
consequences	NNS	O
of	IN	O
heightened	JJ	O
RAGE	NNP	O
expression	NN	O
in	IN	O
neurons	NNS	O
,	,	O
and	CC	O
could	MD	O
serve	VB	O
as	IN	O
an	DT	O
important	JJ	O
model	NN	O
system	NN	O
to	TO	O
test	VB	O
RAGE	NNP	O
blockers	NNS	O
,	,	O
either	DT	O
inhibitors	NNS	O
of	IN	O
ligand-receptor	JJ	O
interaction	NN	O
or	CC	O
inhibitors	NNS	O
of	IN	O
RAGE-dependent	NNP	O
intracellular	JJ	O
signaling	NN	O
.	.	O
Cross-breeding	NN	O
of	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
with	IN	O
other	JJ	O
animals	NNS	O
,	,	O
such	JJ	O
as	IN	O
those	DT	O
expressing	VBG	O
a	DT	O
transgene	NN	O
causing	VBG	O
overexpression	NN	O
of	IN	O
mutant	JJ	O
amyloid	NN	O
precursor	NN	O
protein	NN	O
(	(	O
resulting	VBG	O
in	IN	O
increased	JJ	O
production	NN	O
of	IN	O
amyloid-beta	JJ	O
peptide	NN	O
)	)	O
provide	VBP	O
a	DT	O
model	NN	O
system	NN	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
RAGE	NNP	O
in	IN	O
an	DT	O
Aβ-rich	JJ	O
environment	NN	O
in	IN	O
the	DT	O
brain	NN	O
relevant	NN	O
to	TO	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
isolation	NN	O
and	CC	O
culture	NN	O
of	IN	O
embryonic	JJ	O
neurons	NNS	O
from	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
allows	VBZ	O
study	NN	O
of	IN	O
the	DT	O
consequences	NNS	O
of	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
RAGE	NNP	O
in	IN	O
vitro	NN	O
in	IN	O
actual	JJ	O
neurons	NNS	O
.	.	O
These	DT	O
are	VBP	O
several	JJ	O
examples	NNS	O
of	IN	O
how	WRB	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
contribution	NN	O
of	IN	O
RAGE	NNP	O
,	,	O
analyzed	VBD	O
according	VBG	O
to	TO	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
systems	NNS	O
,	,	O
to	TO	O
situations	NNS	O
potentially	RB	O
relevant	VBP	O
to	TO	O
human	JJ	O
disease	NN	O
.	.	O
Introduction	NNP	O
Receptor	NNP	O
for	IN	O
Advanced	NNP	O
Glycation	NNP	O
Endproducts	NNP	O
(	(	O
RAGE	NNP	O
)	)	O
is	VBZ	O
a	DT	O
multiligand	JJ	O
member	NN	O
of	IN	O
the	DT	O
immunoglobulin	JJ	O
superfamily	NN	O
of	IN	O
cell	NN	O
surface	NN	O
molecules1	NN	O
.	.	O
In	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
,	,	O
RAGE	NNP	O
is	VBZ	O
present	JJ	O
at	IN	O
high	JJ	O
levels	NNS	O
in	IN	O
early	JJ	O
development	NN	O
,	,	O
but	CC	O
then	RB	O
its	PRP$	O
expression	NN	O
falls	VBZ	O
off	IN	O
with	IN	O
maturity2,3	NN	O
.	.	O
However	RB	O
,	,	O
with	IN	O
development	NN	O
of	IN	O
a	DT	O
pathology	NN	O
in	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
,	,	O
such	JJ	O
as	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
(	(	O
AD	NNP	O
)	)	O
,	,	O
RAGE	NNP	O
expression	NN	O
increases	NNS	O
to	TO	O
high	JJ	O
levels4	NN	O
.	.	O
Similarly	RB	O
,	,	O
in	IN	O
murine	JJ	O
models	NNS	O
of	IN	O
stroke	NN	O
RAGE	NNP	O
expression	NN	O
also	RB	O
increases	VBZ	O
.	.	O
This	DT	O
suggests	VBZ	O
that	IN	O
RAGE	NNP	O
may	MD	O
participate	VB	O
in	IN	O
the	DT	O
host	NN	O
response	NN	O
,	,	O
though	IN	O
it	PRP	O
is	VBZ	O
not	RB	O
clear	JJ	O
if	IN	O
its	PRP$	O
participation	NN	O
would	MD	O
be	VB	O
favorable	JJ	O
or	CC	O
deleterious	JJ	O
to	TO	O
the	DT	O
outcome	NN	O
.	.	O
There	EX	O
are	VBP	O
several	JJ	O
ways	NNS	O
to	TO	O
dissect	VB	O
the	DT	O
contribution	NN	O
of	IN	O
RAGE	NNP	O
in	IN	O
physiologic	NN	O
and	CC	O
pathophysiologic	JJ	O
settings	NNS	O
.	.	O
One	CD	O
method	NN	O
which	WDT	O
we	PRP	O
have	VBP	O
used	VBN	O
extensively	RB	O
is	VBZ	O
administration	NN	O
of	IN	O
soluble	JJ	O
RAGE	NNP	O
,	,	O
the	DT	O
extracellular	JJ	O
domain	NN	O
,	,	O
which	WDT	O
serve	VBP	O
as	IN	O
a	DT	O
decoy	NN	O
for	IN	O
ligands	NNS	O
seeking	VBG	O
out	RP	O
cell	NN	O
surface	NN	O
receptor	NN	O
,	,	O
and	CC	O
anti-RAGE	JJ	O
IgG5-7	NNP	O
.	.	O
However	RB	O
these	DT	O
reagents	NNS	O
are	VBP	O
principally	RB	O
useful	JJ	O
in	IN	O
tissues	NNS	O
served	VBN	O
by	IN	O
the	DT	O
systemic	JJ	O
circulation	NN	O
which	WDT	O
provides	VBZ	O
the	DT	O
means	NNS	O
for	IN	O
delivery	NN	O
.	.	O
Tissues	NNS	O
behind	IN	O
the	DT	O
blood-brain	JJ	O
barrier	NN	O
,	,	O
such	JJ	O
as	IN	O
neurons	NNS	O
(	(	O
e.g.	NN	O
,	,	O
the	DT	O
entire	JJ	O
central	JJ	O
nervous	JJ	O
system	NN	O
)	)	O
pose	VB	O
a	DT	O
more	RBR	O
difficult	JJ	O
problem	NN	O
since	IN	O
macromolecules	NNS	O
do	VBP	O
not	RB	O
have	VB	O
ready	JJ	O
access	NN	O
under	IN	O
most	JJS	O
conditions	NNS	O
.	.	O
For	IN	O
this	DT	O
reason	NN	O
,	,	O
we	PRP	O
sought	VBD	O
to	TO	O
create	VB	O
genetic	JJ	O
models	NNS	O
to	TO	O
dissect	VB	O
the	DT	O
contribution	NN	O
of	IN	O
RAGE	NNP	O
.	.	O
In	IN	O
this	DT	O
context	NN	O
,	,	O
there	EX	O
are	VBP	O
three	CD	O
general	JJ	O
approaches	NNS	O
:	:	O
Targeted	VBN	O
over-expression	NN	O
of	IN	O
wild-type	JJ	O
RAGE	NNP	O
wherein	VBD	O
the	DT	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
would	MD	O
exhibit	VB	O
exaggerated	JJ	O
effects	NNS	O
of	IN	O
RAGE	NNP	O
in	IN	O
the	DT	O
particular	JJ	O
tissue/cell	NN	O
under	IN	O
study	NN	O
(	(	O
the	DT	O
RAGE	NNP	O
is	VBZ	O
overexpressed	VBN	O
in	IN	O
a	DT	O
tissue	NN	O
specific	JJ	O
manner	NN	O
.	.	O
Targeted	VBN	O
overexpression	NN	O
of	IN	O
a	DT	O
mutant	JJ	O
form	NN	O
of	IN	O
the	DT	O
receptor	NN	O
in	IN	O
which	WDT	O
the	DT	O
RAGE	NNP	O
cytosolic	JJ	O
tail	NN	O
has	VBZ	O
been	VBN	O
deleted	VBN	O
.	.	O
This	DT	O
form	NN	O
of	IN	O
the	DT	O
molecule	NN	O
functions	NNS	O
as	IN	O
a	DT	O
dominant-negative	JJ	O
,	,	O
thereby	RB	O
blocking	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
ligand	NN	O
engagement	NN	O
of	IN	O
wild-type	JJ	O
RAGE	NNP	O
.	.	O
Deletion	NN	O
of	IN	O
the	DT	O
RAGE	NNP	O
gene	NN	O
by	IN	O
homologous	JJ	O
recombination	NN	O
(	(	O
this	DT	O
can	MD	O
also	RB	O
be	VB	O
carried	VBN	O
out	RP	O
using	VBG	O
conditional	JJ	O
strategies	NNS	O
to	TO	O
achieve	VB	O
tissue-specific	JJ	O
knockout	NN	O
.	.	O
(	(	O
Also	RB	O
termed	VBN	O
,	,	O
a	DT	O
RAGE	NNP	O
knockout	NN	O
transgenic	JJ	O
non-human	JJ	O
animal	NN	O
.	.	O
)	)	O
This	DT	O
report	NN	O
describes	VBZ	O
the	DT	O
generation	NN	O
of	IN	O
mice	NN	O
with	IN	O
targeted	JJ	O
overexpression	NN	O
of	IN	O
human	JJ	O
RAGE	NNP	O
in	IN	O
neurons	NNS	O
using	VBG	O
the	DT	O
PDGF	NNP	O
B-chain	NNP	O
promoter	NN	O
,	,	O
termed	VBD	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
we	PRP	O
describe	VBP	O
the	DT	O
effect	NN	O
of	IN	O
stroke	NN	O
on	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
,	,	O
and	CC	O
the	DT	O
results	NNS	O
of	IN	O
crossing	VBG	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
with	IN	O
animals	NNS	O
overexpressing	VBG	O
a	DT	O
mutant	JJ	O
form	NN	O
of	IN	O
amyloid	JJ	O
precursor	NN	O
protein	NN	O
(	(	O
APP	NNP	O
)	)	O
which	WDT	O
causes	VBZ	O
increased	JJ	O
production	NN	O
of	IN	O
amyloid-beta	JJ	O
peptide	NN	O
(	(	O
Aβ	NNP	O
)	)	O
.	.	O
Methods	NNS	O
Construction	NN	O
of	IN	O
the	DT	O
transgene	NN	O
and	CC	O
making	VBG	O
the	DT	O
transgenic	NN	O
(	(	O
Tg	NNP	O
)	)	O
mice	NN	O
.	.	O
The	DT	O
platelet-derived	JJ	O
growth	NN	O
factor	NN	O
(	(	O
PDGF	NNP	O
)	)	O
B-chain	NNP	O
promoter	NN	O
was	VBD	O
used	VBN	O
to	TO	O
drive	VB	O
overexpression	NN	O
of	IN	O
RAGE	NNP	O
in	IN	O
neurons	NNS	O
of	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
of	IN	O
transgenic	JJ	O
(	(	O
Tg	NNP	O
)	)	O
mice8	NN	O
.	.	O
Transgene	NNP	O
constructs	NNS	O
were	VBD	O
prepared	VBN	O
using	VBG	O
a	DT	O
previously	RB	O
described	VBN	O
vector9,10	NN	O
.	.	O
Briefly	NNP	O
,	,	O
the	DT	O
CMV	NNP	O
immediate/early	RB	O
promoter	NN	O
was	VBD	O
excised	VBN	O
from	IN	O
the	DT	O
commercial	JJ	O
expression	NN	O
vector	NN	O
pCI	NN	O
(	(	O
Promega	NNP	O
,	,	O
Madison	NNP	O
Wis.	NNP	O
)	)	O
,	,	O
and	CC	O
replaced	VBD	O
with	IN	O
an	DT	O
oligonucleotide	JJ	O
polylinker	NN	O
.	.	O
The	DT	O
PDGF	NNP	O
B-chain	NNP	O
promoter	NN	O
fragment	NN	O
was	VBD	O
mobilized	VBN	O
as	IN	O
an	DT	O
Xba1	NNP	O
fragment8	NN	O
and	CC	O
cloned	VBD	O
into	IN	O
a	DT	O
unique	JJ	O
Spe1	NNP	O
site	NN	O
designed	VBN	O
within	IN	O
the	DT	O
synthetic	JJ	O
linker	NN	O
.	.	O
The	DT	O
full-length	JJ	O
human	JJ	O
RAGE	NNP	O
cDNA	NN	O
was	VBD	O
inserted	VBN	O
into	IN	O
the	DT	O
NotI	NNP	O
site	NN	O
of	IN	O
the	DT	O
original	JJ	O
polylinker	NN	O
.	.	O
A	DT	O
schematic	JJ	O
representation	NN	O
of	IN	O
this	DT	O
construct	NN	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
1A	CD	O
(	(	O
upper	JJ	O
panel	NN	O
)	)	O
.	.	O
An	DT	O
≈3	JJ	O
kb	NN	O
fragment	NN	O
containing	VBG	O
the	DT	O
promoter	NN	O
,	,	O
cDNA	NN	O
and	CC	O
required	VBD	O
other	JJ	O
sequences	NNS	O
was	VBD	O
then	RB	O
excised	VBN	O
from	IN	O
the	DT	O
plasmid	NN	O
backbone	NN	O
as	IN	O
a	DT	O
PvuI	NNP	O
fragment	NN	O
(	(	O
FIG	NNP	O
.	.	O
1B	CD	O
,	,	O
lower	JJR	O
panel	NN	O
)	)	O
and	CC	O
microinjected	VBN	O
mouse	NN	O
B6CBAF1/J	NNP	O
oocytes	VBZ	O
.	.	O
The	DT	O
latter	NN	O
were	VBD	O
implanted	VBN	O
into	IN	O
pseudopregnant	JJ	O
females	NNS	O
and	CC	O
mated	VBN	O
with	IN	O
B6CBAF1/J	NNP	O
males	NNS	O
resulting	VBG	O
in	IN	O
the	DT	O
generation	NN	O
of	IN	O
independent	JJ	O
founders	NNS	O
.	.	O
Breeding	NN	O
of	IN	O
these	DT	O
mice	NNS	O
demonstrated	VBD	O
germ-line	JJ	O
transmission	NN	O
and	CC	O
was	VBD	O
used	VBN	O
to	TO	O
produce	VB	O
lines	NNS	O
of	IN	O
animals	NNS	O
termed	VBN	O
Tg	NNP	O
PD-RAGE	NNP	O
.	.	O
Founders	NNS	O
were	VBD	O
initially	RB	O
identified	VBN	O
by	IN	O
Southern	NNP	O
blotting	VBG	O
performed	VBN	O
on	IN	O
DNA	NN	O
extracted	VBN	O
from	IN	O
mouse	NN	O
tails	NNS	O
.	.	O
DNA	NN	O
was	VBD	O
digested	VBN	O
,	,	O
run	VB	O
on	IN	O
agarose	JJ	O
gels	NNS	O
,	,	O
and	CC	O
hybridized	VBN	O
with	IN	O
32P-labelled	JJ	O
cDNA	NN	O
for	IN	O
human	JJ	O
RAGE	NNP	O
.	.	O
Tails	NNS	O
were	VBD	O
digested	VBN	O
with	IN	O
proteinase	NN	O
K	NNP	O
(	(	O
500	CD	O
μg/ml	NN	O
)	)	O
in	IN	O
digestion	NN	O
buffer	NN	O
(	(	O
50	CD	O
mM	NN	O
Tris	NNP	O
,	,	O
pH	NN	O
8.0	CD	O
,	,	O
100	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
0.5	CD	O
%	NN	O
SDS	NNP	O
)	)	O
at	IN	O
55°	CD	O
C.	NNP	O
for	IN	O
overnight	JJ	O
.	.	O
Then	RB	O
,	,	O
purified	VBD	O
DNA	NNP	O
was	VBD	O
cleaved	VBN	O
with	IN	O
EcoRI	NNP	O
overnight	VBD	O
at	IN	O
37°	CD	O
C.	NNP	O
Labelling	NNP	O
of	IN	O
the	DT	O
probe	NN	O
was	VBD	O
done	VBN	O
using	VBG	O
the	DT	O
Stratagene	NNP	O
's	POS	O
Probe	NNP	O
Labeling	NNP	O
Kit™	NNP	O
.	.	O
Autoradiography	NNP	O
was	VBD	O
then	RB	O
performed	VBN	O
.	.	O
Subsequent	JJ	O
screening	NN	O
of	IN	O
progeny	NN	O
was	VBD	O
by	IN	O
PCR	NNP	O
using	VBG	O
the	DT	O
following	JJ	O
primers	NNS	O
:	:	O
5′-AGCGGCTGGAATGGAAACTGAACA-3′	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:7	NNP	O
)	)	O
and	CC	O
3′-GAAGGGGCAAGGGCACACCATC-5′	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
.	.	O
Total	JJ	O
RNA	NNP	O
was	VBD	O
isolated	VBN	O
using	VBG	O
Trizol®	NNP	O
,	,	O
and	CC	O
RT-PCR	NNP	O
was	VBD	O
performed	VBN	O
with	IN	O
the	DT	O
following	VBG	O
thermocycling	NN	O
parameters	NNS	O
:	:	O
30	CD	O
sec	NN	O
for	IN	O
each	DT	O
cycle	NN	O
consisting	VBG	O
of	IN	O
incubations	NNS	O
at	IN	O
95°	CD	O
C.	NNP	O
for	IN	O
20	CD	O
sec	NN	O
,	,	O
57°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
sec	NN	O
and	CC	O
72°	CD	O
C.	NNP	O
for	IN	O
1	CD	O
sec	NN	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
35	CD	O
cycles	NNS	O
.	.	O
Products	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
agarose	JJ	O
gel	JJ	O
electrophoresis	NN	O
(	(	O
1	CD	O
%	NN	O
)	)	O
and	CC	O
visualized	VBN	O
by	IN	O
ethidium	NN	O
bromide	IN	O
staining	VBG	O
under	IN	O
ultraviolet	JJ	O
illumination	NN	O
.	.	O
The	DT	O
size	NN	O
of	IN	O
the	DT	O
RAGE	NNP	O
amplicon	NN	O
with	IN	O
these	DT	O
primers	NNS	O
corresponded	VBD	O
to	TO	O
701	CD	O
bp	NN	O
.	.	O
Northern	NNP	O
and	CC	O
immunoblotting	VBG	O
utilized	VBD	O
the	DT	O
same	JJ	O
procedures	NNS	O
as	IN	O
above	IN	O
,	,	O
except	IN	O
that	DT	O
tissue	NN	O
was	VBD	O
homogenized	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
Trizol	NNP	O
(	(	O
RNA	NNP	O
)	)	O
or	CC	O
in	IN	O
homogenization	NN	O
buffer	NN	O
(	(	O
Tris/HCl	NNP	O
,	,	O
10	CD	O
mM	NN	O
,	,	O
pH	VBZ	O
7.4	CD	O
;	:	O
NaCl	NNP	O
,	,	O
100	CD	O
mM	NN	O
;	:	O
phenylmethylsulfonylfluoride	NN	O
,	,	O
100	CD	O
μg/ml	NN	O
;	:	O
EDTA	NNP	O
,	,	O
1	CD	O
mM	NN	O
;	:	O
aprotonin	NN	O
,	,	O
1	CD	O
μg/ml	NN	O
)	)	O
.	.	O
Note	NN	O
that	IN	O
immunoblotting	VBG	O
and	CC	O
immunostaining	NN	O
of	IN	O
brain	NN	O
tissue	NN	O
from	IN	O
Tg	NNP	O
PD-ABAD	NNP	O
mice	NN	O
used	VBD	O
anti-human	JJ	O
RAGE	NNP	O
IgG7	NNP	O
.	.	O
Characterization	NN	O
of	IN	O
RAGE	NNP	O
expression	NN	O
in	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
Northern	NNP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
total	JJ	O
RNA	NNP	O
isolated	VBD	O
from	IN	O
cerebral	JJ	O
cortex	NN	O
,	,	O
hippocampus	NN	O
and	CC	O
cerebellum	NN	O
.	.	O
RNA	NNP	O
was	VBD	O
isolated	VBN	O
using	VBG	O
Trizol®	NNP	O
followed	VBN	O
by	IN	O
electrophoresis	NN	O
on	IN	O
0.8	CD	O
%	NN	O
agarose	JJ	O
gels	NNS	O
(	(	O
30	CD	O
μg	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
each	DT	O
lane	NN	O
)	)	O
,	,	O
transfer	VBP	O
to	TO	O
nitrocellulose	VB	O
membranes	NNS	O
,	,	O
and	CC	O
hybridization	NN	O
with	IN	O
32P-labelled	JJ	O
human	JJ	O
RAGE	NNP	O
cDNA	NN	O
.	.	O
The	DT	O
RAGE	NNP	O
cDNA	NN	O
was	VBD	O
labelled	VBN	O
by	IN	O
as	IN	O
above	NN	O
.	.	O
Western	JJ	O
blotting	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
protein	NN	O
extracts	NNS	O
of	IN	O
brain	NN	O
subregions	NNS	O
.	.	O
Proteins	NNS	O
were	VBD	O
extracted	VBN	O
from	IN	O
minced	JJ	O
pieces	NNS	O
of	IN	O
brains	NNS	O
by	IN	O
exposing	VBG	O
the	DT	O
tissue	NN	O
to	TO	O
lysis	VB	O
buffer	NN	O
(	(	O
Tris/HCl	NNP	O
,	,	O
20	CD	O
mM	NN	O
;	:	O
pH	CC	O
7.4	CD	O
;	:	O
Triton	NNP	O
X-100	NNP	O
,	,	O
1	CD	O
%	NN	O
;	:	O
phenylmethylsulfonylfluoride	NN	O
,	,	O
2	CD	O
mM	NN	O
;	:	O
EDTA	NNP	O
,	,	O
1	CD	O
mM	NN	O
,	,	O
aprotonin	NN	O
,	,	O
10	CD	O
μg/ml	NN	O
;	:	O
leupeptin	CC	O
,	,	O
10	CD	O
μg/ml	NN	O
)	)	O
using	VBG	O
a	DT	O
ratio	NN	O
of	IN	O
1	CD	O
ml	NN	O
of	IN	O
buffer	NN	O
per	IN	O
0.5	CD	O
gm	NN	O
of	IN	O
tissue	NN	O
.	.	O
Extracts	NNS	O
were	VBD	O
then	RB	O
boiled	VBN	O
in	IN	O
reducing	VBG	O
SDS-sample	JJ	O
buffer	NN	O
,	,	O
and	CC	O
applied	VBD	O
to	TO	O
SDS-PAGE	NNP	O
according	VBG	O
to	TO	O
Laemmli11	NNP	O
.	.	O
Immunostaining	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
paraformaldehyde	NN	O
(	(	O
4	CD	O
%	NN	O
)	)	O
-fixed	CD	O
,	,	O
paraffin	NN	O
embedded	VBD	O
sections	NNS	O
(	(	O
6	CD	O
μm	NN	O
)	)	O
of	IN	O
mouse	NN	O
brains	NNS	O
prepared	VBD	O
according	VBG	O
to	TO	O
standard	JJ	O
methods4,7	NN	O
.	.	O
The	DT	O
sections	NNS	O
were	VBD	O
deparaffinized	VBN	O
and	CC	O
dehydrated	VBN	O
,	,	O
and	CC	O
then	RB	O
stained	VBD	O
with	IN	O
rabbit	NN	O
anti-human	JJ	O
RAGE	NNP	O
IgG	NNP	O
(	(	O
50	CD	O
μg/ml	NN	O
)	)	O
followed	VBN	O
by	IN	O
goat	JJ	O
anti-rabbit	JJ	O
biotin-conjugated	JJ	O
IgG	NNP	O
and	CC	O
ExtrAvidin-conjugated	JJ	O
with	IN	O
alkaline	JJ	O
phosphatase	NN	O
(	(	O
Biotin	NNP	O
ExtrAvidin®	NNP	O
kit	NN	O
;	:	O
Sigma	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
Mo	NNP	O
.	.	O
)	)	O
.	.	O
Preparation	NN	O
of	IN	O
anti-RAGE	JJ	O
IgG	NNP	O
,	,	O
using	VBG	O
recombinant	JJ	O
soluble	JJ	O
RAGE	NN	O
as	IN	O
the	DT	O
immunogen	NN	O
,	,	O
has	VBZ	O
been	VBN	O
described4,7	VBN	O
.	.	O
Induction	NN	O
of	IN	O
stroke	NN	O
in	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
Functional	JJ	O
consequences	NNS	O
of	IN	O
overexpression	NN	O
of	IN	O
RAGE	NNP	O
were	VBD	O
first	RB	O
assessed	VBN	O
in	IN	O
response	NN	O
to	TO	O
ischemic	VB	O
stress	NN	O
,	,	O
the	DT	O
transient	NN	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
occlusion	NN	O
model	NN	O
.	.	O
Murine	NNP	O
stroke	VBD	O
model	NN	O
Mice	NNP	O
(	(	O
C57BL6/J	NNP	O
,	,	O
male	NN	O
)	)	O
were	VBD	O
subjected	VBN	O
to	TO	O
stroke	VB	O
according	VBG	O
to	TO	O
previously	RB	O
published	VBN	O
procedures12	NN	O
.	.	O
Following	VBG	O
anesthesia	NN	O
,	,	O
the	DT	O
carotid	NN	O
artery	NN	O
was	VBD	O
accessed	VBN	O
using	VBG	O
the	DT	O
operative	JJ	O
approach	NN	O
previously	RB	O
described	VBN	O
in	IN	O
detail13	NN	O
,	,	O
including	VBG	O
division/coagulation	NN	O
of	IN	O
the	DT	O
occipital	JJ	O
and	CC	O
pterygopalatine	JJ	O
arteries	NNS	O
to	TO	O
obtain	VB	O
improved	JJ	O
visualization	NN	O
and	CC	O
vascular	JJ	O
access	NN	O
.	.	O
A	DT	O
nylon	JJ	O
suture	NN	O
was	VBD	O
then	RB	O
introduced	VBN	O
into	IN	O
the	DT	O
common	JJ	O
carotid	NN	O
artery	NN	O
,	,	O
and	CC	O
threaded	VBD	O
up	RP	O
the	DT	O
internal	JJ	O
carotid	NN	O
artery	NN	O
to	TO	O
occlude	VB	O
the	DT	O
origin	NN	O
of	IN	O
the	DT	O
right	JJ	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
(	(	O
MCA	NNP	O
)	)	O
.	.	O
Nylon	NNP	O
(	(	O
polyamide	NN	O
)	)	O
suture	NN	O
material	NN	O
was	VBD	O
obtained	VBN	O
from	IN	O
United	NNP	O
States	NNPS	O
Surgical	NNP	O
Corporation	NNP	O
(	(	O
Norwalk	NNP	O
,	,	O
Conn.	NNP	O
)	)	O
,	,	O
and	CC	O
consisted	VBD	O
of	IN	O
5.0	CD	O
nylon/13	JJ	O
mm	NN	O
length	NN	O
for	IN	O
27-36	JJ	O
g	NN	O
mice	NN	O
,	,	O
and	CC	O
6.0	CD	O
nylon/12	JJ	O
mm	NN	O
length	NN	O
for	IN	O
22-26	JJ	O
g	NN	O
mice	NN	O
.	.	O
After	IN	O
45	CD	O
minutes	NNS	O
of	IN	O
occlusion	NN	O
,	,	O
the	DT	O
suture	NN	O
was	VBD	O
withdrawn	VBN	O
to	TO	O
achieve	VB	O
a	DT	O
reperfused	JJ	O
model	NN	O
of	IN	O
stroke	NN	O
.	.	O
Although	IN	O
no	DT	O
vessels	NNS	O
were	VBD	O
tied	VBN	O
off	RP	O
after	IN	O
the	DT	O
suture	NN	O
was	VBD	O
removed	VBN	O
,	,	O
the	DT	O
external	JJ	O
carotid	NN	O
arterial	JJ	O
stump	NN	O
was	VBD	O
cauterized	VBN	O
to	TO	O
prevent	VB	O
frank	JJ	O
hemorrhage	NN	O
.	.	O
Measurements	NNS	O
of	IN	O
relative	JJ	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
were	VBD	O
obtained	VBN	O
as	IN	O
previously	RB	O
reported12-15	JJ	O
using	VBG	O
a	DT	O
straight	JJ	O
laser	NN	O
doppler	NN	O
flow	NN	O
probe	NN	O
placed	VBD	O
2	CD	O
mm	NN	O
posterior	NN	O
to	TO	O
the	DT	O
bregma	NN	O
,	,	O
and	CC	O
6	CD	O
mm	NN	O
to	TO	O
each	DT	O
side	NN	O
of	IN	O
midline	NN	O
using	VBG	O
a	DT	O
stereotactic	JJ	O
micromanipulator	NN	O
,	,	O
keeping	VBG	O
the	DT	O
angle	NN	O
of	IN	O
the	DT	O
probe	NN	O
perpendicular	NN	O
to	TO	O
the	DT	O
cortical	JJ	O
surface	NN	O
.	.	O
These	DT	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
measurements	NNS	O
,	,	O
expressed	VBN	O
as	IN	O
the	DT	O
ratio	NN	O
of	IN	O
ipsilateral	JJ	O
to	TO	O
contralateral	JJ	O
blood	NN	O
flow	NN	O
,	,	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
immediately	RB	O
prior	JJ	O
to	TO	O
MCA	NNP	O
occlusion	NN	O
,	,	O
45	CD	O
minutes	NNS	O
after	IN	O
MCA	NNP	O
occlusion	NN	O
,	,	O
and	CC	O
at	IN	O
several	JJ	O
time	NN	O
points	NNS	O
after	IN	O
withdrawal	NN	O
of	IN	O
the	DT	O
occluding	JJ	O
suture	NN	O
.	.	O
Measurement	NN	O
of	IN	O
Cerebral	NNP	O
Infarction	NNP	O
Volumes	NNP	O
:	:	O
After	IN	O
24	CD	O
hours	NNS	O
,	,	O
animals	NNS	O
were	VBD	O
euthanized	VBN	O
and	CC	O
their	PRP$	O
brains	NNS	O
rapidly	RB	O
harvested	VBD	O
.	.	O
Infarct	NNP	O
volumes	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
staining	VBG	O
serial	JJ	O
cerebral	JJ	O
sections	NNS	O
with	IN	O
triphenyl	JJ	O
tetrazolium	NN	O
chloride	NN	O
and	CC	O
performing	VBG	O
computer-based	JJ	O
planimetry	NN	O
of	IN	O
the	DT	O
negatively	RB	O
(	(	O
infarcted	VBN	O
)	)	O
staining	VBG	O
areas	NNS	O
to	TO	O
calculate	VB	O
infarct	JJ	O
volume	NN	O
(	(	O
using	VBG	O
NIH	NNP	O
image	NN	O
software	NN	O
)	)	O
.	.	O
Neurological	JJ	O
Exam	NN	O
:	:	O
Prior	NNP	O
to	TO	O
giving	VBG	O
anesthesia	NN	O
,	,	O
mice	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
neurological	JJ	O
deficit	NN	O
23	CD	O
h	NN	O
after	IN	O
reperfusion	NN	O
using	VBG	O
a	DT	O
four-tiered	JJ	O
grading	NN	O
system	NN	O
:	:	O
a	DT	O
score	NN	O
of	IN	O
1	CD	O
was	VBD	O
given	VBN	O
if	IN	O
the	DT	O
animal	NN	O
demonstrated	VBD	O
normal	JJ	O
spontaneous	JJ	O
movements	NNS	O
;	:	O
a	DT	O
score	NN	O
of	IN	O
2	CD	O
was	VBD	O
given	VBN	O
if	IN	O
the	DT	O
animal	NN	O
was	VBD	O
noted	VBN	O
to	TO	O
be	VB	O
turning	VBG	O
towards	IN	O
the	DT	O
ipsilateral	JJ	O
side	NN	O
;	:	O
a	DT	O
score	NN	O
of	IN	O
3	CD	O
was	VBD	O
given	VBN	O
if	IN	O
the	DT	O
animal	NN	O
was	VBD	O
observed	VBN	O
to	TO	O
spin	VB	O
longitudinally	RB	O
(	(	O
clockwise	NN	O
when	WRB	O
viewed	VBN	O
from	IN	O
the	DT	O
tail	NN	O
)	)	O
;	:	O
and	CC	O
,	,	O
a	DT	O
score	NN	O
of	IN	O
4	CD	O
was	VBD	O
given	VBN	O
if	IN	O
the	DT	O
animal	NN	O
was	VBD	O
unresponsive	JJ	O
to	TO	O
noxious	JJ	O
stimuli	NNS	O
.	.	O
This	DT	O
scoring	NN	O
system	NN	O
has	VBZ	O
been	VBN	O
previously	RB	O
described	VBN	O
in	IN	O
mice12-14	NN	O
,	,	O
and	CC	O
is	VBZ	O
based	VBN	O
upon	IN	O
similar	JJ	O
scoring	VBG	O
systems	NNS	O
used	VBN	O
in	IN	O
rats16	NN	O
.	.	O
Immunostaining	NN	O
of	IN	O
cerebral	JJ	O
cortex	NN	O
following	VBG	O
induction	NN	O
of	IN	O
stroke	NN	O
in	IN	O
wild-type	JJ	O
mice	NN	O
was	VBD	O
performed	VBN	O
as	IN	O
described	VBN	O
above	IN	O
using	VBG	O
a	DT	O
rabbit	NN	O
polyclonal	JJ	O
antibody	NN	O
made	VBD	O
using	VBG	O
purified	JJ	O
recombinant	JJ	O
murine	NN	O
ABAD	NNP	O
as	IN	O
the	DT	O
immunogen	NN	O
.	.	O
Quantitation	NN	O
of	IN	O
microscopic	NN	O
images	NNS	O
was	VBD	O
accomplished	VBN	O
with	IN	O
the	DT	O
Universal	NNP	O
Imaging	NNP	O
System	NNP	O
.	.	O
Cross-breeding	NN	O
of	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
with	IN	O
Tg	NNP	O
hAPP	NN	O
mice	NN	O
.	.	O
Tg	NNP	O
mice	NN	O
overexpressing	VBG	O
an	DT	O
alternatively	RB	O
spliced	JJ	O
hAPP	NN	O
minigene	NN	O
that	WDT	O
encodes	VBZ	O
hAPP695	NN	O
,	,	O
hAPP751	NN	O
,	,	O
and	CC	O
hAPP770	JJ	O
bearing	NN	O
mutations	NNS	O
linked	VBD	O
to	TO	O
familial	JJ	O
AD	NNP	O
(	(	O
V717F	NNP	O
,	,	O
K670M/N671L	NNP	O
)	)	O
have	VBP	O
been	VBN	O
produced	VBN	O
by	IN	O
Dr.	NNP	O
Lennart	NNP	O
Mucke17	NNP	O
,	,	O
and	CC	O
provided	VBD	O
to	TO	O
us	PRP	O
for	IN	O
use	NN	O
in	IN	O
cross-breeding	JJ	O
studies	NNS	O
with	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
In	IN	O
these	DT	O
mice	NNS	O
,	,	O
expression	NN	O
of	IN	O
the	DT	O
transgene	NN	O
is	VBZ	O
also	RB	O
driven	VBN	O
by	IN	O
the	DT	O
PDGF	NNP	O
B-chain	NNP	O
promoter	NN	O
.	.	O
Cross-breeding	NN	O
was	VBD	O
performed	VBN	O
and	CC	O
double-transgenic	JJ	O
mice	NN	O
expressing	VBG	O
both	DT	O
hAPP	NN	O
and	CC	O
PD-RAGE	JJ	O
transgenes	NNS	O
were	VBD	O
identified	VBN	O
with	IN	O
specific	JJ	O
primers	NNS	O
.	.	O
The	DT	O
primers	NNS	O
for	IN	O
the	DT	O
hAPP	NN	O
transgene	NN	O
were	VBD	O
:	:	O
5′-GACAAGTATCTCGAGACACCTGGGGATGAG-3′	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
)	)	O
and	CC	O
3′-AAAGAACTTGTAGGTTGGATTTTCGTACC-5′	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:10	NNP	O
)	)	O
PCR	NNP	O
conditions	NNS	O
for	IN	O
the	DT	O
amplifying	VBG	O
the	DT	O
hAPP	NN	O
transgene	NN	O
were	VBD	O
the	DT	O
same	JJ	O
as	IN	O
those	DT	O
described	VBN	O
above	IN	O
,	,	O
and	CC	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
amplicon	NN	O
was	VBD	O
1169	CD	O
bp	NN	O
.	.	O
Characterization	NN	O
of	IN	O
Tg	NNP	O
PD-RAGE/hAPP	NNP	O
mice	NN	O
.	.	O
Mice	NNP	O
were	VBD	O
anesthetized	VBN	O
according	VBG	O
to	TO	O
standard	JJ	O
procedures	NNS	O
and	CC	O
then	RB	O
flush-perfused	JJ	O
transcardially	RB	O
with	IN	O
solution	NN	O
containing	VBG	O
NaCl	NNP	O
(	(	O
0.9	CD	O
%	NN	O
)	)	O
.	.	O
Brains	NNS	O
will	MD	O
then	RB	O
be	VB	O
rapidly	RB	O
removed	VBN	O
and	CC	O
divided	VBN	O
sagitally	RB	O
.	.	O
One	CD	O
hemibrain	NN	O
was	VBD	O
postfixed	VBN	O
in	IN	O
phosphate-buffered	JJ	O
saline	NN	O
(	(	O
PBS	NNP	O
)	)	O
containing	VBG	O
paraformaldehyde	NN	O
(	(	O
4	CD	O
%	NN	O
;	:	O
pH	CC	O
7.4	CD	O
)	)	O
at	IN	O
4°	CD	O
C.	NNP	O
for	IN	O
48	CD	O
hrs	NN	O
prior	RB	O
to	TO	O
vibratome	VB	O
sectioning	NN	O
.	.	O
Hemibrains	NNS	O
were	VBD	O
stored	VBN	O
in	IN	O
cryoprotectant	JJ	O
medium	NN	O
(	(	O
phosphate-buffered	JJ	O
saline	NN	O
containing	VBG	O
glycerin	NN	O
and	CC	O
ethylene	VB	O
glycol	NN	O
)	)	O
until	IN	O
sectioning	VBG	O
.	.	O
This	DT	O
portion	NN	O
of	IN	O
the	DT	O
brain	NN	O
was	VBD	O
employed	VBN	O
for	IN	O
studies	NNS	O
of	IN	O
neuronal	JJ	O
integrity	NN	O
and	CC	O
degeneration	NN	O
.	.	O
There	EX	O
is	VBZ	O
ample	JJ	O
evidence	NN	O
that	IN	O
loss	NN	O
of	IN	O
synaptophysin-immunoreactivity	NN	O
in	IN	O
presynaptic	JJ	O
terminals	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
AD	NNP	O
brain	NN	O
,	,	O
a	DT	O
marker	NN	O
which	WDT	O
correlates	VBZ	O
with	IN	O
extent	NN	O
of	IN	O
cognitive	JJ	O
impairments18-23	NN	O
.	.	O
Additionally	RB	O
,	,	O
immunoreactivity	NN	O
for	IN	O
Microtubule-associated	JJ	O
protein	NN	O
(	(	O
MAP	NNP	O
)	)	O
-2	NN	O
was	VBD	O
examined	VBN	O
as	IN	O
a	DT	O
marker	NN	O
of	IN	O
neuronal	JJ	O
cell	NN	O
bodies	NNS	O
and	CC	O
dendrites	NNS	O
,	,	O
as	IN	O
a	DT	O
significant	JJ	O
decrease	NN	O
of	IN	O
MAP-2	NNP	O
immunoreactive	JJ	O
dendrites	NNS	O
has	VBZ	O
been	VBN	O
observed	VBN	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
brains	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
neurodegeneration	JJ	O
subsequent	NN	O
to	TO	O
HIV-1	NNP	O
encephalitis24	NN	O
.	.	O
Hemibrains	NNS	O
were	VBD	O
subjected	VBN	O
to	TO	O
sagittal	VB	O
sectioning	VBG	O
employing	VBG	O
a	DT	O
Leica	NNP	O
Vibratome®	NNP	O
1000E	CD	O
.	.	O
Sections	NNS	O
,	,	O
40	CD	O
μm	NN	O
thick	NN	O
,	,	O
were	VBD	O
prepared	VBN	O
and	CC	O
collected	VBN	O
into	IN	O
the	DT	O
wells	NNS	O
of	IN	O
12-well	JJ	O
tissue	NN	O
culture	NN	O
plates	VBZ	O
in	IN	O
cryoprotectant	JJ	O
medium	NN	O
and	CC	O
stored	VBN	O
at	IN	O
−20°	NNP	O
C.	NNP	O
until	IN	O
immunostaining	VBG	O
was	VBD	O
performed	VBN	O
.	.	O
Two	CD	O
sections	NNS	O
per	IN	O
mouse	NN	O
were	VBD	O
randomly	RB	O
selected	VBN	O
for	IN	O
further	JJ	O
study	NN	O
,	,	O
based	VBN	O
on	IN	O
full	JJ	O
integrity	NN	O
of	IN	O
the	DT	O
sample	NN	O
,	,	O
i.e.	FW	O
,	,	O
clearly	RB	O
delineated	VBN	O
neocortex	NN	O
,	,	O
and	CC	O
CA1	NNP	O
,	,	O
CA2	NNP	O
and	CC	O
CA3	NNP	O
were	VBD	O
completely	RB	O
intact	JJ	O
.	.	O
Prior	RB	O
to	TO	O
immunohistochemistry	VB	O
,	,	O
free-floating	JJ	O
sections	NNS	O
were	VBD	O
placed	VBN	O
individually	RB	O
in	IN	O
wells	NNS	O
of	IN	O
24-well	JJ	O
tissue	NN	O
culture	NN	O
plates	NNS	O
and	CC	O
washed	VBD	O
twice	RB	O
in	IN	O
phosphate-buffered	JJ	O
saline	NN	O
(	(	O
PBS	NNP	O
;	:	O
pH	VBZ	O
7.4	CD	O
;	:	O
containing	VBG	O
calcium/magnesium	NN	O
)	)	O
.	.	O
Sections	NNS	O
were	VBD	O
then	RB	O
permeabilized	VBN	O
in	IN	O
PBS	NNP	O
containing	VBG	O
Triton	NNP	O
X-100	NNP	O
(	(	O
0.2	CD	O
%	NN	O
)	)	O
for	IN	O
20	CD	O
min	NN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O
Sections	NNS	O
were	VBD	O
stained	VBN	O
with	IN	O
antibodies	NNS	O
to	TO	O
perform	VB	O
assessment	NN	O
of	IN	O
neuronal	JJ	O
integrity	NN	O
.	.	O
Anti-synaptophysin	NNP	O
IgG	NNP	O
(	(	O
Boehringer	NNP	O
)	)	O
was	VBD	O
employed	VBN	O
as	IN	O
a	DT	O
marker	NN	O
of	IN	O
presynaptic	JJ	O
terminals	NNS	O
.	.	O
Anti-MAP-2	JJ	O
IgG	NNP	O
(	(	O
Boehringer	NNP	O
)	)	O
was	VBD	O
employed	VBN	O
as	IN	O
a	DT	O
marker	NN	O
of	IN	O
neuronal	JJ	O
cell	NN	O
bodies/dendrites	NNS	O
.	.	O
The	DT	O
appropriate	JJ	O
nonimmune	NN	O
IgG	NNP	O
was	VBD	O
employed	VBN	O
as	IN	O
a	DT	O
control	NN	O
(	(	O
Boehringer	NNP	O
Mannheim	NNP	O
)	)	O
.	.	O
After	IN	O
appropriate	JJ	O
blocking	VBG	O
steps	NNS	O
,	,	O
primary	JJ	O
antibodies	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
sections	NNS	O
and	CC	O
then	RB	O
washed	VBD	O
in	IN	O
PBS	NNP	O
.	.	O
FITC-labeled	JJ	O
secondary	JJ	O
antibodies	NNS	O
(	(	O
Vector	NNP	O
system	NN	O
;	:	O
ABC	NNP	O
)	)	O
were	VBD	O
employed	VBN	O
to	TO	O
visualize	VB	O
sites	NNS	O
of	IN	O
primary	JJ	O
antibody	NN	O
binding	NN	O
.	.	O
After	IN	O
washing	VBG	O
,	,	O
sections	NNS	O
were	VBD	O
mounted	VBN	O
using	VBG	O
Vectashield	NNP	O
on	IN	O
glass	NN	O
slides	NNS	O
and	CC	O
then	RB	O
coverslips	NNS	O
placed	VBD	O
atop	IN	O
the	DT	O
sections	NNS	O
.	.	O
Sections	NNS	O
will	MD	O
then	RB	O
be	VB	O
kept	VBN	O
in	IN	O
the	DT	O
dark	NN	O
at	IN	O
4°	CD	O
C.	NNP	O
,	,	O
for	IN	O
no	DT	O
more	JJR	O
than	IN	O
two	CD	O
weeks	NNS	O
prior	RB	O
to	TO	O
analysis	NN	O
.	.	O
Semiquantitative	JJ	O
evaluation	NN	O
of	IN	O
neuronal	JJ	O
integrity	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
laser	RBR	O
scanning	VBG	O
confocal	JJ	O
microscopy	NN	O
.	.	O
Neuronal	JJ	O
integrity	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
the	DT	O
neocortex	NN	O
and	CC	O
pyramidal	NN	O
cell	NN	O
layer	NN	O
of	IN	O
the	DT	O
hippocampus	NN	O
(	(	O
CA1	NNP	O
subfield	NN	O
)	)	O
in	IN	O
six	CD	O
sections	NNS	O
per	IN	O
mouse	NN	O
(	(	O
two	CD	O
for	IN	O
each	DT	O
antibody	NN	O
marker	NN	O
)	)	O
.	.	O
For	IN	O
each	DT	O
mouse	NN	O
,	,	O
4-8	JJ	O
confocal	JJ	O
images	NNS	O
(	(	O
3-4/section	JJ	O
)	)	O
of	IN	O
the	DT	O
neocortex	NN	O
,	,	O
and	CC	O
2-4	JJ	O
confocal	JJ	O
images	NNS	O
(	(	O
1-2/section	JJ	O
)	)	O
of	IN	O
the	DT	O
hippocampal	JJ	O
CA1	NNP	O
subfield	NN	O
,	,	O
each	DT	O
covering	VBG	O
an	DT	O
area	NN	O
of	IN	O
210×140	CD	O
μm	NNS	O
,	,	O
were	VBD	O
obtained	VBN	O
.	.	O
Under	IN	O
60×	CD	O
,	,	O
oil	NN	O
immersion	NN	O
,	,	O
the	DT	O
sample	NN	O
was	VBD	O
focused	VBN	O
and	CC	O
iris	JJ	O
and	CC	O
gain	NN	O
levels	NNS	O
adjusted	VBN	O
to	TO	O
obtain	VB	O
images	NNS	O
with	IN	O
a	DT	O
pixel	NN	O
intensity	NN	O
within	IN	O
a	DT	O
linear	JJ	O
range	NN	O
.	.	O
Each	DT	O
final	JJ	O
image	NN	O
was	VBD	O
processed	VBN	O
sequentially	RB	O
in	IN	O
Lasersharp	NNP	O
.	.	O
Digitized	VBN	O
images	NNS	O
were	VBD	O
then	RB	O
transferred	VBN	O
to	TO	O
a	DT	O
Macintosh	NNP	O
computer	NN	O
using	VBG	O
Adobe	NNP	O
Photoshop	NNP	O
,	,	O
JPEG	NNP	O
compression	NN	O
and	CC	O
analyzed	VBN	O
with	IN	O
NIH	NNP	O
Image	NNP	O
.	.	O
The	DT	O
area	NN	O
of	IN	O
the	DT	O
neuropil	NN	O
occupied	VBN	O
by	IN	O
MAP-2-labeled	JJ	O
dendrites	NNS	O
or	CC	O
by	IN	O
synaptophysin-labeled	JJ	O
presynaptic	JJ	O
terminals	NNS	O
was	VBD	O
quantified	VBN	O
and	CC	O
expressed	VBN	O
as	IN	O
a	DT	O
percentage	NN	O
of	IN	O
the	DT	O
total	JJ	O
image	NN	O
area	NN	O
as	IN	O
described24	NN	O
.	.	O
Final	JJ	O
analysis	NN	O
of	IN	O
digitized	JJ	O
images	NNS	O
for	IN	O
area	NN	O
neuropil	NN	O
occupied	VBD	O
was	VBD	O
determined	VBN	O
by	IN	O
two	CD	O
independent	JJ	O
investigators	NNS	O
.	.	O
Mean±standard	NNP	O
deviation	NN	O
is	VBZ	O
reported	VBN	O
for	IN	O
each	DT	O
section	NN	O
.	.	O
Control	NNP	O
sections	NNS	O
were	VBD	O
studied	VBN	O
under	IN	O
conditions	NNS	O
in	IN	O
which	WDT	O
primary	JJ	O
antibody	NN	O
was	VBD	O
omitted	VBN	O
,	,	O
and	CC	O
no	DT	O
signal	NN	O
was	VBD	O
observed	VBN	O
with	IN	O
secondary	JJ	O
antibody	NN	O
alone	RB	O
.	.	O
Immunostaining	NN	O
of	IN	O
mouse	NN	O
brain	NN	O
for	IN	O
other	JJ	O
markers	NNS	O
employed	VBN	O
commercially	RB	O
available	JJ	O
goat	NN	O
antibody	NN	O
to	TO	O
murine	VB	O
macrophage-colony	JJ	O
stimulating	JJ	O
factor	NN	O
(	(	O
goat	JJ	O
anti-M-CSF	NN	O
IgG	NNP	O
;	:	O
10	CD	O
μg/ml	NN	O
;	:	O
Santa	NNP	O
Cruz	NNP	O
)	)	O
,	,	O
rabbit	NN	O
antibody	NN	O
to	TO	O
activated	VBN	O
caspase	NN	O
3	CD	O
(	(	O
50	CD	O
μg/ml	NN	O
;	:	O
PharMingen	NNP	O
)	)	O
,	,	O
and	CC	O
mouse	VBP	O
monoclonal	JJ	O
antibody	NN	O
to	TO	O
phosphorylated	VBN	O
tau	NN	O
(	(	O
AT8	NNP	O
;	:	O
10	CD	O
μg/ml	NN	O
;	:	O
Immunogenetics	NNP	O
)	)	O
.	.	O
In	IN	O
each	DT	O
case	NN	O
,	,	O
the	DT	O
immunostaining	NN	O
protocol	NN	O
used	VBN	O
standard	NN	O
techniques	NNS	O
according	VBG	O
to	TO	O
the	DT	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
.	.	O
Rabbit	NNP	O
anti-murine	JJ	O
Interleukin	NNP	O
(	(	O
IL	NNP	O
)	)	O
6	CD	O
IgG	NNP	O
was	VBD	O
provided	VBN	O
by	IN	O
Dr.	NNP	O
Gerald	NNP	O
Fuller	NNP	O
(	(	O
University	NNP	O
of	IN	O
Alabama	NNP	O
Medical	NNP	O
Center	NNP	O
,	,	O
Birmingham	NNP	O
)	)	O
and	CC	O
has	VBZ	O
been	VBN	O
used	VBN	O
in	IN	O
previous	JJ	O
studies25	NN	O
.	.	O
Sections	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
primary	JJ	O
antibodies	NNS	O
overnight	VBD	O
at	IN	O
4°	CD	O
C.	NNP	O
,	,	O
followed	VBN	O
by	IN	O
blocking	VBG	O
with	IN	O
appropriate	JJ	O
antisera	NN	O
and	CC	O
addition	NN	O
of	IN	O
biotin-conjugated	JJ	O
goat	NN	O
anti-rabbit	NN	O
,	,	O
goat	VB	O
anti-mouse	NN	O
or	CC	O
mouse	VB	O
anti-goat	JJ	O
IgG	NNP	O
(	(	O
1:25	CD	O
dilution	NN	O
)	)	O
for	IN	O
30	CD	O
min	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
Then	RB	O
ExtrAvidin®	NNP	O
conjugated	VBD	O
to	TO	O
peroxidase	VB	O
or	CC	O
to	TO	O
alkaline	VB	O
phosphatase	NN	O
(	(	O
1:25	CD	O
dilution	NN	O
)	)	O
was	VBD	O
added	VBN	O
for	IN	O
25	CD	O
min	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
Slides	NNP	O
were	VBD	O
then	RB	O
washed	VBN	O
and	CC	O
developed	VBN	O
with	IN	O
3-amino-9-ethyl	JJ	O
carbazole	NN	O
or	CC	O
fast	RB	O
red	JJ	O
.	.	O
Sections	NNS	O
were	VBD	O
viewed	VBN	O
in	IN	O
an	DT	O
Olympus	NNP	O
microscope	NN	O
,	,	O
and	CC	O
images	NNS	O
were	VBD	O
quantified	VBN	O
using	VBG	O
the	DT	O
Universal	NNP	O
imaging	NN	O
system	NN	O
.	.	O
Activation	NN	O
of	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
NF-kB	NNP	O
was	VBD	O
studied	VBN	O
in	IN	O
brains	NNS	O
of	IN	O
mice	NN	O
and	CC	O
in	IN	O
neurons	NNS	O
cultured	VBN	O
from	IN	O
this	DT	O
tissue	NN	O
(	(	O
see	VB	O
below	IN	O
)	)	O
.	.	O
Nuclear	JJ	O
extracts	NNS	O
were	VBD	O
prepared	JJ	O
according	VBG	O
to	TO	O
the	DT	O
method	NN	O
of	IN	O
Dignam	NNP	O
et	FW	O
al.26	NN	O
,	,	O
and	CC	O
were	VBD	O
incubated	VBN	O
with	IN	O
32P-labelled	JJ	O
double	NN	O
stranded	VBD	O
consensus	NN	O
oligonucleotide	NN	O
probe	NN	O
for	IN	O
NF-kB	NNP	O
(	(	O
Santa	NNP	O
Cruz	NNP	O
)	)	O
followed	VBN	O
by	IN	O
polyacrylamide	NN	O
gel	NN	O
electrophoresis	NN	O
and	CC	O
autoradiography	NN	O
.	.	O
These	DT	O
methods	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
previously	RB	O
using	VBG	O
brain	NN	O
tissue	NN	O
and	CC	O
cultured	JJ	O
cells	NNS	O
as	IN	O
the	DT	O
samples	NNS	O
for	IN	O
preparation	NN	O
of	IN	O
nuclear	JJ	O
extracts4	NN	O
.	.	O
Isolation	NN	O
and	CC	O
characterization	NN	O
of	IN	O
neurons	NNS	O
from	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
Brains	NNS	O
of	IN	O
E16-18	NNP	O
mouse	NN	O
embryos	NN	O
were	VBD	O
processed	VBN	O
by	IN	O
a	DT	O
modification	NN	O
of	IN	O
a	DT	O
previously	RB	O
described	VBN	O
method27	NN	O
.	.	O
In	IN	O
brief	NN	O
,	,	O
Embryos	NNP	O
were	VBD	O
washed	VBN	O
in	IN	O
ethanol	NN	O
(	(	O
75	CD	O
%	NN	O
)	)	O
,	,	O
transferred	VBN	O
to	TO	O
a	DT	O
dish	NN	O
with	IN	O
sterile	JJ	O
phosphate-buffered	JJ	O
saline	NN	O
(	(	O
PBS	NNP	O
)	)	O
at	IN	O
4°	CD	O
C.	NNP	O
under	IN	O
a	DT	O
tissue	NN	O
culture	NN	O
hood	NN	O
.	.	O
Two	CD	O
embryos	NNS	O
were	VBD	O
dissected	VBN	O
at	IN	O
a	DT	O
time	NN	O
immersed	VBN	O
in	IN	O
Neurobasal	NNP	O
Medium	NNP	O
(	(	O
GIBCO	NNP	O
)	)	O
with	IN	O
NaCl	NNP	O
(	(	O
22	CD	O
mM	NN	O
)	)	O
,	,	O
NaHCO3	NNP	O
(	(	O
4.4	CD	O
mM	NN	O
)	)	O
,	,	O
penicillin	NN	O
(	(	O
50	CD	O
units/ml	NN	O
)	)	O
and	CC	O
streptomycin	NN	O
(	(	O
50	CD	O
μg/ml	NN	O
)	)	O
.	.	O
The	DT	O
embryo	NN	O
tail	NN	O
was	VBD	O
removed	VBN	O
and	CC	O
analyzed	VBN	O
by	IN	O
PCR	NNP	O
to	TO	O
determine	VB	O
genotype	NN	O
(	(	O
as	IN	O
above	NN	O
)	)	O
.	.	O
Cerebral	NNP	O
cortex	NN	O
was	VBD	O
dissected	VBN	O
free	JJ	O
from	IN	O
the	DT	O
cerebellum	NN	O
and	CC	O
brainstem	NN	O
,	,	O
sliced	VBD	O
into	IN	O
1	CD	O
mm	NN	O
pieces	NNS	O
,	,	O
and	CC	O
transferred	VBD	O
to	TO	O
1.5	CD	O
ml	NNS	O
eppendorf	JJ	O
tubes	NNS	O
in	IN	O
the	DT	O
above	JJ	O
medium	NN	O
.	.	O
The	DT	O
tube	NN	O
was	VBD	O
centrifuged	VBN	O
at	IN	O
400	CD	O
rpm	NN	O
,	,	O
the	DT	O
pellet	NN	O
was	VBD	O
washed	VBN	O
in	IN	O
PBS	NNP	O
,	,	O
and	CC	O
resuspended	VBD	O
in	IN	O
PBS	NNP	O
.	.	O
Then	RB	O
,	,	O
trypsin	NN	O
(	(	O
0.25	CD	O
%	NN	O
;	:	O
0.5	CD	O
ml	NN	O
)	)	O
and	CC	O
DNAse	NNP	O
(	(	O
250	CD	O
units/ml	NN	O
)	)	O
were	VBD	O
added	VBN	O
and	CC	O
the	DT	O
incubation	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
15	CD	O
min	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
with	IN	O
gentle	JJ	O
shaking	NN	O
.	.	O
The	DT	O
mixture	NN	O
was	VBD	O
decanted	VBN	O
,	,	O
washed	VBD	O
twice	RB	O
in	IN	O
PBS	NNP	O
by	IN	O
inverting	VBG	O
the	DT	O
tube	NN	O
and	CC	O
gently	RB	O
spinning	VBG	O
at	IN	O
400	CD	O
rpm	NN	O
for	IN	O
5	CD	O
min	NN	O
.	.	O
Neurons	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
growth	NN	O
medium	NN	O
(	(	O
Neurobasal	NNP	O
Medium	NNP	O
with	IN	O
B27	NNP	O
,	,	O
2	CD	O
%	NN	O
,	,	O
L-glutamine	NNP	O
,	,	O
2	CD	O
mM	NN	O
,	,	O
penicillin	NN	O
,	,	O
50	CD	O
units/ml	NN	O
,	,	O
streptomycin	NN	O
,	,	O
50	CD	O
μg/ml	NN	O
)	)	O
in	IN	O
wells	NNS	O
coated	VBN	O
with	IN	O
poly-L-lysine	NN	O
.	.	O
Neurons	NNS	O
were	VBD	O
identified	VBN	O
immunocytochemically	RB	O
using	VBG	O
antibody	NN	O
to	TO	O
neurofilament	NN	O
(	(	O
Sigma	NNP	O
)	)	O
and	CC	O
the	DT	O
methods	NNS	O
for	IN	O
immunostaining	VBG	O
described	VBN	O
above	IN	O
.	.	O
Cultures	NNS	O
of	IN	O
neurons	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
preformed	VB	O
Aβ	NNP	O
(	(	O
1-42	JJ	O
)	)	O
fibrils	NNS	O
for	IN	O
5	CD	O
hrs	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
Aβ	NNP	O
(	(	O
1-42	JJ	O
)	)	O
synthetic	JJ	O
peptide	NN	O
was	VBD	O
purchased	VBN	O
from	IN	O
QCB	NNP	O
,	,	O
and	CC	O
was	VBD	O
incubated	VBN	O
for	IN	O
5	CD	O
days	NNS	O
at	IN	O
37°	CD	O
C.	NNP	O
to	TO	O
allow	VB	O
fibril	JJ	O
formation	NN	O
to	TO	O
occur	VB	O
.	.	O
The	DT	O
presence	NN	O
of	IN	O
fibrils	NNS	O
was	VBD	O
confirmed	VBN	O
by	IN	O
electron	NN	O
microscopy	NN	O
.	.	O
Fibril	NNP	O
preparations	NNS	O
were	VBD	O
then	RB	O
frozen	JJ	O
(	(	O
−20°	NNP	O
C.	NNP	O
)	)	O
until	IN	O
use	NN	O
.	.	O
Just	RB	O
prior	RB	O
to	TO	O
an	DT	O
experiment	NN	O
,	,	O
fibril	JJ	O
preparations	NNS	O
were	VBD	O
thawed	VBN	O
,	,	O
vortexed	FW	O
,	,	O
and	CC	O
then	RB	O
added	VBD	O
to	TO	O
culture	NN	O
medium	NN	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
0.5	CD	O
μM	NNS	O
for	IN	O
5	CD	O
hrs	NN	O
(	(	O
NF-kB	NNP	O
activation	NN	O
)	)	O
or	CC	O
30-40	JJ	O
hrs	NN	O
(	(	O
detection	NN	O
of	IN	O
activated	JJ	O
caspase	NN	O
3	CD	O
)	)	O
at	IN	O
37°	CD	O
.	.	O
Nuclear	JJ	O
extracts	NNS	O
were	VBD	O
prepared	JJ	O
and	CC	O
EMSA	NNP	O
was	VBD	O
performed	VBN	O
as	IN	O
above	NN	O
.	.	O
Where	WRB	O
indicated	VBN	O
,	,	O
anti-RAGE	JJ	O
IgG	NNP	O
was	VBD	O
added	VBN	O
during	IN	O
incubation	NN	O
of	IN	O
Aβ	NNP	O
fibrils	NNS	O
with	IN	O
the	DT	O
cells	NNS	O
.	.	O
Caspase	NNP	O
3	CD	O
activity	NN	O
was	VBD	O
studied	VBN	O
using	VBG	O
a	DT	O
kit	NN	O
from	IN	O
Clontech	NNP	O
.	.	O
Results	NNS	O
Identification	NNP	O
of	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
Southern	JJ	O
analysis	NN	O
identifying	VBG	O
three	CD	O
Tg	NNP	O
PD-RAGE	NNP	O
founders	NNS	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
2	CD	O
.	.	O
These	DT	O
mice	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
generate	VB	O
lines	NNS	O
of	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
in	IN	O
whom	WP	O
the	DT	O
progeny	NN	O
were	VBD	O
identified	VBN	O
by	IN	O
PCR	NNP	O
using	VBG	O
the	DT	O
primers	NNS	O
described	VBN	O
in	IN	O
the	DT	O
methods	NNS	O
section	NN	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
PCR	NNP	O
detection	NN	O
of	IN	O
positive	JJ	O
founders	NNS	O
,	,	O
versus	FW	O
negative	JJ	O
non-Tg	JJ	O
animals	NNS	O
is	VBZ	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
3	CD	O
.	.	O
Characterization	NN	O
of	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
Expression	NN	O
of	IN	O
the	DT	O
transgene	NN	O
in	IN	O
the	DT	O
brain	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
Northern	NNP	O
analysis	NN	O
of	IN	O
total	JJ	O
RNA	NNP	O
extracted	VBD	O
from	IN	O
cerebral	JJ	O
cortex	NN	O
with	IN	O
32P-labelled	JJ	O
cDNA	NN	O
for	IN	O
human	JJ	O
RAGE	NNP	O
(	(	O
FIG	NNP	O
.	.	O
4A	CD	O
)	)	O
.	.	O
An	DT	O
intense	JJ	O
band	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
nontransgenic	JJ	O
littermate	NN	O
controls	NNS	O
.	.	O
Similarly	RB	O
Western	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
protein	NN	O
extracts	NNS	O
of	IN	O
cerebral	JJ	O
cortex	NN	O
from	IN	O
transgenic	JJ	O
mice	NN	O
using	VBG	O
antibody	NN	O
to	TO	O
the	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
recombinant	JJ	O
human	JJ	O
RAGE	NN	O
.	.	O
Again	NNP	O
,	,	O
a	DT	O
strong	JJ	O
band	NN	O
of	IN	O
immunoreactivity	NN	O
migrating	VBG	O
above	IN	O
the	DT	O
46	CD	O
kDa	NN	O
molecular	JJ	O
weight	NN	O
marker	NN	O
confirmed	VBD	O
the	DT	O
presence	NN	O
of	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
RAGE	NNP	O
antigen	NN	O
in	IN	O
brains	NNS	O
of	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
compared	VBN	O
with	IN	O
nontransgenic	JJ	O
littermate	NN	O
controls	NNS	O
(	(	O
FIG	NNP	O
.	.	O
4B	CD	O
)	)	O
.	.	O
Immunoblotting	NN	O
was	VBD	O
then	RB	O
performed	VBN	O
on	IN	O
brain	NN	O
subregions	NNS	O
,	,	O
including	VBG	O
cerebral	JJ	O
cortex	NN	O
,	,	O
hippocampus	NN	O
and	CC	O
cerebellum	NN	O
,	,	O
with	IN	O
anti-RAGE	JJ	O
IgG	NNP	O
(	(	O
FIG	NNP	O
.	.	O
5	CD	O
)	)	O
.	.	O
In	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
,	,	O
intense	JJ	O
immunoreactive	JJ	O
bands	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
cerebral	JJ	O
cortex	NN	O
and	CC	O
hippocampus	NN	O
,	,	O
compared	VBN	O
with	IN	O
lower	JJR	O
levels	NNS	O
of	IN	O
transgene	NN	O
expression	NN	O
in	IN	O
the	DT	O
cerebellum	NN	O
.	.	O
Immunostaining	VBG	O
with	IN	O
anti-RAGE	JJ	O
IgG	NNP	O
confirmed	VBD	O
that	IN	O
the	DT	O
increased	JJ	O
levels	NNS	O
of	IN	O
RAGE	NNP	O
in	IN	O
Tg	NNP	O
PD-RAGE	NN	O
animals	NNS	O
were	VBD	O
in	IN	O
neurons	NNS	O
(	(	O
FIG	NNP	O
.	.	O
6A-B	JJ	O
)	)	O
.	.	O
These	DT	O
data	NNS	O
indicate	VBP	O
that	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NNP	O
provide	VB	O
a	DT	O
model	NN	O
system	NN	O
in	IN	O
which	WDT	O
neurons	NNS	O
of	IN	O
the	DT	O
brain	NN	O
,	,	O
especially	RB	O
cerebral	JJ	O
cortex	NNS	O
and	CC	O
hippocampus	NN	O
express	RB	O
high	JJ	O
levels	NNS	O
of	IN	O
RAGE	NNP	O
.	.	O
To	TO	O
examine	VB	O
consequences	NNS	O
of	IN	O
enhanced	JJ	O
neuronal	JJ	O
RAGE	NNP	O
expression	NN	O
for	IN	O
ischemic	JJ	O
stress	NN	O
experiments	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
a	DT	O
murine	JJ	O
model	NN	O
of	IN	O
transient	JJ	O
occlusion	NN	O
of	IN	O
the	DT	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
(	(	O
FIG	NNP	O
.	.	O
7	CD	O
)	)	O
.	.	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
nonTg	JJ	O
littermate	NN	O
controls	NNS	O
weighed	VBD	O
≈26	JJ	O
grams	NNS	O
and	CC	O
were	VBD	O
≈10	NNP	O
wks	JJ	O
old	JJ	O
.	.	O
Neurologic	NNP	O
deficit	NN	O
score	NN	O
,	,	O
evaluated	VBN	O
at	IN	O
the	DT	O
24	CD	O
hr	NN	O
point	NN	O
,	,	O
was	VBD	O
reduced	VBN	O
in	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
compared	VBN	O
with	IN	O
nonTg	JJ	O
littermates	NNS	O
.	.	O
The	DT	O
volume	NN	O
of	IN	O
infarcted	JJ	O
cerebral	JJ	O
tissue	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
≈50	NN	O
%	NN	O
in	IN	O
Tg	NNP	O
mice	NN	O
(	(	O
FIG	NNP	O
.	.	O
7	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.05	CD	O
)	)	O
.	.	O
Characterization	NN	O
of	IN	O
Tg	NNP	O
PD-RAGE/hAPP	NNP	O
mice	NN	O
.	.	O
The	DT	O
increased	JJ	O
expression	NN	O
of	IN	O
RAGE	NNP	O
in	IN	O
AD	NNP	O
brain	NN	O
,	,	O
compared	VBN	O
with	IN	O
age-matched	JJ	O
non-demented	JJ	O
brain	NN	O
,	,	O
suggested	VBD	O
that	IN	O
the	DT	O
receptor	NN	O
might	MD	O
be	VB	O
associated	VBN	O
with	IN	O
AD	NNP	O
pathology	NN	O
.	.	O
Consistent	JJ	O
with	IN	O
this	DT	O
hypothesis	NN	O
,	,	O
our	PRP$	O
pilot	NN	O
studies	NNS	O
with	IN	O
Tg	NNP	O
hAPP	NN	O
mice	NN	O
displayed	VBD	O
increased	JJ	O
levels	NNS	O
of	IN	O
RAGE	NNP	O
in	IN	O
cerebral	JJ	O
cortex	NN	O
by	IN	O
4	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
which	WDT	O
is	VBZ	O
prior	JJ	O
to	TO	O
plaque	VB	O
formation	NN	O
.	.	O
Tg	NNP	O
hAPP	NN	O
mice	NN	O
are	VBP	O
especially	RB	O
useful	JJ	O
for	IN	O
studies	NNS	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
introduction	NN	O
of	IN	O
the	DT	O
PD-RAGE	NNP	O
transgene	NN	O
since	IN	O
they	PRP	O
have	VBP	O
been	VBN	O
characterized	VBN	O
in	IN	O
previous	JJ	O
studies	NNS	O
with	IN	O
respect	NN	O
to	TO	O
neuropathologic	VB	O
and	CC	O
electrophysiologic	VB	O
properties	NNS	O
.	.	O
If	IN	O
RAGE-Aβ	NNP	O
interaction	NN	O
promoted	VBD	O
neuronal	JJ	O
stress	NN	O
,	,	O
we	PRP	O
reasoned	VBD	O
that	IN	O
expression	NN	O
of	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
RAGE	NNP	O
at	IN	O
early	JJ	O
times	NNS	O
in	IN	O
the	DT	O
brains	NNS	O
of	IN	O
animals	NNS	O
expressing	VBG	O
the	DT	O
hAPP	NN	O
transgene	NN	O
might	MD	O
result	VB	O
in	IN	O
magnified	VBN	O
cell	NN	O
stress	NN	O
and	CC	O
cytotoxicity	NN	O
(	(	O
the	DT	O
transgenic	NN	O
model	NN	O
introduces	VBZ	O
higher	JJR	O
levels	NNS	O
of	IN	O
RAGE	NNP	O
expression	NN	O
than	IN	O
were	VBD	O
present	JJ	O
in	IN	O
Tg	NNP	O
hAPP	JJ	O
mice	NN	O
alone	RB	O
,	,	O
and	CC	O
thus	RB	O
,	,	O
potentially	RB	O
represents	VBZ	O
a	DT	O
model	NN	O
of	IN	O
exaggerated	JJ	O
effects	NNS	O
of	IN	O
RAGE	NNP	O
due	JJ	O
to	TO	O
overexpression	NN	O
of	IN	O
the	DT	O
receptor	NN	O
)	)	O
.	.	O
Cross-breeding	JJ	O
studies	NNS	O
were	VBD	O
performed	VBN	O
and	CC	O
double	JJ	O
transgenic	JJ	O
mice	NN	O
were	VBD	O
identified	VBN	O
by	IN	O
PCR	NNP	O
using	VBG	O
primers	NNS	O
specific	JJ	O
for	IN	O
the	DT	O
PD-RAGE	NNP	O
transgene	NN	O
and	CC	O
the	DT	O
hAPP	NN	O
transgene	NN	O
.	.	O
Results	NNS	O
of	IN	O
a	DT	O
representative	JJ	O
PCR	NNP	O
analysis	NN	O
are	VBP	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
8	CD	O
demonstrating	VBG	O
amplicons	NNS	O
for	IN	O
both	DT	O
the	DT	O
PD-RAGE	NNP	O
and	CC	O
hAPP	JJ	O
genes	NNS	O
in	IN	O
the	DT	O
double-transgenic	JJ	O
animals	NNS	O
versus	VBP	O
single	JJ	O
transgenics	NNS	O
and	CC	O
nontransgenic	JJ	O
littermate	NN	O
controls	NNS	O
.	.	O
The	DT	O
double	JJ	O
transgenic	JJ	O
mice	NNS	O
have	VBP	O
been	VBN	O
termed	VBN	O
Tg	NNP	O
PD-RAGE/hAPP	NNP	O
mice	NN	O
.	.	O
Double	NNP	O
transgenic	JJ	O
mice	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
three-four	JJ	O
months	NNS	O
and	CC	O
evidence	NN	O
of	IN	O
neuronal	JJ	O
stress	NN	O
was	VBD	O
then	RB	O
analyzed	VBN	O
by	IN	O
studying	VBG	O
expression	NN	O
of	IN	O
M-CSF	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
9A	CD	O
,	,	O
9B1-B3	CD	O
,	,	O
9C	CD	O
)	)	O
and	CC	O
IL-6	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
10A	CD	O
,	,	O
10B1-B3	JJ	O
,	,	O
10C	CD	O
)	)	O
,	,	O
and	CC	O
activation	NN	O
of	IN	O
NF-kB	NNP	O
(	(	O
FIG	NNP	O
.	.	O
11	CD	O
)	)	O
.	.	O
Northern	NNP	O
analysis	NN	O
of	IN	O
cerebral	JJ	O
cortex	NN	O
showed	VBD	O
increased	JJ	O
levels	NNS	O
of	IN	O
transcripts	NNS	O
for	IN	O
M-CSF	NNP	O
in	IN	O
Tg	NNP	O
PD-RAGE/hAPP	NNP	O
mice	NN	O
compared	VBN	O
with	IN	O
single	JJ	O
transgenics	NNS	O
(	(	O
Tg	NNP	O
hAPP	NN	O
and	CC	O
Tg	NNP	O
PD-RAGE	NNP	O
)	)	O
and	CC	O
nonTg	JJ	O
littermate	NN	O
controls	NNS	O
(	(	O
FIG	NNP	O
.	.	O
9A	CD	O
)	)	O
.	.	O
Immunostaining	VBG	O
with	IN	O
anti-M-CSF	JJ	O
IgG	NNP	O
confirmed	VBD	O
that	IN	O
the	DT	O
increase	NN	O
in	IN	O
M-CSF	NNP	O
antigen	NN	O
was	VBD	O
predominately	RB	O
in	IN	O
neurons	NNS	O
,	,	O
and	CC	O
that	IN	O
double-transgenics	NNS	O
showed	VBD	O
elevated	JJ	O
levels	NNS	O
of	IN	O
antigen	NN	O
compared	VBN	O
with	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
(	(	O
FIGS	NNP	O
.	.	O
9B1	CD	O
,	,	O
9B2	CD	O
,	,	O
9B3	CD	O
and	CC	O
9C	CD	O
)	)	O
.	.	O
Similar	JJ	O
results	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
respect	NN	O
to	TO	O
increased	VBN	O
expression	NN	O
of	IN	O
IL-6	NNP	O
transcripts	NNS	O
and	CC	O
antigen	NN	O
(	(	O
FIGS	NNP	O
.	.	O
10A	CD	O
,	,	O
10B1-B3	JJ	O
,	,	O
10C	CD	O
)	)	O
)	)	O
.	.	O
Since	IN	O
activation	NN	O
of	IN	O
NF-kB	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
cellular	JJ	O
stress	NN	O
responses	NNS	O
and	CC	O
can	MD	O
underlie	VB	O
expression	NN	O
of	IN	O
M-CSF	NNP	O
and	CC	O
IL-6	NNP	O
,	,	O
we	PRP	O
analyzed	VBD	O
nuclear	JJ	O
translocation	NN	O
of	IN	O
NF-kB	NNP	O
in	IN	O
nuclear	JJ	O
extracts	NNS	O
prepared	VBN	O
from	IN	O
brains	NNS	O
of	IN	O
the	DT	O
transgenic	JJ	O
mice	NN	O
by	IN	O
EMSA	NNP	O
(	(	O
FIG	NNP	O
.	.	O
11	CD	O
)	)	O
.	.	O
Analysis	NN	O
of	IN	O
double	JJ	O
transgenic	JJ	O
mice	NN	O
invariably	RB	O
displayed	VBD	O
a	DT	O
strong	JJ	O
gel	NN	O
shift	NN	O
band	NN	O
,	,	O
whose	WP$	O
intensity	NN	O
varied	VBD	O
somewhat	RB	O
in	IN	O
the	DT	O
different	JJ	O
animals	NNS	O
,	,	O
whereas	JJ	O
weak/absent	NN	O
bands	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
single	JJ	O
transgenics	NNS	O
.	.	O
These	DT	O
data	NNS	O
were	VBD	O
consistent	JJ	O
with	IN	O
increased	JJ	O
neuronal	JJ	O
stress	NN	O
in	IN	O
Tg	NNP	O
PD-RAGE/hAPP	NNP	O
mice	NN	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
indicate	VB	O
whether	IN	O
the	DT	O
outcome	NN	O
of	IN	O
this	DT	O
stress	NN	O
would	MD	O
be	VB	O
neuroprotection	NN	O
or	CC	O
neurotoxicity	NN	O
.	.	O
To	TO	O
analyze	VB	O
this	DT	O
situation	NN	O
neuropathologic	JJ	O
studies	NNS	O
were	VBD	O
performed	VBN	O
,	,	O
and	CC	O
study	NN	O
of	IN	O
markers	NNS	O
more	RBR	O
clearly	RB	O
associated	VBN	O
with	IN	O
toxicity	NN	O
,	,	O
such	JJ	O
as	IN	O
activated	JJ	O
caspase	NN	O
3	CD	O
,	,	O
was	VBD	O
undertaken	VBN	O
.	.	O
Immunostaining	NN	O
of	IN	O
hippocampus	NN	O
(	(	O
lacunosum	JJ	O
moleculare	NN	O
layer	NN	O
)	)	O
from	IN	O
double	JJ	O
transgenic	JJ	O
mice	NN	O
(	(	O
age	NN	O
3-4	CD	O
months	NNS	O
)	)	O
with	IN	O
antibody	NN	O
to	TO	O
synaptophysin	VB	O
demonstrated	VBN	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
area	NN	O
of	IN	O
neuropil	NNS	O
occupied	VBN	O
by	IN	O
synaptophysin-labeled	JJ	O
presynaptic	JJ	O
terminals	NNS	O
(	(	O
FIG	NNP	O
.	.	O
12	CD	O
)	)	O
.	.	O
Similar	JJ	O
studies	NNS	O
with	IN	O
antibody	NN	O
to	TO	O
MAP-2	NNP	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
area	NN	O
of	IN	O
neuropil	NNS	O
occupied	VBN	O
by	IN	O
MAP-2-labeled	JJ	O
dendrites	NNS	O
(	(	O
FIG	NNP	O
.	.	O
13	CD	O
)	)	O
.	.	O
Although	IN	O
stereologic	JJ	O
studies	NNS	O
will	MD	O
be	VB	O
required	VBN	O
to	TO	O
determine	VB	O
actual	JJ	O
neuronal	JJ	O
loss	NN	O
,	,	O
these	DT	O
results	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
evidence	NN	O
of	IN	O
neurotoxicity	NN	O
.	.	O
Consistent	JJ	O
with	IN	O
this	DT	O
impression	NN	O
,	,	O
analysis	NN	O
of	IN	O
older	JJR	O
double	JJ	O
transgenic	JJ	O
mice	NN	O
(	(	O
8-9	JJ	O
months	NNS	O
of	IN	O
age	NN	O
)	)	O
showed	VBD	O
increased	VBN	O
staining	VBG	O
with	IN	O
an	DT	O
antibody	NN	O
selective	NN	O
for	IN	O
the	DT	O
activated	JJ	O
form	NN	O
of	IN	O
caspase	NN	O
3	CD	O
(	(	O
FIGS	NNP	O
.	.	O
14A1-4	JJ	O
,	,	O
14B	CD	O
)	)	O
and	CC	O
phosphorylated	VBN	O
tau	NN	O
(	(	O
AT8	NNP	O
)	)	O
(	(	O
FIGS	NNP	O
.	.	O
15A1-A4	JJ	O
,	,	O
15B	CD	O
)	)	O
in	IN	O
brains	NNS	O
of	IN	O
double	JJ	O
transgenic	JJ	O
mice	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
.	.	O
Culture	NN	O
of	IN	O
neurons	NNS	O
from	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
Neuronal	JJ	O
cultures	NNS	O
were	VBD	O
made	VBN	O
from	IN	O
the	DT	O
cerebral	JJ	O
cortex	NN	O
from	IN	O
E16	NNP	O
mouse	NN	O
embryos	NN	O
.	.	O
These	DT	O
cultures	NNS	O
were	VBD	O
>	JJ	O
90	CD	O
%	NN	O
neurons	NNS	O
based	VBN	O
on	IN	O
staining	VBG	O
with	IN	O
anti-neurofilament	JJ	O
antibody	NN	O
.	.	O
Cultured	NNP	O
neurons	NNS	O
displayed	VBD	O
high	JJ	O
levels	NNS	O
of	IN	O
RAGE	NNP	O
expression	NN	O
based	VBN	O
on	IN	O
immunoblotting	NN	O
(	(	O
FIG	NNP	O
.	.	O
16	CD	O
)	)	O
.	.	O
Such	JJ	O
neuronal	JJ	O
cultures	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
preformed	JJ	O
Aβ	NNP	O
(	(	O
1-40	JJ	O
)	)	O
fibrils	NNS	O
(	(	O
0.5	CD	O
μM	NN	O
)	)	O
for	IN	O
2	CD	O
hrs	NN	O
,	,	O
and	CC	O
then	RB	O
nuclear	JJ	O
extracts	NNS	O
were	VBD	O
prepared	VBN	O
for	IN	O
EMSA	NNP	O
using	VBG	O
consensus	NN	O
probe	NN	O
for	IN	O
NF-kB	NNP	O
.	.	O
A	DT	O
gel	NN	O
shift	NN	O
band	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
neuronal	JJ	O
cultures	NNS	O
from	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
,	,	O
but	CC	O
such	PDT	O
a	DT	O
band	NN	O
was	VBD	O
either	RB	O
not	RB	O
seen	VBN	O
or	CC	O
present	JJ	O
at	IN	O
much	JJ	O
reduced	VBN	O
intensity	NN	O
with	IN	O
samples	NNS	O
from	IN	O
nontransgenic	JJ	O
littermate	NN	O
control	NN	O
mice	NN	O
(	(	O
FIG	NNP	O
.	.	O
17A	CD	O
)	)	O
.	.	O
That	IN	O
this	DT	O
was	VBD	O
due	JJ	O
to	TO	O
Aβ-RAGE	JJ	O
interaction	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
the	DT	O
dose-dependent	JJ	O
inhibitory	JJ	O
effect	NN	O
of	IN	O
anti-RAGE	NN	O
IgG	NNP	O
,	,	O
but	CC	O
not	RB	O
nonimmune	JJ	O
IgG	NNP	O
(	(	O
FIG	NNP	O
.	.	O
17B	CD	O
)	)	O
.	.	O
To	TO	O
determine	VB	O
whether	IN	O
neurons	NNS	O
overexpressing	VBG	O
RAGE	NNP	O
exposed	VBD	O
to	TO	O
Aβ	NNP	O
fibrils	NNS	O
were	VBD	O
being	VBG	O
forced	VBN	O
down	RP	O
a	DT	O
pathway	NN	O
of	IN	O
enhanced	JJ	O
toxicity	NN	O
evidence	NN	O
of	IN	O
activated	JJ	O
caspase	NN	O
3	CD	O
was	VBD	O
sought	VBN	O
.	.	O
After	IN	O
30-40	JJ	O
hrs	NN	O
of	IN	O
exposing	VBG	O
Aβ	NNP	O
fibrils	NNS	O
to	TO	O
neurons	NNS	O
from	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
,	,	O
increased	VBD	O
caspase	NN	O
3	CD	O
activity	NN	O
was	VBD	O
detected	VBN	O
(	(	O
FIG	NNP	O
.	.	O
18	CD	O
)	)	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
under	IN	O
these	DT	O
conditions	NNS	O
,	,	O
neurons	NNS	O
form	VBP	O
nonTg	JJ	O
littermates	NNS	O
did	VBD	O
not	RB	O
display	VB	O
increased	JJ	O
caspase	NN	O
3	CD	O
activity	NN	O
.	.	O
Discussion	NN	O
We	PRP	O
have	VBP	O
described	VBN	O
the	DT	O
generation	NN	O
of	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
which	WDT	O
display	NN	O
increased	VBD	O
expression	NN	O
of	IN	O
full-length	JJ	O
RAGE	NNP	O
in	IN	O
neurons	NNS	O
.	.	O
The	DT	O
use	NN	O
of	IN	O
these	DT	O
mice	NNS	O
to	TO	O
analyze	VB	O
the	DT	O
contribution	NN	O
of	IN	O
RAGE	NNP	O
to	TO	O
cellular	JJ	O
responses	NNS	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	NN	O
can	MD	O
be	VB	O
summarized	VBN	O
according	VBG	O
to	TO	O
three	CD	O
general	JJ	O
categories	NNS	O
:	:	O
In	IN	O
each	DT	O
case	NN	O
,	,	O
the	DT	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
systems	NNS	O
based	VBN	O
on	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
or	CC	O
cells	NNS	O
derived	VBN	O
from	IN	O
them	PRP	O
are	VBP	O
ideal	JJ	O
for	IN	O
studying	VBG	O
RAGE	NNP	O
inhibitors	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
dissecting	VBG	O
contributions	NNS	O
of	IN	O
RAGE	NNP	O
to	TO	O
physiologic/pathophysiologic	VB	O
outcomes	NNS	O
.	.	O
Example	RB	O
2	CD	O
Induction	NNP	O
of	IN	O
Transient	NNP	O
Middle	NNP	O
Cerebral	NNP	O
Artery	NNP	O
in	IN	O
RAGE	NNP	O
Transgenic	NNP	O
Mice	NNP	O
and	CC	O
use	NN	O
of	IN	O
this	DT	O
Transgenic	NNP	O
Mouse	NNP	O
Model	NNP	O
for	IN	O
Stroke	NNP	O
in	IN	O
Humans	NNPS	O
Methods	NNS	O
:	:	O
Induction	NN	O
of	IN	O
Transient	NNP	O
Middle	NNP	O
Cerebral	NNP	O
Artery	NNP	O
Occlusion	NNP	O
in	IN	O
the	DT	O
Mouse	NNP	O
Induction	NNP	O
of	IN	O
stroke	NN	O
in	IN	O
Tg	NNP	O
PD-RAGE	NNP	O
mice	NN	O
.	.	O
Functional	JJ	O
consequences	NNS	O
of	IN	O
overexpression	NN	O
of	IN	O
RAGE	NNP	O
were	VBD	O
first	RB	O
assessed	VBN	O
in	IN	O
response	NN	O
to	TO	O
ischemic	VB	O
stress	NN	O
,	,	O
the	DT	O
transient	NN	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
occlusion	NN	O
model	NN	O
.	.	O
Murine	NNP	O
stroke	VBD	O
model	NN	O
Mice	NNP	O
(	(	O
C57BL6/J	NNP	O
,	,	O
male	NN	O
)	)	O
were	VBD	O
subjected	VBN	O
to	TO	O
stroke	VB	O
according	VBG	O
to	TO	O
previously	RB	O
published	VBN	O
procedures32	NN	O
.	.	O
Following	VBG	O
anesthesia	NN	O
,	,	O
the	DT	O
carotid	NN	O
artery	NN	O
was	VBD	O
accessed	VBN	O
using	VBG	O
the	DT	O
operative	JJ	O
approach	NN	O
previously	RB	O
described	VBN	O
in	IN	O
detail33	NN	O
,	,	O
including	VBG	O
division/coagulation	NN	O
of	IN	O
the	DT	O
occipital	JJ	O
and	CC	O
pterygopalatine	JJ	O
arteries	NNS	O
to	TO	O
obtain	VB	O
improved	JJ	O
visualization	NN	O
and	CC	O
vascular	JJ	O
access	NN	O
.	.	O
A	DT	O
nylon	JJ	O
suture	NN	O
was	VBD	O
then	RB	O
introduced	VBN	O
into	IN	O
the	DT	O
common	JJ	O
carotid	NN	O
artery	NN	O
,	,	O
and	CC	O
threaded	VBD	O
up	RP	O
the	DT	O
internal	JJ	O
carotid	NN	O
artery	NN	O
to	TO	O
occlude	VB	O
the	DT	O
origin	NN	O
of	IN	O
the	DT	O
right	JJ	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
(	(	O
MCA	NNP	O
)	)	O
.	.	O
Nylon	NNP	O
(	(	O
polyamide	NN	O
)	)	O
suture	NN	O
material	NN	O
was	VBD	O
obtained	VBN	O
from	IN	O
United	NNP	O
States	NNPS	O
Surgical	NNP	O
Corporation	NNP	O
(	(	O
Norwalk	NNP	O
,	,	O
Conn.	NNP	O
)	)	O
,	,	O
and	CC	O
consisted	VBD	O
of	IN	O
5.0	CD	O
nylon/13	JJ	O
mm	NN	O
length	NN	O
for	IN	O
27-36	JJ	O
g	NN	O
mice	NN	O
,	,	O
and	CC	O
6.0	CD	O
nylon/12	JJ	O
mm	NN	O
length	NN	O
for	IN	O
22-26	JJ	O
g	NN	O
mice	NN	O
.	.	O
After	IN	O
45	CD	O
minutes	NNS	O
of	IN	O
occlusion	NN	O
,	,	O
the	DT	O
suture	NN	O
was	VBD	O
withdrawn	VBN	O
to	TO	O
achieve	VB	O
a	DT	O
reperfused	JJ	O
model	NN	O
of	IN	O
stroke	NN	O
.	.	O
Although	IN	O
no	DT	O
vessels	NNS	O
were	VBD	O
tied	VBN	O
off	RP	O
after	IN	O
the	DT	O
suture	NN	O
was	VBD	O
removed	VBN	O
,	,	O
the	DT	O
external	JJ	O
carotid	NN	O
arterial	JJ	O
stump	NN	O
was	VBD	O
cauterized	VBN	O
to	TO	O
prevent	VB	O
frank	JJ	O
hemorrhage	NN	O
.	.	O
Measurements	NNS	O
of	IN	O
relative	JJ	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
were	VBD	O
obtained	VBN	O
as	IN	O
previously	RB	O
reported32-35	JJ	O
using	VBG	O
a	DT	O
straight	JJ	O
laser	NN	O
doppler	NN	O
flow	NN	O
probe	NN	O
placed	VBD	O
2	CD	O
mm	NN	O
posterior	NN	O
to	TO	O
the	DT	O
bregma	NN	O
,	,	O
and	CC	O
6	CD	O
mm	NN	O
to	TO	O
each	DT	O
side	NN	O
of	IN	O
midline	NN	O
using	VBG	O
a	DT	O
stereotactic	JJ	O
micromanipulator	NN	O
,	,	O
keeping	VBG	O
the	DT	O
angle	NN	O
of	IN	O
the	DT	O
probe	NN	O
perpendicular	NN	O
to	TO	O
the	DT	O
cortical	JJ	O
surface	NN	O
.	.	O
These	DT	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
measurements	NNS	O
,	,	O
expressed	VBN	O
as	IN	O
the	DT	O
ratio	NN	O
of	IN	O
ipsilateral	JJ	O
to	TO	O
contralateral	JJ	O
blood	NN	O
flow	NN	O
,	,	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
immediately	RB	O
prior	JJ	O
to	TO	O
MCA	NNP	O
occlusion	NN	O
,	,	O
45	CD	O
minutes	NNS	O
after	IN	O
MCA	NNP	O
occlusion	NN	O
,	,	O
and	CC	O
at	IN	O
several	JJ	O
time	NN	O
points	NNS	O
after	IN	O
withdrawal	NN	O
of	IN	O
the	DT	O
occluding	JJ	O
suture	NN	O
.	.	O
Measurement	NN	O
of	IN	O
Cerebral	NNP	O
Infarction	NNP	O
Volumes	NNP	O
:	:	O
After	IN	O
24	CD	O
hours	NNS	O
,	,	O
animals	NNS	O
were	VBD	O
euthanized	VBN	O
and	CC	O
their	PRP$	O
brains	NNS	O
rapidly	RB	O
harvested	VBD	O
.	.	O
Infarct	NNP	O
volumes	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
staining	VBG	O
serial	JJ	O
cerebral	JJ	O
sections	NNS	O
with	IN	O
triphenyl	JJ	O
tetrazolium	NN	O
chloride	NN	O
and	CC	O
performing	VBG	O
computer-based	JJ	O
planimetry	NN	O
of	IN	O
the	DT	O
negatively	RB	O
(	(	O
infarcted	VBN	O
)	)	O
staining	VBG	O
areas	NNS	O
to	TO	O
calculate	VB	O
infarct	JJ	O
volume	NN	O
(	(	O
using	VBG	O
NIH	NNP	O
image	NN	O
software	NN	O
)	)	O
.	.	O
Neurological	JJ	O
Exam	NN	O
:	:	O
Prior	NNP	O
to	TO	O
giving	VBG	O
anesthesia	NN	O
,	,	O
mice	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
neurological	JJ	O
deficit	NN	O
23	CD	O
h	NN	O
after	IN	O
reperfusion	NN	O
using	VBG	O
a	DT	O
four-tiered	JJ	O
grading	NN	O
system	NN	O
:	:	O
a	DT	O
score	NN	O
of	IN	O
1	CD	O
was	VBD	O
given	VBN	O
if	IN	O
the	DT	O
animal	NN	O
demonstrated	VBD	O
normal	JJ	O
spontaneous	JJ	O
movements	NNS	O
;	:	O
a	DT	O
score	NN	O
of	IN	O
2	CD	O
was	VBD	O
given	VBN	O
if	IN	O
the	DT	O
animal	NN	O
was	VBD	O
noted	VBN	O
to	TO	O
be	VB	O
turning	VBG	O
towards	IN	O
the	DT	O
ipsilateral	JJ	O
side	NN	O
;	:	O
a	DT	O
score	NN	O
of	IN	O
3	CD	O
was	VBD	O
given	VBN	O
if	IN	O
the	DT	O
animal	NN	O
was	VBD	O
observed	VBN	O
to	TO	O
spin	VB	O
longitudinally	RB	O
(	(	O
clockwise	NN	O
when	WRB	O
viewed	VBN	O
from	IN	O
the	DT	O
tail	NN	O
)	)	O
;	:	O
and	CC	O
,	,	O
a	DT	O
score	NN	O
of	IN	O
4	CD	O
was	VBD	O
given	VBN	O
if	IN	O
the	DT	O
animal	NN	O
was	VBD	O
unresponsive	JJ	O
to	TO	O
noxious	JJ	O
stimuli	NNS	O
.	.	O
This	DT	O
scoring	NN	O
system	NN	O
has	VBZ	O
been	VBN	O
previously	RB	O
described	VBN	O
in	IN	O
mice32-34	NN	O
,	,	O
and	CC	O
is	VBZ	O
based	VBN	O
upon	IN	O
similar	JJ	O
scoring	VBG	O
systems	NNS	O
used	VBN	O
in	IN	O
rats36	NN	O
.	.	O
Immunostaining	NN	O
of	IN	O
cerebral	JJ	O
cortex	NN	O
following	VBG	O
induction	NN	O
of	IN	O
stroke	NN	O
in	IN	O
wild-type	JJ	O
mice	NN	O
was	VBD	O
performed	VBN	O
as	IN	O
described	VBN	O
above	IN	O
using	VBG	O
a	DT	O
rabbit	NN	O
polyclonal	JJ	O
antibody	NN	O
made	VBD	O
using	VBG	O
purified	JJ	O
recombinant	JJ	O
murine	NN	O
ABAD	NNP	O
as	IN	O
the	DT	O
immunogen	NN	O
.	.	O
Quantitation	NN	O
of	IN	O
microscopic	NN	O
images	NNS	O
was	VBD	O
accomplished	VBN	O
with	IN	O
the	DT	O
Universal	NNP	O
Imaging	NNP	O
System	NNP	O
.	.	O
Results	NNS	O
:	:	O
Transgenic	NNP	O
mice	NN	O
overexpressing	VBG	O
RAGE	NNP	O
under	IN	O
control	NN	O
of	IN	O
the	DT	O
platelet-derived	JJ	O
growth	NN	O
factor	NN	O
promoter	NN	O
were	VBD	O
subjected	VBN	O
to	TO	O
transient	VB	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
occlusion	NN	O
along	IN	O
with	IN	O
non-transgenic	JJ	O
littermates	NNS	O
.	.	O
Mice	NNP	O
were	VBD	O
26-29	JJ	O
grams	NNS	O
in	IN	O
weight	NN	O
and	CC	O
about	IN	O
10	CD	O
weeks	NNS	O
old	JJ	O
.	.	O
The	DT	O
volume	NN	O
of	IN	O
infarcted	JJ	O
cerebral	JJ	O
tissue	NN	O
was	VBD	O
reduced	VBN	O
about	IN	O
50	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
transgenic	JJ	O
mice	NN	O
compared	VBN	O
with	IN	O
the	DT	O
controls	NNS	O
(	(	O
see	VB	O
FIG	NNP	O
.	.	O
19A	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
studies	NNS	O
in	IN	O
all	DT	O
mice	NN	O
,	,	O
and	CC	O
FIG	NNP	O
.	.	O
19B	CD	O
shows	NNS	O
triphenyl	VBP	O
tetrazolium	JJ	O
chloride	NN	O
staining	NN	O
of	IN	O
selected	VBN	O
cerebral	JJ	O
sections	NNS	O
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
note	VB	O
that	IN	O
glucose	JJ	O
levels	NNS	O
were	VBD	O
monitored	VBN	O
in	IN	O
the	DT	O
animals	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
ischemic	JJ	O
episode	NN	O
,	,	O
because	IN	O
of	IN	O
the	DT	O
known	JJ	O
effect	NN	O
of	IN	O
hyperglycemia	NN	O
on	IN	O
infarct	JJ	O
volume	NN	O
.	.	O
The	DT	O
animals	NNS	O
remained	VBD	O
normoglycemic	JJ	O
throughout	IN	O
the	DT	O
procedure	NN	O
.	.	O
These	DT	O
data	NNS	O
indicate	VBP	O
that	IN	O
overexpression	NN	O
of	IN	O
RAGE	NNP	O
in	IN	O
neurons	NNS	O
has	VBZ	O
a	DT	O
neuroprotective	JJ	O
effect	NN	O
.	.	O
Thus	RB	O
,	,	O
it	PRP	O
would	MD	O
be	VB	O
important	JJ	O
to	TO	O
test	VB	O
potential	JJ	O
RAGE	NNP	O
inhibitors	NNS	O
in	IN	O
such	JJ	O
an	DT	O
animal	NN	O
to	TO	O
determine	VB	O
if	IN	O
they	PRP	O
antagonized	VBD	O
this	DT	O
protective	JJ	O
property	NN	O
of	IN	O
the	DT	O
receptor	NN	O
.	.	O
Figure	NN	O
legend	NN	O
:	:	O
for	IN	O
the	DT	O
figure	NN	O
which	WDT	O
you	PRP	O
SHOULD	VBP	O
send	VB	O
a	DT	O
messenger	NN	O
to	TO	O
pick	VB	O
up	RP	O
.	.	O
Induction	NN	O
of	IN	O
stroke	NN	O
in	IN	O
transgenic	JJ	O
mice	NN	O
overexpressing	VBG	O
RAGE	NNP	O
on	IN	O
the	DT	O
platelet-derived	JJ	O
growth	NN	O
factor	NN	O
promoter	NN	O
:	:	O
cerebral	JJ	O
infarct	NN	O
volume	NN	O
(	(	O
FIG	NNP	O
.	.	O
19A	CD	O
)	)	O
and	CC	O
results	NNS	O
of	IN	O
triphenyl	JJ	O
tetrazolium	NN	O
chloride	NN	O
staining	NN	O
of	IN	O
selected	VBN	O
cerebral	JJ	O
sections	NNS	O
(	(	O
FIG	NNP	O
.	.	O
19B	CD	O
)	)	O
.	.	O
